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GENERAL ABSTRACT  
 
Sub Saharan Africa (SSA) region carries the highest burden on HIV globally, with more 
than 75% of people living with HIV and 65% of global new HIV infections according to 
UNAIDS. Despite tremendous efforts made over the last decade to control HIV, especially 
with rapid scale up of Anti-Retroviral Therapy (ART), AIDS remain the main cause of 
deaths among youth 15-24 years old and only 50% of people living with HIV (PLHIV) in 
SSA access ART. The UNAIDS has recently recommended that 90% of people living with 
HIV get tested, 90% of them receive ART and 90% of those on ART suppress viral load 
with the ambition to end IDS by 2030.This goal could be only achieved with strong testing 
services, linkage to care and retention on sustainable and well tolerated regimen.  
We systematically studied these questions using data from the entire Rwanda national HIV 
program and presented different studies and examples of successful policy implementation. 
Our first study assessed the HIV incidence from a longitudinal cohort study, the first ever 
implemented in Rwanda. Previously the country relied heavily on mathematical modelling 
to estimate incidence with several limitations. Findings suggested an estimated national 
incidence of 0.27 infections per 100 person-years, 50% higher than the UNAIDS 
Spectrum/EPP model estimated incidence; however, our study suggested that incidence 
was characterized by multiple breakouts. To understand the linkage and retention in care, 
we conducted two studies on HIV continuum of care and predictors of lost to follow up 
and mortality in Rwanda. We found a high proportion of patients entering care in Rwanda’s 
HIV program retained with a low mortality and high proportion of PLHIV achieving viral 
suppression rates. Nonetheless, older age, low CD4 count at initiation and male sex were 
associated with disengagement from care and mortality on ART. The two studies also 
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provided new evidence that cascade of care is a non-linear pathway wherein patients have 
multiple opportunities to leave and re-engage in care. In line with the new era of treating 
all HIV+ regardless of CD4 count, we assess a phased approach implementation of the new 
policy in Rwanda and what is required to move from evidence to policy change and 
implementation considerations. We also assessed political, and financial implications 
especially required to implement the new HIV guidelines. The second part of this thesis 
evaluated treatment outcome for patients who failed first and second line ART available 
regimens, suggesting that overall, 92.5% of patients on second line ART in Rwanda were 
retained in care and 83% achieved viral suppression. Defaulting from care was significantly 
associated with more recent initiation of ART- PI based regimen, low CD4 cell count and 
HIV viral load at initiation of ART while Viral failure was associated with younger age, 
advanced disease and low CD4 count at initiation. Our study on outcomes from Rwanda’s 
first national cohort of third-line ART indicated that, over 90% of all 55 patients ever 
started on third line ART achieved VL suppression. Only one patient died and all were 
retained in care; however, raised concerns of 10% of multi-drug resistant patients who have 
no other treatment options after failing third line ART. Finally, we assessed the magnitude 
of HIV among female sex workers (FSW), a group with alarming high prevalence (46%) 
and considered to be the bridge of HIV transmission in Rwanda. The study analysed a 
projected incidence of HIV among female sex workers and their male partners in Rwanda 
using a Markov model examining intervention effects. The study found significant success 
of current program interventions (ART, condom use) to reduce HIV incidence among FSW 
and also estimated that introduction of Prep expected in Rwanda in 2019, could prevent 
more new infections among FSW by 0.24%. 
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CHAPTER 1. INTRODUCTION TO THE THESIS 
 
1.1 Background  
 
        Morbidity and mortality among people living with HIV/AIDS (PLHIV) in Rwanda 
has decreased in recent years likely due to high coverage of antiretroviral therapy (ART), 
early treatment initiation and improvements in diagnosis and treatment of opportunistic 
infections (MoH/RBC-Rwanda 2016). The country’s efforts to control HIV is further 
demonstrated by reductions in HIV incidence by approximately half in the last decade, as 
well as a decrease in annual deaths related to AIDS by 68%. The scale-up of ART in 
Rwanda has resulted in an increase of an additional approximate 25 years of life expectancy 
among PLHIV (Nsanzimana, Remera, Kanters, Chan, et al. 2015). Despite these 
achievements, several important challenges to ensuring care across the HIV care 
continuum remain. Many individuals are unaware of their HIV sero-status and as a result, 
miss the opportunity for linkage to HIV testing services and early treatment in case of an 
HIV positive test. Findings from a systematic review of treatment cohorts in Sub-Saharan 
Africa show that 41–54% of people are lost between testing and the assessment of 
eligibility for treatment, and 32% of those considered eligible for ART are lost between 
the assessment of eligibility and initiating ART (Rosen & Fox 2011). Once PLHIV start 
ART, about one quarter temporarily interrupt treatment and another quarter are lost within 
three years (Kranzer & Ford 2011). Among those lost, up to half (46%) may have died. A 
non-published retrospective study conducted in Rwanda on 8,580 adult clients who tested 
HIV positive in 80 heath facilities found that only 25% were linked to care within three 
months of their diagnosis and 50% of all newly tested HIV positive patients were lost to 
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follow-up (LTFU). The strategic efforts to improve linkage and retention are critical for 
Rwanda to achieve full control of the HIV epidemic.  
1.2 The rationale for the studies reported in this thesis 
We conducted studies to assess HIV incidence, linkage and retention in care across 
different ART regimens used in Rwanda. These projects addressed key issues related to 
HIV continuum of care and long-term retention in an entire national program using Rwanda 
as a case study to investigate engagement and retention in care. We have reported on 
patients’ outcomes on first, second and third lines ART as well as modelled different 
scenarios to understand the role of female sex workers as a key mechanistic driver of the 
HIV epidemic in the country.  
Apart from the research objectives described above, these projects provide important 
data for public health officials in Rwanda with respect to currently unknown individual and 
national programmatic features associated with poor linkage and/or retention to HIV care 
services in Rwanda. We believe that our findings will provide the Rwandan Ministry of 
Health with useful estimates for evaluating HIV services in Rwanda. Furthermore, as ART 
is provided on a rapidly increasing scale in low-income countries, it is becoming 
increasingly important to systematically characterize the individual and national 
programmatic features associated with retention in HIV care in low-income settings. This 
PhD thesis project will not only serve to improve aspects of the Rwanda HIV program 
requiring the most attention, but our results will, likewise, inform HIV programs in similar 
settings. This PhD thesis tackles critical stages of the national HIV program conducted by 
the student who is also the current Director of the Rwanda national HIV program and is 
charged with overseeing the implementation of the program. The government of Rwanda 
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highly recommends a combination of program implementation and academic rigor for 
greater precision in decision-making. This thesis is a great example of how the new 
initiative overcame barriers between researchers and program managers. This thesis 
combines data driven projects but also health policy development and implementation 
analysis that is unique for Rwanda’s HIV program and could be replicated elsewhere.  
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CHAPTER 2. GLOBAL EPIDEMIOLOGY OF HIV 
 
2.1 Status of the HIV epidemic  
 
More than three decades ago, the first case of HIV was described in 1981 (Centers for 
Disease Control-USA 1981). Since then, more than 70 million people have been infected 
and about half have died due to HIV (UNAIDS 2017b). UNAIDS reported that in 2016, 
36.7 [30.8-42.9] million people were HIV infected and 1.8 [1.6-2.1] million were newly 
infected, with approximately 1.0 million [830,000-1.2 million] AIDS related deaths 
worldwide. The prevalence of HIV globally is highest in Sub-Saharan Africa (SSA) where 
about 5% of the population are living with HIV (GBD 2015 HIV Collaborators 2016). 
Southern African countries are particularly affected, for example, Swaziland, Namibia, 
Botswana, Zambia, Zimbabwe and South Africa each have an HIV prevalence of more 
than 15% (UNAIDS 2017b). Other regions of the world have a relatively low prevalence 
compared to SSA; North Africa and the Middle East remain less affected with only 0.2% 
of people living with HIV (GBD 2015 HIV Collaborators 2016).   
Although HIV is distributed across all continents new HIV infections continue to 
accumulate. The Sub-Saharan Africa region is most affected; encompassing nearly 65% of 
new global HIV infections in 2016. The global trend of new HIV infections has been flat 
over the years, but from 2010 to 2016, it has observed an 11% decline primarily in countries 
with high HIV burden  (UNAIDS 2017b). There are significant differences in the number 
of new infections by gender and age with young women 15-24 years old having more 
infections than men of a similar age cohort. 
Deaths attributed to HIV have declined by almost 50% over the last decade; a success 
attributed to the large scale up of anti-retroviral treatment (UNAIDS 2017b). Nonetheless, 
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AIDS remain the leading cause of death in Sub-Saharan Africa and among young women 
15-24 in particular. The reduction of AIDS related deaths varied across regions: Eastern 
and Southern Africa marked a record of about 62% less deaths, while it was 52% in the 
Caribbean, 45% in Western, Central Europe and North America, 39% in Asia and Pacific 
island regions and 30% in Central Africa  (UNAIDS 2017b). Notwithstanding the global 
decrease of AIDS related deaths, increases in mortality of approximately 48% were 
observed in the Middle East and North Africa and 38% in Eastern Europe and Central Asia 
(UNAIDS 2017b). The United Nations General Assembly in 2016 committed to achieve 
500,000 fewer new HIV infections by 2020. However, achieving this goal by 2020 appears 
improbable given the slow trend of decline. 
2.2 Global response to AIDS epidemic  
 
HIV was once considered a death sentence in the 1990s before the start of anti-retroviral 
treatment. The first introduction of Highly Active Anti-Retroviral Therapy (HAART) in 
1996, contributed importantly to reduce AIDS related deaths (GBD 2015 HIV 
Collaborators 2016). Following the creation of the UNAIDS in 1996, the United Nations 
started to consider HIV as a global health threat; later on, in 2003, the US President’s 
Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, 
Tuberculosis and Malaria (GFTAM) were created to mobilize necessary resources to tackle 
the AIDS epidemic (Harold Varmus 2013; TheGlobalFund 2013). 
All these efforts led to a tremendous decline of HIV-related mortality in countries most 
affected especially in Sub-Saharan Africa. UNAIDS now promotes a concept of ending the 
AIDS epidemic by 2030 through a combination of preventative, education, treatment and 
research initiatives. Alongside these goals, UNAIDS launched, in 2015, the ambitious “90-
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90-90” target to help end this disease (UNAIDS 2014), by controlling the AIDS epidemic 
in order to achieve overall positive social and health outcomes. The new strategy followed 
the previous strategy “getting to zero”: Zero new HIV infections, zero AIDS related deaths 
and zero discrimination”.  
Through these ambitious targets, the new strategic overarching goal is to end AIDS by 
2030, which articulates three key treatment targets to be achieved by 2030. These include:  
- 90% of all people living with HIV knowing their status  
- 90% of those diagnosed HIV+ have access to lifelong Anti-retroviral treatment 
- and 90% of those on ART achieve viral load suppression below 1000 copies/mL  
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Figure 2-1: HIV Global epidemiology, UNAIDS, 2016  
 
First target:  90% of all people living with HIV will know their HIV status (90% 
diagnosed) by 2020 
 The UNAIDS advisory board set this ambitious target based on progress made in some 
countries that could serve as an experience and best practice to be shared with those lagging 
behind. It was estimated that only 45% of people living in SSA were tested and knew their 
results, yet the plan aimed to achieve 90% within five years. The new target required the 
doubling of efforts and to change, considerably, the existing testing services across all 
populations and sub-populations. New necessary approaches include: self-testing, provider 
initiated counselling and testing, home based testing and aggressive community outreach 
campaigns. A significant challenge to this plan was to ensure that individuals know where 
to access the testing services, access them, be tested, receive results and acquire appropriate 
Legend: Global HIV Prevalence, 2016 
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care and treatment services in a timely manner. This requires improving risk perception, 
information seeking for services on the population side, enhanced accessibility to services 
and adherence tools and interventions, friendly policy environments and infrastructure 
strong monitoring platforms on the supplier side (Hargreaves et al. 2016).  
Second target: 90% of all people with diagnosed HIV infection will receive sustained 
antiretroviral therapy (90% on HIV treatment) 
 
The global effort to scale up ART has been one of the most successful treatment 
interventions in medical history. From 2002-2012, two major programs changed the face 
of the disease, the Global Fund to fight AIDS, Tuberculosis and Malaria together with the 
United States President’s Emergency Plan for AIDS Relief increased (mainly in Sub-
Saharan Africa) access to lifesaving ART more than 100 fold (UNAIDS 2012b).  Until 
2016, CD4 count has been used as an indicator for ART initiation to stop the disease 
progression. However, the HIV Prevention Network trials (HPTN-052) (Cohen et al. 2011) 
and the Strategic Timing of Antiretroviral Treatment (The INSIGHT START Study Group 
2015) clinical trials demonstrated that by providing ART as early as possible will  prevent 
morbidity and mortality related to HIV and AIDS while also significantly reducing the 
transmission of HIV. Findings from this landmark trial confirmed the appropriateness of 
“treatment as prevention” or “Treat All” strategy, adopted in 2016 by the World Health 
Organization consolidated guidelines on the use of anti-retroviral drugs for treating and 
preventing HIV infection (WHO 2016).  
UNAIDS has used this evidence as a strong basis to set up the second 90 target – viewed 
as most likely to be achieved by 2020. For successful achievement of this target, countries 
were urged to increase ART coverage from 37% to 90% by 2020 by optimizing access to 
treatment services and retention in care - ensure uninterrupted supply chain for laboratory 
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and ARVs commodities - and creating a patient friendly environment in order to retain 
individuals in the programs for as long as possible (UNAIDS 2014).   
 
Third target: 90% of all people receiving antiretroviral therapy will have viral 
suppression (90% suppressed) 
 
When the 90-90-90 targets were launched, only 29% of people living with HIV had 
attained a level of HIV viral load suppression below 1000 copies/mL globally and the 
predicted VL testing scale up would only meet 57% of the needs by 2019 (UNAIDS 2015). 
Similar to the first 90, the third would require more investment in VL infrastructure and 
technology, strong monitoring to regularly check treatment success for re-engagement in 
care of those lost to follow up. Some countries demonstrated the feasibility of this target; 
for example, Rwanda achieved 83% of viral load suppression after more than 1 year on 
ART (Elul et al. 2013). In Latin America and the Caribbean, the median viral load 
suppression was 60% in 2013 (WHO 2014) yet, in other countries only one out of four HIV 
infected individuals on ART have a suppressed VL (UNAIDS 2016c).  
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Figure 2-2: UNAIDS 90-90-90 targets by 2020 to help ending AIDS by 2030 
 
2.3 Main challenges in HIV control  
Global efforts to control HIV gained hope with the arrival of ART. However, new 
infections continue to rise in some parts of the world (North Africa and the Middle East). 
These regions continue to be the epicentre of the HIV epidemic and populations including, 
female sex workers, men having sex with men, and injecting drug users are viewed as the 
primary conduits of the epidemic in these regions and contribute more than 30% of HIV 
epidemic new infections in regions where condom use among youth is even sub-optimal. 
In addition, poor access to HIV services and inadequate health infrastructure and systems 
continue to be a major cause of stock depletion of essential medicines and ARVs in many 
parts of SSA (UNAIDS 2011).  
Other regions have additional, localized challenges but across all, the issue of 
sustainable financing is a shared challenge. While in Asia, the Pacific Islands, and Eastern 
6
UNAIDS 90-90-90 targets by 2020
Adapted  from UNAIDS 90–90–90 targets: An ambitious treatment target to help end the AIDS epidemic by 2030
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Europe, HIV testing among people who inject drugs is a major challenge, violations of 
human rights and gender-based violence complicate delivery of preventive and treatment 
services in the Caribbean region and Latin America. In the United States, African-
American men who have sex with men acquire HIV at a rate several times higher than 
those among other men who have sex with men. Western and Central Africa are 
particularly affected with other diseases (such as Ebola) in regions already heavily hit by 
recurrent humanitarian emergencies (seasonal shocks— drought, food insecurity, floods 
and disease outbreaks—and conflicts), which all influence the epidemic and threaten the 
response to HIV (Parpia et al. 2016).  
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CHAPTER 3: THE GENOCIDE AGAINST THE TUTSIS IN 
RWANDA AND ITS IMPACT ON RWANDA HEALTH SYSTEM. 
 
3.1 Country background 
 
In order to understand the epidemiology of HIV in Rwanda, it is important to 
understand the historical context of political and medical issues in the country. Rwanda is 
a land locked country located in the East African Region, bordered by Burundi in the south, 
Uganda in the north, Tanzania in the east and Democratic Republic Congo (DRC) in the 
west (Fig3). It is the most densely-populated country in the world with about 400 people 
per km2. In the recent population and household census, the total population was 11,809, 
295 in 2017 with a 2,39% projected annual increase. The life expectancy for both sexes 
was 66.6 years in 2017, which almost doubled in the last 20 years (Binagwaho et al. 2014). 
More than 80% of the population live in rural areas. The administration is divided into four 
provinces and the capital, Kigali City, hosts about 1,500,0000 people. The official 
languages recognized by the constitution are French, English and Kinyarwanda. Kiswahili 
is largely spoken in Rwanda, and the parliament is debating its recognition as a fourth 
language. 68% of the population above 15 years of age are literate; 72% among males and 
65% among females (NISR-Rwanda 2015). 
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Figure 3: Geographical location of Rwanda in East-Central Africa. 
3.2 The genocide against the Tutsi in 1994. 
 
The roots of the genocide against the Tutsis in Rwanda in 1994 can be traced back a 
century ago. Following the 1884 Berlin Conference, Rwanda was assigned a German 
colony, which ended with the country’s defeat during World War I. Subsequently, Belgium 
assumed reign over Rwanda-Urundi until 1962 when Rwanda achieved independence from 
Belgium with unprecedented ethnic tensions (Prunier 1998).  
The two successive governments were dominated by Hutus extremists who fuelled 
systematic discrimination and violence against Tutsis minorities over 30 years. In October 
1990, the Rwanda Patriotic Front (RPF) Tutsis dominated rebel army attacked Rwanda 
demanding return of refugees who had fled the country in post-colonial period. Periodic 
violence continued against Tutsis held hostage within Rwanda by the regime. On April 6th, 
1994, unknown assailants shot the president of Rwanda Juvénal Habyarimana's plane as it 
prepared to land in Kigali from Tanzania for signature ceremony of peace negotiations with 
RPF. Immediately, an interim government was put in place and urged Hutus to exterminate 
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the Tutsis who were accused for the death of Habyarimana. Experts suggest that the killings 
may have been planned long before, with purchasing of machetes and ammunitions as well 
as the preparation of lists of Tutsis well in order across the country. This was testified by 
the speed of the targeted assassinations against the Tutsis and moderate Hutu political 
opponents.  
The genocide against the Tutsis has been known as one of the worst humanitarian 
tragedies of the 20th Century. Over 100 days, one million people were killed~ an estimated 
10,000 deaths every day. The genocide was put to an end when RPF army led by General 
Paul Kagame defeated the genocidal regime and took over the control of Rwanda in July 
1994. In the aftermath of the genocide, Rwanda’s infrastructure, human resources, and 
social cohesion were devastated by the genocide. Basic infrastructure was also destroyed. 
The majority of professional workers were either massacred, had participated in the killings 
themselves or fled to neighbouring countries. In this context, Rwanda became one of the 
poorest countries in the world (Binagwaho et al. 2014).  
3.3 The genocide and health system in Rwanda  
 
Health and education were among the most devastated systems in Rwanda during the 
genocide against the Tutsis. The end of the genocide was followed by a massive exodus of 
the population; with more than two million people having relocated into neighbouring 
countries –  predominantly to Zaire (today known as DRC). This event was known as the 
great lakes humanitarian crisis, which resulted in a cholera epidemic and other 
communicable diseases in July 1994. The death toll due to cholera was 7000 per week and 
had contaminated all of Eastern Zaire (UNHCR 1997).  
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In Rwanda, less than 5% of the population had access to clean water and nearly 80 % of 
physicians had been killed or had fled the country. Health facilities were destroyed and 
supply chains for drugs and consumables were in ruins. Furthermore, infectious disease 
epidemics were also emerging. Meanwhile, funds to implement health initiatives were 
depleted. In an annual report in 1996, USAID estimated that, “70% of humanitarian 
assistance to Rwanda was channelled to refugees in DRC while the plight of survivors in 
Rwanda, especially women had been seriously neglected” (USAID 1996).  
The newly formed government of Rwanda faced a serious challenge of rebuilding the 
country from scratch following a collapse of the economy. The Ministry of Health (MoH) 
decided in 1995 to reform the health sector resulting into excellent improvements regarding 
infant and child survival, maternal health, HIV, tuberculosis, and malaria control. Today, 
Rwanda is one of few African countries that achieved almost all the health-related 
Millennium Development Goals (MDGs) (Abbott, Sapsford & Binagwaho 2017) .  
The new health system in Rwanda was built on an administrative structure that 
prioritized a strong decentralized system. The major coordinating bodies are the ministry 
of Health responsible for health strategies, policies and oversight of all health matters in 
the country and the “Rwanda Biomedical Center” who leads the implementation of all 
health policies and programs such as HIV/AIDS, malaria, tuberculosis, immunization and 
non-communicable diseases. The additional coordinating bodies; the national reference 
laboratory and its networks, the national blood transfusion centre, and the maternal, child 
and community health programs.  
Approximately 80% of the health sector in Rwanda is public (55% is Government of 
Rwanda (GoR) owned and 22% are faith-based with GoR funding) and there are very few 
private clinics. The lowest level is a health post at the level of a cell, followed by a health 
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center covering a sector to a district hospital for each administrative district, with each of 
the five provinces served by a provincial hospital. The tertiary level is composed of three 
referral specialized hospitals and two University teaching hospitals. The country still lacks 
enough skilled personnel with only 525 physicians, 8273 nurses, and 240 midwives for 
more than 10 million people (MoH-Rwanda 2011).  
 To address the shortage of qualified healthcare workers, the ministry of health initiated 
and trained a team of 45,000 “Community Health Workers” three per village, who were 
elected by their peers in the communities. These workers play a major role in promoting 
maternal and child health, vaccination, and linkage to health facilities. As their experience 
and trust grew, they were trained to diagnose and treat empirical malaria and diarrhoea in 
the communities (Shapira et al. 2017).  
Meanwhile, approximately 90% of the population is covered by community based 
health insurance program “mutuelle de santé”, which subsidizes costs to medical services 
and other commodities. Initiated in 1999 to provide affordable basic services, the “mutuelle 
program” has successfully demonstrated that eliminating financial barriers to accessing 
healthcare and other social services improved health outcomes. The second major health 
system innovation was the implementation of Performance Based Financing (PBF) in 
2001. The Government of Rwanda collaborated with two NGOs and the School of Public 
Health at the National University of Rwanda to experiment with the implementation of 
PBF. The PBF program provided payments to health workers to incentivize high-quality 
care and, in 2006, the program was scaled-up across the country with positive results 
(Logie, Rowson & Ndagije 2008).  
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The health care sector of Rwanda is facing a number of challenges. One of the most critical 
is the severe shortage of qualified medical staff. In 2010, a doctor-population ratio was 1 
/16,001; nurse-population ratio was 1 / 1,291 with a target to reach 1 / 11,993 and 1 / 1,000 
respectively by 2018 (MoH-Rwanda 2014).  
Other issues included: insufficient medical equipment and a general dependency on 
foreign donor support, making it difficult for the country to establish a sustainable health 
care system. The health sector is currently heavily reliant on donor support (about 60% in 
2016) and the government has been working on a medium- and long-term sustainable 
financing mechanisms.  
 
Figure 4: The pyramid of Rwanda health system  
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3.4 Overview of HIV epidemic in Rwanda and the national response. 
 
The HIV program in Rwanda is coordinated under the Ministry of Health through its 
large implementing agency known as Rwanda Biomedical Center. The national program 
coordinates all activities related to HIV prevention and management under the National 
HIV Strategic Plan (NSP) which serves as a reference document to all sectors, donors and 
implementing partners. HIV interventions are highly decentralized and integrated in the 
health system in over 98% of health facilities across the country. Although the program 
has been cited as a good example of success, its past has been marked with several planning 
and implementation challenges that served as lessons learnt. 
The first case of HIV in Rwanda was reported in 1983 at the Kigali Teaching Hospital 
(Van de Perre et al. 1984). By 1983, Rwanda was one of first countries in SSA most 
severely affected by the virus, with an HIV prevalence of 17.8% in urban and 1.3% in rural 
areas. The situation was exacerbated by the 1994 genocide against the Tutsis through 
widespread systematic sexual violence against women and girls. About 250,000 women 
had been systematically raped during the genocide and intentionally infected with HIV by 
their killers in the effort to torture and cause maximum pain (Donovan 2002). Nearly 5000 
children were born to women who were raped and some were born HIV infected (African-
Rights 2004). During a substantial historical population wave that followed the defeat of 
the genocide regime; infectious diseases including HIV were rampant and uncontained. An 
estimated 4 million people moved in and out of Rwanda between 1994-1996 at the height 
of the HIV epidemic. 
In 1998, HIV prevalence in Rwanda was 27% among urban residents, 13% among 
semi-urban residents, and 7% among rural residents, during the same period when AIDS 
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related mortality was above 60%. In 1999, the Rwanda Ministry of Health began to scale 
up HIV testing services and Prevention of HIV transmission from Mother to Child 
(PMTCT). One year later, the universal ART treatment program begun in a few health 
facilities and under strict selection criteria for ART eligibility. The creation of GF and 
PEPFAR in 2003 increased considerably access to testing and ART. Today, there is an 
estimated 220,108 people living with HIV in Rwanda, including approximately 10,000 
children below the age of 15 (Nsanzimana, Prabhu, McDermott, Karita, et al. 2015).  
Most recent findings from the Rwanda Demographic and Health Survey, 2015 indicate 
that, HIV prevalence has remained stable at 3% in the last ten years (NISR-Rwanda 2014). 
Young women aged 18-19 years are ten times more likely to acquire HIV than young men 
of the same age. Results of the DHS showed that 3% of women and 2.2% of men are HIV 
positive. The prevalence differs by geographical area and age group. In urban areas, it is 
6.2% while it is 2.2% in rural. The lowest HIV prevalence was found in the Northern 
Province (2.3%) and the highest in Kigali City (6.3%). The analysis of HIV prevalence 
data in 2010 and 2015 stratified by sex and age groups indicate that the HIV epidemic in 
Rwanda is evolving, as HIV prevalence shift over time towards older adult cohorts 
(Nsanzimana, Kanters, Remera, Forrest, et al. 2015).  
The country is also experiencing a mixed HIV epidemic, with aspects of a generalized 
epidemic among the population at large and a more concentrated epidemic among key 
population groups (female sex workers and their clients, men who have sex with men, truck 
drivers, prisoners and HIV sero-discordant couples). HIV prevalence among female sex 
workers is particularly high at 45% nationally while it is 4% among men who have sex 
with men and 3% or less in all other categories. Other groups who are vulnerable to HIV 
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infections are people living with disabilities, refugees, orphans and other vulnerable 
children (MoH/RBC-Rwanda 2012).  
The primary mechanism of HIV transmission in Rwanda is through unprotected sexual 
intercourse. Modes of Transmission (MOT) suggested in 2013 that heterosexual 
transmission  account for 64% of new HIV infections, clients of sex workers for 19%, and 
sex out of marriage is estimated to account for approximately 10% of new infections 
(MoH/RBC-Rwanda 2012). 
Female sex workers (FSWs) comprise an important sub-population in the epidemiology 
of HIV infection in Rwanda, as evidenced by a HIV prevalence amongst FSWs often being 
10 to 20-fold higher than in the general population (Mutagoma et al. 2017). The 
Behavioural Surveillance Survey (BSS) conducted among FSWs in 2015 indicated that the 
total HIV prevalence among FSWs was 45%, with the highest rates in the City of Kigali 
(57%) and lowest in the Eastern province (34%). In 2012, the Rwanda Biomedical Center 
(RBC) conducted a study to estimate the size of the population of FSWs and found an 
estimated 12,278 FSWs, mostly concentrated in the capital city (Kigali) and two cities 
around the borders of the Democratic Republic of Congo (Rusizi and Rubavu) (Mutagoma 
et al. 2015). A study conducted in 2010 found that HIV incidence among a population of 
397 FSWs in Kigali after 12 months was estimated at 3.5 per 100 person-years (Braunstein 
et al. 2009). 
Over the last decade, the country updated its comprehensive HIV treatment guidelines 
raising the ART initiation CD4 cell count threshold from 200 cell/mm3 in 2007, to <350 
cells/mm3 in 2009, and to <500 cells/mm3 in 2013. The latest guidelines from 2016 
recommend immediate start of ART (independent from CD4 cell count) ideally the same 
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day for all individuals with newly  identified HIV+  (MoH/RBC-Rwanda 2013). The same 
guidelines suggest first, second and third line ART combinations to be built on: 
− First line: Two nucleoside reverse transcriptase plus one non-nucleoside reverse 
transcriptase (2NRT+1NNRTI). 
− Second line: Two nucleoside reverse transcriptase with one boosted protease 
inhibitor (2NRT+PI). 
− Third Line: One integrase inhibitor plus a second generation of non-nucleoside 
reverse transcriptase plus boosted non-peptide inhibitor of protease 
(1NRTI+1NNRTI+PR). 
 
Figure 5: HIV guidelines changes overtime in Rwanda 2005-2018 
 
 
While, we recognize the tremendous progress made to control the HIV epidemic in Rwanda 
over two decades, there are programmatic gaps along the cascade of care. 
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CHAPTER 4. AIMS, OBJECTIVES, HYPOTHESIS AND METHODS 
 
  
 
4.1  Overall objective of the present thesis 
 
The overall purpose of this PhD project was to assess key epidemiological, individual 
and national programmatic features associated with the diagnosis of HIV (accurate 
estimates of HIV incidence), retention in HIV care during pre-ART period and linkage to 
ART and performance of individuals under the treatment programs in Rwanda. Results 
from the thesis projects will directly contribute to identifying programmatic gaps in the 
HIV care continuum and suggest interventions that can be applied to reduce the 
disengagement in HIV programs and to improve the performance of ART treatment 
programs. These interventions may be replicated in other similar countries with generalized 
HIV epidemics. 
 
a. Specific aims 
 
Specific aim 1: To generate key epidemiological parameters of the HIV epidemic in 
Rwanda allowing for better precision in planning and alignment of HIV program 
interventions. 
Specific aim 2: To assess the clinical and immunological outcomes of HIV+ patients at 
different stages of the continuum of care in order to identify when patients are at greatest 
risk of disengagement in care; particularly, when evaluating treatment outcomes of patients 
on second- and third-line ART regimens in Rwanda.  
Specific aim 3: To estimate the burden of HIV and its determinants among key populations 
and their connections to the general population in Rwanda.   
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5.1 Abstract 
 
Background: In Rwanda, HIV prevalence among adults aged 15 to 49 years has been 
stable at 3% since 2005. The aim of this study was to characterize HIV incidence.  
Methods: We conducted a nationally-representative, prospective HIV incidence survey for 
the period of 2013-2014 using two-stage sampling. We randomly selected 492 villages in 
the first stage and 14 households in the second stage, resulting in 14·222 respondents from 
6·792 households. Participants completed a questionnaire and 14·140 were tested where 
13·728 tested HIV negative, and were enrolled in the incidence cohort and re-tested and 
re-surveyed after 12 months.  
Findings: Among 12·593 completers, 5965 were male (47·4%) and the mean age was 
30 years. The majority 12,120 (88%) lived in rural areas; 4,826 (38%) were single and 
7140 (57%) were married or cohabitating. Over the year, 35 participants sero-converted, 
resulting in an incidence of 0·27 per 100 person years (PY) (95% CI: 0·18-0·35); 0·21 per 
100 PY (95% CI 0·10 – 0·32) among men and 0·32 per 100 PY (95% CI 0·19 – 0·45) 
among women. Findings were indicative of multiple breakouts, with 3 villages and 2 
households having multiple sero-conversions. Incidence was higher among adults aged 36-
45 years (0.37 per 100 person-years; aHR 4.5, 95% CI: 1.3-14.7), in Western province 
(aHR 5.9; 95% CI: 1.33-25.28) and in urban areas (aHR 3.1; 95% CI: 1.28-6.99).  
Interpretation: Characterizing incident infections can help the national HIV program 
plan for prevention interventions tailored to those most at-risk. 
Funding: Global fund to fight HIV, TB and Malaria, WHO/ Rwanda, 
UNAIDS/Rwanda and the Government of Rwanda.  
Keywords: HIV, Incidence, household 
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5.2 Introduction 
 
HIV remains a leading cause of death and disability globally (Wang et al. 2016). In 
2015, there were 1·1 million HIV-related deaths, 2·1 million new HIV infections, and a 
total of 36·7 million people living with HIV (UNAIDS 2016c). The majority of the burden 
is in Sub-Saharan Africa, where 73% of deaths, 65% of new infections occur and 70% of 
people living with HIV live (UNAIDS 2016c). The global response to the epidemic has 
been impressive. As of 2015, 17 million people were receiving antiretroviral therapy 
(ART) and this contributed to an estimated 43% reduction in AIDS-related deaths since 
2003 (UNAIDS 2016c). In 2016, the United Nations General Assembly agreed to fast-track 
the end of the HIV epidemic by achieving three global goals by 2020: (1) reduce new HIV 
infections to fewer than 500·000 globally; (2) reduce AIDS-related deaths to fewer than 
500·000; and (3) eliminate HIV-related stigma and discrimination (Unite Nations. General 
Assembly. Human Rights Council 2008). 
 In Rwanda, HIV incidence peaked in the mid-90s and apparently started to decline 
after the implementation of population prevention measures including screening of donated 
blood, health education, and prevention services such as condoms. This decline was 
accelerated with the scale-up of ART nationally (Binagwaho et al. 2014). At the end of 
2015, 160·000 people were receiving treatment and 86% of those on ART suppressed the 
virus in their blood (below 40 copies per mL) (Nsanzimana, Kanters, Remera, Forrest, et 
al. 2015). Reducing new HIV infections will require countries to understand incidence 
nationally, sub-nationally, and within different populations. HIV incidence remains the 
most informative measure towards understanding the nature of an HIV epidemic, such as 
where new infections are occurring and who are incurring the new infections. The World 
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Health Organization (WHO) recommends various methods to measure incidence 
(WHO/UNAIDS 2013).  The gold standard is directly measuring incidence in a cohort of 
individuals who do not have HIV infection. While ideal, it is resource intensive and not 
always feasible. The most common alternative option for measuring incidence is 
mathematical modelling of data that affects incidence (e.g. HIV prevalence rates and risk 
behaviour). Some limitations of this approach are the robustness of the data used in 
modelling and the modelling methodologies (Hallett 2011). Modelling encompasses a 
much greater degree of uncertainty and room for error. 
The national HIV control program in Rwanda had yet to conduct a national incidence 
cohort study since the initiation of ART scale-up in 2004. It has relied heavily on 
mathematical models from UNAIDS Spectrum/Estimation and Projection Package (EPP) 
for key indicators, including number of people living with HIV, incidence, AIDS related 
deaths and number of adults and children in need of ART (Stover, Brown & Marston 2012). 
These estimates are crucial for national planning, commodities quantification, policy 
directions and evaluations of interventions.  However, the limitations of using national 
models for subnational planning persist, as many biases may be introduced in model 
assumptions and the national situation may not always represent what is happening at the 
local level (Stover et al. 2014). To inform national programming towards the end of the 
epidemic, Rwanda’s Ministry of Health collaborated with The Global Fund to fight AIDS, 
Tuberculosis, Malaria and other partners to undertake the first study on national HIV 
incidence, the Rwanda HIV incidence survey. Thus, in order to have the most accurate and 
comprehensive HIV marker estimates, this study relied on the gold standard for measuring 
HIV incidence longitudinally in a cohort. Although there have been community-based 
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cohort studies in Eastern and Southern Africa (Wambura et al. 2007; Reniers et al. 2016; 
Lopman et al. 2009; Kranzer et al. 2008; Tanser et al. 2012) to our knowledge limited 
cohort studies (Justman et al. 2017) have been designed for measuring national incidence 
rates. 
5.3 Methods 
 
Sampling 
We constructed a national prospective HIV incidence cohort by first conducting a 
nationally representative survey in 2013 and following all HIV negative individuals within 
that survey for one year through to 2014. The initial sampling survey was conducted in all 
five Rwandan provinces using two-stage sampling. In the first stage, we randomly selected 
492 villages using probability proportional to the village size. In the second stage, 14 
households per village were systematically selected. The sampled villages covered all five 
provinces of Rwanda and each of the 30 Districts of Rwanda, with 58 villages in urban 
areas and 434 in rural areas. The survey design considered the clustering of our data in the 
set-up and analysis of our data. Following the selection of villages, a comprehensive 
household listing activity was conducted within them; all households located in the selected 
villages were listed to construct a sampling frame. The study population included women 
aged 15-49 and men aged 15-59 living in sampled residential households. The sampling 
methods are the same as those used by the Rwanda demographic and health survey 
(RDHS). 
We obtained a sample of 13·728 respondents from 6·792 households. The survey 
involved both individual interviews and blood sample collection. Two types of 
questionnaires were used for interviews. The household questionnaire helped identify 
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eligible participants for the interview in the selected household, according to age and usual 
resident of the household, as primary inclusion criteria. The individual questionnaire 
covered the following key topics: socio-demographic characteristics; sexual behaviour 
during the last 12 months; knowledge and attitudes towards HIV and related services; 
attitudes and use of condom; voluntary counselling and testing during the last 12 months; 
sexually transmitted infections during the last 12 months; male circumcision; exposure to 
HIV programs; and, contraceptive Methods. Both questionnaires were loaded onto 
Personal Digital Assistants that were used to conduct interviews.  
Participants were also tested for HIV using rapid tests and ELISA. Those testing HIV 
negative were enrolled in the cohort and those testing HIV positives were only included in 
the baseline survey. The cohort was followed for 12 months from the time of first HIV test 
to the end point (last HIV test), with no special intervention or education. Two follow up 
visits were done, in February and May 2014 aimed to ensure that eligible participants are 
staying in the same villages and for collecting new addresses for the participants who 
resettled as well as ensuring that they were still willing to participate in the HIV incidence 
survey. All study participants regardless of the new HIV status were visited to avoid 
eventual social stigma related to the serological status, but only HIV negative participants 
were considered in the HIV incidence cohort. HIV incidence in the cohort prospective 
study was estimated as the number of HIV sero-conversions per 100 persons-years of 
follow-up. HIV incidence was the primary endpoint for our study.  
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HIV testing  
All selected participants were enrolled after providing a signed consent form. HIV rapid 
tests were performed at the nearest health facility (HF)’s laboratory for swift return to the 
participants at baseline and at 12 months’ follow-up. Respondents who agreed to provide 
a blood sample for HIV testing were provided with an HIV specimen result request voucher 
referring them to the nearest HIV counselling and testing centre to access their HIV-test 
results, while the HIV ELISA tests were done at the National Reference Laboratory (NRL) 
for confirmation. Respondents who tested HIV-positive were given counselling to be 
enrolled and followed up into HIV care and treatment services. Dried blood spot (DBS) 
specimens were collected by trained and qualified laboratory personnel through a finger-
prick. Laboratory technicians collected and labelled three cryovials and the DBS specimens 
prepared at the (HF) laboratory each day were processed and tracked by recording 
specimen information on a specimen transportation manifest from the health facility 
laboratories and on receipt at the NRL in Kigali. All samples at baseline and end of follow 
up were tested using both (enzyme immunoassay (EIA) and rapid diagnostics according to 
the national HIV testing algorithm. At HF, HIV rapid test was performed on whole blood 
obtained by venipuncture using Colloidal Gold (Shanghai Kehua Bioengineering Co., Ltd, 
China) and Determine HIV-1/2 Ag/Ab (Alere, Japan) as screening tests and Uni-Gold HIV 
test (Trinity Biotech, Ireland) as confirmatory. For the survey testing results confirmation, 
the specimens were tested at the NRL using a 4th generation (Vironostika HIV-1/2 
antigen/antibody, BioMérieux, France) as a screening and a 3rd generation (Murex 
HIV·1·2. O, Murex Biotech, Dartford, United Kingdom) HIV EIA second as a 
confirmation test in a serial testing algorithm. All blood specimens received from the field 
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were registered electronically against the respondent’s identification number using a bar-
code reader. Each specimen was assigned a unique laboratory number during the 
registration process and laboratory testing and storage in the repository was carried out 
against that number. The Emory University, Project San Francisco Lab in Kigali conducted 
the lab quality control whereby 10% positive and 5% negative specimens were re-tested 
using the same testing algorithm mentioned previously. Specimens with results discordant 
between two laboratories were resolved by repeating testing algorithm.  
The specimens were stored at -80oC prior to commencement of the testing. After testing 
was completed, results were added to the new survey data file. The unique random 
identification number originally assigned to each study respondent’s questionnaire and 
venous blood sample served as the means for merging the survey and testing files.  
Statistical analysis 
The aims of the analyses were three-fold: 1) to estimate incidence after 12 months in 
the general population; 2) to understand where new infections were occurring and who 
were incurring the new infections; and 3) to understand which variables are associated with 
new HIV incidence. Data were collected using the structured questionnaire programed in 
the PDA (Personal Digital Assistance) and back up on daily basis in Rwanda Biomedical 
Centre Servers. Data editing and cleaning was conducted including checking of range, 
structure and internal consistency. Baseline, follow up and end points data were linked 
through the Participant ID. 
Sampling weight was calculated based on a separate sampling probability for each 
sampling stage and for each sampling cluster. All analyses were weighted to adjust for the 
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complex sampling methods and non-response to achieve a national representative analysis. 
Weighted percentages were round up to the nearest whole number.  
The incidence analysis was based on the 12·611(92%) participants who were found at 
the end point. For the purpose of better understanding HIV incidence, we used simple 
descriptive statistics and the Cox Proportion Regression, with 95% confidence interval. 
Incidence was calculated per 100 person-years. All analyses were conducted in Stata 
(Version 13). Furthermore, villages where new infections occurred were mapped using 
Arch GIS (Version 10.3) to understand more where new infections occurred. To determine 
if observed villages and households with multiple infections were to be expected or not, 
we derived probabilities of events as extreme or more extreme occurring using the 
Binomial distribution. 
Role of the funding source 
The main funder (Global fund to fight HIV, TB and Malaria), contributing more than 
95% of the study budget had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. Other funders (Government of Rwanda, 
WHO/Rwanda and UNAIDS/Rwanda), provided technical guidance in areas of study 
design, data collection and analysis and report writing. The corresponding author had full 
access to all the data in the study and had final responsibility for the decision to submit for 
publication. 
Ethics 
The survey protocol was reviewed and approved by the Rwanda National Ethics 
Committee and the National Institute of Statistics of Rwanda.  
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5.4 Results 
 
Participation and HIV prevalence. 
The Rwanda HIV incidence survey had a high response rate. Out of 14·456 eligible 
participants from 6·792 sampled households, we obtained a sample of 14·222 respondents. 
This included 7·419 women and 6·803 men aged 15-59. Thus, the individual response rate 
was 98·4%. Blood samples for HIV testing were obtained for 14·140 (99·4%) of the 14·222 
respondents. 
Table 1 presents the demographic characteristics of the cohort as well as the prevalence 
estimates according to various subgroups. Of participants tested for HIV, 439 (3·0%; 95% 
[CI]: 2·6-3·4), were HIV sero-positive, which aligns very well with previous national 
prevalence estimates. It was higher among women at 270/7·678 (3·5%; 95% CI: 3·0-4·0) 
than men at 169/7·013 (2·4%; 95% CI: 2·1-2·8). HIV prevalence in urban areas was higher 
92(5·6%) compared to 320 (2·6%) in rural areas. The difference in HIV prevalence by sex 
was also present in both urban and rural areas, where it was 59 (7·2%) among women in 
urban areas compared to 33 (4·0%) among men in urban areas. Similarly, it was 194 (3·0%) 
among women in rural areas compared to 126 (2·2%) among men in rural areas. 
At the end of both follow-up visits, 12·593 out of 13·728, representing 91·7% of the 
baseline sample (excluding the participants who tested HIV-positive) participated in the 
endpoint data collection activities. By sex, the data collection activities were conducted for 
6·628 (52·6%) women and 5·965 (47·4%) men. Among completers, the mean age was 30 
years. The majority 12·120 (88%) lived in rural areas, 4·826 (38%) were single and 7·140 
(57%) were married or cohabitating. 
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HIV incidence 
Over the year of follow-up from November 5th, 2013 to November 15th, 2014; 35 cohort 
members sero-converted resulting in an HIV incidence of 0·27 per 100 person-years (95% 
CI: 0·18-0·36) in adults who had tested HIV negative at the baseline, as shown in Table 2. 
The incidence increased with age. Incidence was lowest in adults aged 26-35 years (0·21 
per 100 person-years) and highest in adults aged 46-55 years (0·38 per 100 person-years). 
The incidence rate among young people aged 16-25 was 0·24 per 100 person-years; 
however, it should be noted that 12 of the 35 cases occurred in this age group and that 19 
of 35 incident cases occurred among cohort members aged 30 or less. HIV incidence was 
higher among women than men; higher among the widowed, never married and the 
divorced relative to married couples; and was higher in urban areas relative to rural areas 
(Table 2).  
We further explored the HIV incidence relationship with other variables. Table 3 shows 
that the incidence was higher among adults aged 36-45 (aHR 4.5, 95% CI: [1.30 - 14.70]). 
Similarly, the western province was 5·9 times more likely to seroconvert (95% CI: [1.33 - 
25.28]). The HIV incidence showed urban/rural variation with higher incidence in urban 
areas (aHR 3.1 95% CI [1.28 - 6.99]. It was 10-fold higher among those that experienced 
rape or forced sex (95% CI: [1.95 - 37.73]). Contrarily, being in relationship was less likely 
associated to sero-conversion (aHR 0.2, 95% CI [0.07 - 0.52]). 
Figure 1 illustrates the map of Rwanda and distribution of new infection across the 
provinces. It also shows that with 17 infections a larger than expected number of infections 
occurring in the Western province, which does not represent a large portion of the overall 
population. A closer look at these cases finds that three villages experienced multiple 
 44 
infections. Two pairs of cases also occurred within the same house, although one was a 
pair of brothers and the other was a mother and her daughter, so these were clearly not 
couples. Based on the number of participants, number of households and the estimated 
0·27 per 100 person-years incidence rate, the probability is very low (0·0012) of observing 
two more such households. Similarly, the estimated probability of seeing two or more 
villages with three or more households with infections was 0·0001. Thus, these multiple 
cases within villages and households (accounting for nine infections) suggest that HIV 
outbreaks played a role in the spreading of HIV in Rwanda. The three villages are all 
located on the Northern shores of Lake Kivu, a large lake making up much of Rwanda’s 
Western border. Those infected in the three villages tended to be farmers and there was no 
indication that any of them were migrant workers, such as fishermen. More generally, the 
results show that 60% of the new infections were in women while 40% were in men. Half 
of all new infections were among the never married (51·0%) while one third (33·6%) came 
from those in union. Also, though the divorced and widowed had higher incidence, they 
only contributed 15·43% of the overall HIV incidence.  
5.5 Discussion 
 
The first Rwanda HIV household incidence prospective survey suggests that 
remarkable improvements in the control of HIV have been made. However, new infections 
still occur with an estimated incidence of 0.27 infections per 100 person-years. For a long 
time, HIV incidence in Rwanda has been estimated using mathematical models and this 
research provides informative insights into the results of these models and the current state 
of the HIV epidemic in Rwanda.  
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The incidence in Rwanda is comparatively low in a region where wide variations occur 
across groups and demographics. It is, however, somewhat larger than may be expected in 
a country with a relatively stable prevalence of 3%. Other nearby countries have reported 
high incidence within different populations and at different times. This international 
geographic heterogeneity is consistent with findings from a recent systematic review that 
reported incidence ranged from 0·8-7·5% in Tanzania, 2·3-16 % in Kenya, 1·8- 17% in 
South Africa, and 0·5-9% in Uganda (Braunstein, van de Wijgert & Nash 2009). In the 
past, the incidence of HIV in Rwanda may have been underestimated by mathematical 
models by more than 50%; the estimates provided by this survey therefore provide more 
accurate data for future planning. According to EPP Spectrum model of UNAIDS (Stover 
et al. 2014; Stover, Brown & Marston 2012), the estimated incidence of HIV in Rwanda 
by 2014-2015 was 0·08% CI [0·05- 0·14%] and estimated number of new infections among 
adults and children was 7·342 [5·379–9·279] (MoH/RBC-Rwanda 2015a). These estimates 
were used by the national HIV program in strategic planning activities. However, questions 
of large confidence intervals and uncertainty of the model assumptions were regular 
discussions between country Monitoring and Evaluation team and the UNAIDS reference 
group (Stover, Brown & Marston 2012) . With these new results, suggesting slightly more 
than 14·000 new infections annually (0·27% incidence per 5·392·209 projected population 
aged 15- 49 years); the model estimates will likely be better adjusted to provide more 
accurate data for decision making. There is a necessity for follow-up surveys to determine 
the accuracy of our current findings. Given the coverage of ART in Rwanda, and relatively 
low HIV-associated mortality, this somewhat high incidence rate seems potentially 
inflated. Although youth did not have discernibly higher incidence, they make up a large 
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portion of Rwandan society and as a result account for most new infections. Efforts aimed 
at single young adults may help curb the current HIV incidence.  
The incidence was largely driven by young adults and singles that account for more 
than half of all infections. This is probably due to low condom use among youth (51·1%), 
relatively low comprehensive knowledge (60%) about HIV among this particular group 
aged 14-25 (NISR-Rwanda 2014) . These results are particularly concerning given that 
HIV is a chronic disease that requires lifelong treatment. Another potential driver of 
incidence were local outbreaks. As noted, 26% of the seroconversions occurred among 
persons selected in three villages. We could not correlate the origin of the infection from 
individuals in those villages. Specifically, none appeared to have been migrant workers, 
none appeared to have engaged with sex workers and none appeared to be in discordant 
couples. Outbreaks are likely to be caused by acute infections, so these results possibly 
indicate that multiple sexual partnerships among young rural Rwandans is higher than 
reported in previous studies and that this plays a role in the spread of HIV infection in rural 
areas where condom use was also reported very low (NISR-Rwanda 2014).  
We also noted that the HIV incidence was higher among adults in urban than in rural 
areas that stresses the importance of geographical locations to HIV dynamics. This 
observation has also been observed across the sub-Saharan African region (Braunstein, van 
de Wijgert & Nash 2009; MoH-Uganda 2004). The trend towards higher incidence in urban 
settings and the shift towards a growing urban population will require that we be extra 
vigilant moving forward with HIV care in urban settings. In South Africa, adults having 
multiple sexual partners had also higher HIV incidence (2·2%) compared to those who 
reported only one partner (1·4%) (Zuma et al. 2016). Previous estimates suggested that 
 47 
most heterosexual HIV transmission in urban Zambia and Rwanda takes place within 
married and cohabiting couples (Dunkle et al. 2008); however, the risk of getting HIV is 
likely the result of extra marital relationships. Such a trend was not observed in our study; 
however, we did observe higher incidence among widowed, never married and divorced 
persons and these are more likely to have different casual partners than stable couples.  
Despite the evidence that male circumcision reduces the susceptibility to HIV (Bailey et 
al. 2007) we did not find a significance difference between circumcised and non-
circumcised men.  
There are strengths and limitations to consider in our analysis. This is the largest HIV 
household prospective incidence survey ever conducted in Rwanda, with high participation 
and retention rates. It enrolled a robust sample size weighted at national and provincial 
levels. The first limitation to this study is the small number of sero-conversions, which 
limited our ability to estimate risk factors with greater certainty and to adjust for 
confounding variables within analyses of risk factors. Second, because of a low number of 
infection events, it is possible that our study is biased by temporal trends that we were 
unable to examine in any post-hoc analysis. Follow-up incidence surveys will be necessary 
to ensure robust policy decision-making. Third, by only testing at the end of the year, it 
was not possible to discern the time of infection and as such estimate hazard ratios and 
other measures that could have been more informative. Additionally, though we conducted 
precise testing steps to eliminate false positives, recent protocols suggest a third high 
specific EIA serial confirmatory test. Fourth, although the retention rate was quite high, 
response rates to certain behavioural questions were relatively low. This at times made it 
difficult to use this information to better comprehend the results of this study. Fifth, given 
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the low number of infections, exploring differences between characteristics of infected and 
uninfected individuals is challenging and should be interpreted with caution. It is possible 
that not all participants answered all questions truthfully, particularly as questions relate to 
sexual behaviour.  
Despite the progress made in HIV control globally, more data are needed to understand 
precisely the magnitude of the HIV epidemic in specific countries. This survey 
demonstrated that HIV new infections have been underestimated in previous measures 
using mathematical models. Reaching 90-90-90 global targets will require both resources 
and evidence for better decision making. As Rwanda has committed to ending AIDS by 
2030, this study allows greater precision in decision-making. 
5.6 Panel: research in context 
 
Evidence before this study 
Rwanda has a mature HIV epidemic with a stable 3% prevalence in the adult population 
for the past decade. Its HIV program has been successful at reaching impressive goals with 
respect to the HIV continuum of care and providing ART and care to those eligible. Despite 
a strong surveillance program, Rwanda has depended on mathematical models and 
programs to estimate the HIV incidence. We searched in Pubmed for studies containing 
the search terms “HIV incidence”, “Household survey” and “longitudinal cohort” up to 
January 15th, 2017 and found only one study (Justman et al. 2017) on Swaziland HIV 
incidence measurement over 6 months’ cohort follow up. We also found UNAIDS 
spectrum modelling from Rwanda for year 2015 estimating HIV incidence of 0·15 per 100 
person-years (UNAIDS, Geneva aids info 2015). 
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Added value of this study 
This study provides a nationally representative estimate of incidence as well as insights 
into the factors influencing incidence that was less than twice the 2015 UNAIDS EPP 
Spectrum estimates. The results were higher than those provided by mathematical models. 
The study also showed that non-married young adults were among the drivers of HIV 
incidence. Data also suggest that the nature in which new infections occur also involve 
outbreaks. 
Implications to all available evidence 
With increasingly complex HIV programs, better information is required for decision 
makers. Nationally representative prospective incidence surveys are feasible and could 
provide vital information to other HIV programs. Investing in primary data collection, such 
as incidence studies will likely have profound implications on modelling the epidemic. 
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Table 1: Patients characteristics and prevalence results from the Rwanda HIV 
incidence survey of 2013-2014 
Background characteristics Baseline characteristics Prevalence 
N (Weighted) %  N (Weighted) % 
Overall  14782 100 14691 3·0 
Age group       
15-19 3420 23·1 3407 0·4 
19-24 2453 16·6 2435 1·0 
25-29 2458 16·6 2437 2·1 
30-34 2143 14·5 2125 4·4 
35-39 1478 10·0 1469 5·0 
40-44 1135 7·7 1130 7·2 
45-49 987 6·7 982 6·4 
50-54 407 2·8 405 6·0 
55-59 301 2·0 300 4·8 
Gender     
Female 7716 52.2 7678 3.5 
Male 7066 47.8 7013 2.4 
Marital status      
Single  6331 42·8 6281 1·1 
Married/Cohabiting  7598 51·4 7561 3·7 
Divorced/Separated /Widowed 853 5·8 849 11·1 
Residence      
Urban 1927 13·0 1887 5·6 
Rural 12855 87·0 12804 2·6 
Province        
East 3373 22·8 2360 1·9 
North 2362 16·0 3738 2·6 
South 3739 25·3 3366 2·2 
West 3286 22·2 3260 3·1 
Kigali city 2022 13·7 1967 6·1 
Education level      
No education 2160 14·6 2150 4·0 
Primary 9426 63·8 9387 2·9 
Vocational 269 1·8 268 5·6 
Secondary 2542 17·2 2518 2·1 
Highest education 385 2·6 368 3·1 
Religion      
Other 461 3·1 453 6.2 
Catholic 6511 44·0 6482 2.5 
Protestant/Adventists 7479 50·6 7428 3.1 
Muslim 332 2·2 328 6.9 
Wealth index      
Lowest 2696 18·2 2684 3.1 
Second 2842 19·2 2836 2.6 
Middle 2813 19·0 2807 2.7 
Fourth 3128 21·2 3109 2.9 
Highest 3302 22·3 3255 3.6 
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Table 2: HIV incidence by selected demographic characteristics and risk factors in 
the Rwanda HIV incidence survey cohort of 2013-2014 
 
Demographic characteristics 
N  
(Weighted) 
HIV Incidence [95% CI] 
(per 100 person years) 
Overall 13056 0·27 [0·18 – 0·36] 
Age group     
16-25 5097 0·24 (0·11 – 0·37) 
26-35 4163 0·21 (0·07 – 0·35) 
36-45 2260 0·37 (0·12 – 0·62) 
46-55 1270 0·38 (0·04 – 0·72) 
56+ 266 0·36 (0·00 – 1·08) 
Sex     
Male 6182 0·21 (0·10 – 0·32) 
Female 6874 0·32 (0·19 – 0·45) 
Province     
North 2249 0.09 [0.03- 0.22] 
South 3432 0.20 [0.05 - 0.37] 
East 3000 0.14 [0.02 - 0.27] 
West 2929 0.57 [0.31- 0.87] 
Kigali 1409 0.40 [0.05 - 0.69] 
Marital status     
Single 5007 0·35 (0·19 – 0·51) 
Married 5266 0·14 (0·04 – 0·24) 
Cohabiting 2132 0·20 (0·01 – 0·39) 
Divorced 331 0·36 (0·00 – 1·01) 
Widowed 320 1·30 (0·06 – 2·54) 
Residence     
Rural 11636 0·22 (0·13 – 0·31) 
Urban 1420 0·65 (0·23 – 1·07) 
Had paying sex in the last 12 months     
No 13001 0·25 (0·16 – 0·34) 
Yes 55 3·67 (0·00 – 8·64) 
Circumcision status     
Not circumcised 4715 0·17 (0·05 – 0·29) 
Circumcised 1464 0·34 (0·04 – 0·64) 
Experienced rape/forced sex in the last 12 
months 
    
No 8160 0·31 (0·19 – 0·43) 
Yes 58 3·32 (0·00 – 7·93) 
Had STIs during last 12 months     
No 12480 0·25 (0·16 – 0·34) 
Yes 575 0·55 (0·00 – 1·15) 
Currently pregnant     
No 6355 0·31 (0·17 – 0·45) 
Yes 458 0·22 (0·00 – 0·65) 
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Table 3: Bivariate and Multivariate analysis 
  Bivariate Multivariate 
 HR [95% CI] aHR [95% CI] 
Overall     
Age group     
16-25 (Ref) 1·0 1·0 
26-35 0·8 [0·36-1·99] 2·0 [0·78 - 5·14] 
36-45 1·4 [0·57-3·33] 4·49 [1·30 – 14·70] 
46-55 1·3 [0·45-3·55] 3·70 [0·94 – 14·60] 
Sex     
Male (Ref) 1·0 1·0 
Female 1·4 [0·69-2·66] 1·14 [0·56 – 2·36] 
Province     
North (Ref) 1·0 1·0 
South 2·3 [0·49-11·25] 2·3 [0·48 – 11·06] 
East 1·5 [0·28-8·29] 1·5 [0·27 - 8·05] 
West 6·5 [1·49-27·97] 5·9 [1·33 – 25·28] 
Kigali 4·1 [0·79-21·06] 1·7 [0·31 – 10·03] 
Marital status     
Single (Ref) 1·0 1·0 
Married/ Cohabitating 0·4 [0·19-0·82] 0·2 [0·07 – 0·52] 
Divorced 0·8 [0·11-6·95] 0·3 [0·04 – 2·89] 
Widowed 3·3 [1·11-9·63] 0·9 [0·22 – 4·04] 
Residence     
Rural (Ref) 1·0 1·0 
Urban 2·9 [1·37-5·96] 3·1 [1·28 – 6·99] 
Experienced rape/forced sex in 
the last 12 months 
  
  
         No (Ref) 1·0 1·0 
         Yes 10·9 [3·45-59·88] 10·2 [1·95 – 37·73] 
 
 
 
 
 
 
  
 53 
Figure 1: Distribution of new HIV infection across Rwandan provinces   
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CHAPTER 6. HIV CONTINUUM OF CARE, PREDICTING LOST 
TO FOLLOW UP, AND MORTALITY IN RWANDA. 
 
6.1 Summary 
 
In order to understand the disengagement and defaulting from HIV care in Rwanda, 
we need to understand the different possible pathways from diagnosis to viral 
suppression, leakage and the possibility of returning into care at different time points. 
This phenomenon known as churning in and out of HIV care has been examined 
previously in Rwanda (Nsanzimana et al. 2014). Different reasons for leakage from care 
can be due to lost to follow up or mortality and the main predictor has been CD4 count. 
We conducted two studies to analyse the HIV continuum of care and predictors of 
attrition using routinely collected national data from multiple sources.  
The findings summarised under this chapter were published as part of this PhD 
project preparatory work: 
“HIV Care Continuum in Rwanda: A cross-sectional analysis of the national 
programme Published in The Lancet HIV 2015, Volume 2, No. 5, e208–e215, May 2015 
http://dx.doi.org/10.1016/S2352-3018(15)00024-7” 
 
and  
 
“Effect of baseline CD4 cell count at linkage to HIV care and at initiation of 
antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: A nationwide 
cohort study published in The Lancet HIV, Volume 2, No. 9, e376–e384, September 2015 
https://doi.org/10.1016/S2352-3018(15)00112-5” 
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6.2 Introduction 
 
The scale-up of antiretroviral therapy (ART) for HIV treatment remains among the 
largest pharmacological interventions of all time (WHO/UNAIDS/UNICEF 2008, 2013). 
The benefits of ART extend beyond the individual, decreasing the likelihood of sexual 
transmission among those with undetectable plasma viral loads, as demonstrated by the 
HIV Prevention Trials Network (HPTN) 052 study (Cohen et al. 2011), and other 
observational and modelling analyses (Granich et al. 2009). In many regions, and, in 
particular, Sub-Saharan Africa, programs such as the US President’s Emergency Plan for 
AIDS Relief (PEPFAR) (PEPFAR 2012) and the Global Fund to Fight AIDS, Tuberculosis 
and Malaria (GFATM) have increased access to treatment by more than 100-fold in less 
than a decade (UNAIDS 2012a). Despite the progress that has been made, HIV/AIDS 
continues to be a leading cause of death in Sub-Saharan Africa, with an estimated 1.2 
million attributable deaths in 2011 (WHO 2012).  
CD4 T-cell counts at the time of initiation of antiretroviral therapy (ART) is among the 
strongest predictors of mortality in patients with HIV (Sterne, Hernan & Ledergerber 2005; 
May, Sterne & Costagliola 2006; Mills, Bakanda & Birungi 2011; Braitstein et al. 
2006).The World Health Organization (WHO) guidelines, 2013 recommend that ART be 
initiated for all people living with HIV who have CD4 cell counts of 500 cells/mm3 or less, 
all HIV-positive pregnant women, all HIV-positive children younger than five years of age, 
all individuals with concomitant hepatitis B and chronic liver disease, and active 
tuberculosis, irrespective of CD4 cell count. However, despite these changes in global 
clinical guidance, CD4 counts at linkage to care and at ART initiation in Sub-Saharan 
Africa have not appreciably increased over the past decade (Siedner et al. 2015).  
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Previous evaluations of the prognostic value of CD4 cell counts on the survival of 
people living with HIV in sub-Saharan Africa are generally limited to an era with poor 
ART uptake, to small sample sizes and relatively low CD4 cell counts at ART initiation 
(Fox, Sanne & Conradie 2010; Gallant, Mehta & Sugarman 2013; May, Boulle & Phiri 
2010; Mills, Bakanda & Birungi 2012); they have also been limited to evaluating the 
prognostic value of CD4 cell counts at ART initiation rather than also at clinical linkage 
with care. These and other studies concur that lower CD4 cell counts, particularly at 
initiation of ART are associated with worse survival (Cain, Logan & Robins 2011; Mills, 
Bakanda & Birungi 2012). Earlier linkage to clinical care may also have important benefits 
with respect to survival because it provides clinical and social support that may include 
health education, anti-infective and nutritional support prior to initiation of ART. Given 
that late ART initiation is most often the result of late clinical linkage and that the 
mechanisms by which clinical linkage and ART initiation affect survival are 
distinguishable, there is a need to understand the effect of CD4 cell counts at ART 
initiation, but also at linkage to care.  
Among Sub-Saharan African countries, Rwanda has made remarkable progress 
towards rebuilding a shattered health system in the two decades following the 1994 
genocide (Farmer et al. 2013; Binagwaho et al. 2014). Rwanda began its ART scale-up in 
2004 and by 2007 Botswana and Rwanda were the first two countries in Sub-Saharan 
Africa to reach universal ART coverage (defined as having ≥80% of eligible patients on 
treatment according to current guidelines). The Rwandan Ministry of Health has been 
consistently raising the CD4 cell count threshold for ART initiation aiming for treating all 
people living with HIV regardless of CD4 count (Nsanzimana 2014).  
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However, the successful delivery of ART to achieve universal coverage cannot be 
accomplished in the absence of a thoughtful and robust system of monitoring and 
evaluation that helps guide implementers through overcoming programmatic and logistical 
barriers. For example, poor engagement in care by HIV-positive individuals substantially 
limits the effectiveness of expanded access to ART.  
Using the cascade of HIV care as a framework, the following two analyses aim to 
evaluate the Rwanda national HIV program by quantifying the engagement of HIV-
positive individuals in care for the year 2013 and report factors associated with mortality 
in the ART and pre-ART stages and examine the predictive value of baseline CD4 cell 
count at clinical linkage to care and at ART initiation on mortality among HIV positive 
patients in Rwanda. 
6.3 Methods 1: Quantifying disengagement in the HIV Continuum of care  
 
Framework  
The conventional model of the cascade of care fails to account for the cyclical aspects 
of engagement and re-engagement in care. Therefore, we extended this framework to better 
capture the multiple entries and exits of HIV-positive patients engaging in care in Rwanda. 
Figure 1 displays this re-conceptualized framework. The stages of care include: being 
diagnosed, linking to care, initiating pre-ART, initiating ART and becoming virally 
suppressed. Additional stages may include being adherent to ART and being ART eligible. 
Currently, ART adherence is not assessed within the Rwandan national HIV-surveillance 
system, so it was not considered in these analyses. We do account for ART eligibility, but 
do not include it as a stage of the cascade.  
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Study Setting and Sources of Data 
The prevalence of HIV in Rwanda remains stable at approximately 3.0% of the adult 
population (NISR-Rwanda 2014).The Ministry of Health (MoH), using the UNAIDS 
mathematical modelling program Spectrum (USAID 2009), estimates that there were 
approximately 252,670 HIV-positive Rwandans in 2013. 
As no single data source can inform the entire cascade of HIV care in Rwanda, our 
study collated four principle data sources to quantify engagement in HIV care in Rwanda: 
the TRACnet database (Nsanzimana et al. 2012), electronic medical records (EMR), the 
IQ Charts, and an unpublished MoH study investigating linkage from diagnosis. The MoH 
study investigated 8598 newly diagnosed patients at 20 health facilities from 2010 through 
to 2011. Each source of data thus complements the other to capture each step in the cascade 
of HIV care in Rwanda.  
The primary data source was the TRACnet database. Launched in 2003, TRACnet 
is a nation-wide surveillance database specific to HIV care. It captures data on all patients 
that are linked to HIV care; these data are aggregated at the health facility level and 
collected monthly. Data are captured at all of the over 500 health facilities providing HIV 
care in Rwanda, of which 465 provide ART delivery. Data are collected at the individual 
level prior to aggregation and TRACnet IDs are monitored to minimize double counting 
across clinics. We used TRACnet data for the year 2013, capturing 176,225 patients, to 
inform the Pre-ART and ART stages of the cascade of HIV care.  
The secondary data source was the EMRs. Rwanda is currently in the process of 
converting to a national database of electronic medical records for all citizens, irrespective 
of HIV status. At present, these data remain stored locally at the health facility, rather than 
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centralized. Our team visited ten representative health facilities across all five provinces to 
extract EMR data on all HIV patients at those establishments (two facilities per province). 
The ten facilities captured individual-level data on 21,995 patients up to February 2014. 
These data capture many variables, including viral load measures, dates of diagnosis and 
linkage to care. We used EMR data to inform the viral suppression stage of the cascade of 
HIV care and transitions from and to that stage. 
The final principal data source used for this analysis was the IQ Charts, a database 
of health indicators for all HIV patients receiving care at 110 of the 465 (24%) health 
facilities providing ART in Rwanda. These data are individual-level data that pertain to 
87,613 patients spanning from 2004 – 2011 (approximately 50% of HIV patients receiving 
care). Health indicators include CD4 measurements, WHO disease stage, linkage date, 
dates of ART initiation and exit dates (including transfers, loss to follow-up and death). 
We used IQ charts to inform the probabilities of transitions between stages, as well as to 
draw inferences on mortality and loss to follow-up.  
Variables and Definitions 
Mortality and loss to follow-up (LTFU) were ascertained and recorded within 
hospital medical records and include deaths that occur outside of the health center setting. 
Family members and community often follow up with healthcare providers on unobserved 
deaths, and there are minimal deaths that remain unaccounted for among patients LTFU. 
Loss to follow-up is defined as failing to engage in care for three consecutive months. All 
pre-ART patients are prescribed monthly co-trimoxazole, and over the entire study period 
all patients are expected to see a healthcare provider and pick-up medication on a monthly 
basis.  
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To model factors associated with LTFU and mortality, we included age, sex, marital 
status, method of diagnosis (ANC, voluntary counseling and testing [VCT] or other), CD4 
cell count at enrolment and at ART initiation, TB status, WHO disease stage, whether the 
health facility was religious, the type of health facility (health center or hospital) and the 
staff to patient ratio. 
Analyses 
We first calculated the proportions of individuals at each stage and the transition 
probabilities between stages of the cascade of HIV care. To determine factors associated 
with mortality, we fit Cox proportional hazards regression models, one for the pre-ART 
stage and another for the ART stage. Both CD4 cell counts and age were adjusted between 
models all other variables were baseline variables at enrolment. As three of the variables 
were at the facility level, a random effect for the health facility was added to create a 
hierarchical model.  All tests were two-sided and conducted at the 0.05 significance level. 
All analyses were conducted in SAS 9.3 (Cary, North Carolina) and R 3.1.1 (Vienna, 
Austria). This study was approved by the Rwanda Health Research Committee. 
6.4 Methods 2: Effect of CD4 cell count at enrolment and ART initiation on loss 
to follow-up and mortality 
 
Study Design and Participants 
This study was based on patient-level data sources of routinely collected data used 
by RBC for the purpose of research and surveillance: the IQ Charts database and EMR. 
Both IQ Charts and EMR contain demographic and clinical characteristics as well as 
longitudinal, HIV-specific clinical factors and vital statistics on HIV-positive patients 
enrolled in care. The records contain data on both pre-ART and ART periods of care. This 
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database contains patient information on all HIV-positive patients from 110 health 
facilities, representing 25% of ART providing health facilities in Rwanda. The sampled 
health facilities slightly over-represent rural settings; however, the patient sample appears 
to be representative as it is comparable to the overall HIV population as reported by 
TRACnet, the national surveillance database, with respect to mortality, loss to follow-up 
and other demographic and clinical variables.20 We included patients aged 15 years or older 
with a known follow-up time (i.e., did not enter and exit the program on the same day) and 
who were linked to care or initiated ART between January 1997 and April 2014. There 
were fewer than 100 patients who initiated prior to 2003. For the first data set we 
additionally required that patients have a known ART initiation date (n = 345 excluded). 
The resulting dataset contains 50,147 patients having initiated ART of the estimated 
205,000 persons living with HIV in Rwanda (Nsanzimana, Kanters, Remera, Forrest, et al. 
2015).20 The second dataset, not restricted to patients having initiated ART, included 
72,061 patients. 
Outcomes 
The analyses were conducted using mortality and follow-up time. Follow-up time 
was measured from time of ART initiation to study exit for the primary analysis and from 
linkage to HIV care to study exit in the secondary analysis. Study exit was defined by one 
of four outcomes: end of study period, death, loss to follow-up, and transfer out to facilities 
outside of the study. Mortality data were ascertained in health facilities and through home 
follow-ups. Demographic variables considered for this analysis included sex and age at 
ART initiation (categorized by decade of life). Clinical variables included CD4 cell count 
(<50, 50-99, 100-199, 200-349, 350-499, 500+ cells/mm3, unreported) at ART initiation, 
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year linkage, WHO disease stage (I, II, III, IV, or unknown), TB screening (positive, 
negative or unknown) and reason for diagnosis. Methods of diagnosis included voluntary 
counseling and testing (VCT), prevention of mother to child transmission (PMTCT) and 
other means; the other category includes provider initiated testing (PIT), which began in 
2010, HIV associated hospitalizations, and testing initiated by indication of comorbidities. 
Year of linkage was dichotomized into a later era (2008 or later) and an early era (prior to 
2008). This marks a distinct turning point in testing availability, patient behavior and ART 
guidelines (Nsanzimana, Remera, Kanters, Chan, et al. 2015). Outcomes were stratified by 
CD4 cell count at time of linkage to HIV care. Both CD4 cell count variables included an 
unreported category, 3825 at ART initiation and 667 at linkage. CD4 cell counts at ART 
initiation was set to missing if measured more than six months prior to ART initiation or 
more than two weeks following initiation. Lastly, we created a composite variable 
specifying whether patients had an indication to initiate ART other than CD4 cell count 
status. These reasons included having a WHO disease stage of III or IV at linkage to care, 
a positive TB screen, hospitalization as the reason for ART initiation or initiating ART 
through a prevention of mother-to-child transmission program. Figure 1 summarizes the 
reasons for patients starting at CD4 cell counts of ≥500 cells/mm3. 
Statistical Analysis 
We described data sources using summary statistics. The first analysis consisted of 
evaluating the association between CD4 cell counts at time of ART initiation and mortality, 
with a particular emphasis on the 500 cells/mm3 and 350 cells/mm3 CD4 cell count cut-
offs. The second analysis evaluated the association between CD4 cell counts at time of 
linkage to care and mortality and related this to CD4 cell counts at ART initiation. Both 
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analyses used Cox proportional hazard regression models. In the first analysis, the 
composite indication variable was used as an effect modifier to CD4 cell count at ART 
initiation, with initiating between 200-349 cells/mm3 without known additional indications 
for ART initiation as the reference category. The second analysis used similar models with 
CD4 cell count at linkage to care rather than CD4 cell count at ART initiation. In both 
models, time was used as an effect modifier as well. Models were fit to determine whether 
time was an effect modifier to all variables; however, the model with the triple effect 
modification between CD4, indication and time and no other modification had the best fit. 
All conditions for survival analysis were verified using tests based on the Schoenfeld 
residuals and all assumptions were met (Grambsch & Therneau 1994). Transfers are 
vigilantly recorded and verified in Rwanda and thus should be viewed as a non-informative 
censoring mechanism. For loss to follow-up a comparison of propensity score distributions 
for mortality between those lost to follow-up and those not suggested non-informative 
priors. Those lost to follow-up tended to be young and healthy.  
All significance tests were 2-sided, and p-values of less than 0.05 were considered 
statistically significant. All analyses were performed using SAS software version 9.3 (SAS 
Institute, Cary, North Carolina) and R version 3.1.1 (Vienna, Austria). 
 
6.5 Results 1: Quantifying disengagement in the HIV Continuum of care  
 
The complete results of our analysis on the cascade of HIV care in Rwanda are 
summarized in Table 1a that accompanies Figure 1a. Table 1a captures both the statistics 
of interest and identifies the data source for these statistics. The three following sub-
sections describe and expand upon both.  
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Proportions of Patients at Each Stage of Cascade of HIV Care 
The estimated number of HIV-positive individuals in Rwanda in 2013 was 252,670. 
This serves as the initial state for analyses related to the cascade of HIV care. Statistics in 
the middle of the cascade had the strongest evidence because they were observed, rather 
than estimated, through the TRACnet system. They are extremely precise and many steps 
were taken to minimize bias. Among HIV-positive Rwandans, 176,174 were retained in 
either pre-ART or ART care in 2013, accounting for 69.7% of all HIV-positive Rwandans. 
Further down the cascade, 129,405 (51.2%) HIV-positive individuals either initiated or 
already had initiated ART in 2013.  
Statistics at the extremities of the cascade are estimated. Until recently, there was a 
single testing unit for viral monitoring within Rwanda, limiting the ability to monitor viral 
loads. Within the EMR database, 82.1% (95% confidence interval [CI]: 80.7-83.4%) of 
patients with viral loads were virally suppressed using a cut-off of 40 copies/ml (n=3,066). 
This translates into an estimated 106,371 virally suppressed HIV-positive individuals on 
ART (42.1% of all HIV-positive Rwandans) in 2013. At the front end of the cascade of 
HIV care, data on linkage to care are not captured by TRACnet. Using IQ charts, we 
estimated the percentage of patients that fail to be retained in care following linkage and 
those that die shortly after linkage (C2 and D1 in Table 1). Adding these values to the 
number of HIV-positive patients retained in care, we estimate that 183,515 (72.6%) HIV-
positive individuals had linked to care. This excludes persons who engaged in care and 
died prior to 2013. Therefore, the percentages of HIV-positive individuals at each step of 
the 2013 cascade of HIV care were: 73% linked to care, 70% retained in care, 55% ART-
eligible, 51% on ART and 42% virally suppressed. 
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Progression Towards Viral Suppression on ART 
At linkage to HIV care, following staging, 70.4% of patients transitioned to pre-
ART. Patients eligible for treatment at linkage were more often eligible due to low CD4 
cell counts or opportunistic infections. Approximately 40% of accelerated ART initiation 
was through ANC according to 2011 data. In determining the percentage of patients 
eligible at linkage that entered Pre-ART, we used a one-month cut-off and found that 66% 
of patients that were ART-eligible at linkage initiated within a month. Healthcare providers 
suggest that many of the 34% of patients that are not put on treatment within a month can 
be explained by the fact that patients with co-infections (e.g., TB) are first placed on 
medications for the co-infection and stabilized prior to initiating ART. Data on this process 
do not exist at present. Using Spectrum, RBC estimates that 93% of all eligible patients 
were on ART, in accordance with 2013 Rwanda ART guidelines. 
Exiting and Other Transitions 
Among HIV-positive Rwandans receiving care, 304 (0.6%) patients died while in 
pre-ART and 1255 (1.0%) patients died while in ART. The mortality rate is lower in the 
ART period (Table 1a: D2 and D3) because there are many more people on ART and the 
length of time in pre-ART is often short. Loss to follow-up, at 3.9%, was higher within the 
pre-ART period than the ART period (2.2%), and even lower among patients that were 
virally suppressed (estimated at 1%).  
The number of patients returning to care was 40% as large as the number of patients 
lost to follow-up in 2013, implying that the actual proportion of patients disengaged from 
care was actually lower than the 3.9% and 2.2% reported for Pre-ART and ART, 
respectively. Moreover, though lost to follow-up was larger in pre-ART than ART, rates 
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of return were higher in ART than pre-ART (Table 1: B4 and B5), suggesting that some 
disengage from pre-ART only to come back in time for ART. 
Factors Associated with Mortality 
Figure 2a and 3a presents the results of the Cox-proportional hazards regression 
models exploring the factors associated with mortality and LTFU within HIV care. Late 
initiation had an increasingly larger risk for mortality. None of the structural variables were 
significantly associated with mortality. More deaths were observed in hospitals with better 
capacity. However, this is due to confounding by indication because those centers with the 
best capacity (most trained medical staff per patient) are those to which the individuals 
with the poorest health are sent. Social support and being a woman were both protective in 
the Pre-ART period. Being diagnosed through a method other than VCT or ANC increased 
the risk of mortality because this category includes those diagnosed through 
hospitalization. Finally, the only age category that stood out was children, who had a higher 
mortality risk than all other age groups except those aged 50 years and older. Associations 
were similar in the ART time period compared to the Pre-ART time period. Children no 
longer stood out as having high mortality and diagnosis methods no longer appeared 
statistically significant. For LTFU, younger aged patients and male gender was associated 
with LTFU at both pre-ART and on ART.  
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Table 1a: HIV care cascade 2013 statistics and transitions with data sources. 
Label Description Statistic Data Source 
Stages of the Cascade of HIV Care 
N1 Estimated size of HIV positive 
population 
252,670 (100%) MOH estimate 
N2 Number of total diagnoses Unknown None 
N3 Number of patients that have linked 
to care 
183,515 (72.6%) TRACnet, not 
directly measured. 
N4 Number of patients currently linked 
to care. 
176,225 (69.7%); 
Currently 46,820 
currently in Pre-ART 
TRACnet, directly 
measured 
N5 Number of patients in pre-ART 58,182 (23.0%) of 
which 46,820 (18.5%) 
at the end of 2013 
TRACnet, directly 
measured 
N6 Number of patients initiating ART 129,405 (51.2%) TRACnet, directly 
measured 
N7 Number virally suppression 106,371 (42.1%) EMR estimate* 
Progressing along the Cascade of HIV Care 
A1 From diagnosis to linkage to care 50% of diagnosed 
cases linked to within 3 
months and 32.6% 
were staged (see A5). 
RBC/MOH Study 
A2 From linkage to care to pre-ART 
initiation 
70.4% of patients who 
linked to care initiated 
pre-ART. 
IQ Charts 
A3 From pre-ART to ART 93.1% of eligible 
patients on ART 
RBC estimate 
using Spectrum 
A4 From ART to viral suppression 82.2% of ART patients 
achieve viral 
suppression 
EMR estimate* 
A5 From diagnosis, directly to ART 
through antenatal care 
16.7% of diagnosed 
cases linked to ART 
through ANC 
RBC/MOH Study 
A6 From linkage to ART in 2013 26.5% initiated ART 
within one month of 
linkage 
IQ Charts 
Churning, exiting and re-entering care 
B1 Loss to follow-up at pre-ART 3.9% (2247) of those in 
pre-ART lost to follow-
up 
TRACnet, directly 
measured 
B2 Loss to follow-up on ART 2.2% (2847) of those 
on ART lost to follow-
up, 1850 unsuppressed. 
TRACnet, directly 
measured 
B3 Loss to follow-up virally suppressed 1.0% (997) of virally 
suppressed patients on 
ART 
EMR estimate 
B4 Returning to pre-ART 13.7% of those lost to 
follow-up in pre-ART 
or later return to pre-
ART 
TRACnet, ratio of 
measurements 
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B5 Returning to ART 26.3% of those lost to 
follow-up in pre-ART 
or later return to ART 
TRACnet, ratio of 
measurements 
Other Pathways 
C1 Loss to follow-up at diagnosis 50% of diagnosed 
cases did not link 
within 3 months of 
diagnosis 
RBC/MOH Study 
C2 Loss to follow-up at linkage to care 3.7% of those linked to 
care lost after first visit 
IQ Charts 
Mortality 
D1 From linkage to care to death 0.46% die before being 
retained in care 
IQ Charts 2004-
2011 
D3 From pre-ART to death 9.7 deaths per 1000 
person-years 
TRACnet, 2013 
D3 From ART to death 6.5 deaths per 1000 
person-years 
TRACnet, 2013 
and EMR 2006-
2014 
D4 From viral suppression to death 3.6 deaths per 1000 
person-years 
EMR 2006-2014 
MOH: Ministry of Health; RBC: Rwanda Biomedical Center; EMR: Electronic Medical Records; ANC: 
Antenatal care. *Based on suppression among those with viral loads 
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Figure 1a: The cascade of HIV care through multiple trajectories 
 
 
Legend: Statistics corresponding to each label (e.g. A1) are provided in Table 1. Other pathways (grey) 
include delayed engagement and virological failures. This is a simplification, as the red exit lines include 
individuals that will never re-engage in care and the grey entry lines include symptomatic persons who will 
engage in care without ever testing. 
 
 
 
 
 Figure 2a: Factors associated with mortality within the pre-ART and ART stages of the cascade 
of HIV care in Rwanda 
 
Legend: VCT: voluntary counseling and testing; PMTCT: prevention of mother to child transmission. 
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Figure 3a. Factors associated with loss-to-follow-up within the pre-ART and ART periods of the 
cascade of HIV care in Rwanda 
 
Legend: VCT: voluntary counseling and testing; PMTCT: prevention of mother to child transmission. 
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6.6 Results 2: Effect of CD4 cell count at enrolment and ART initiation on loss to 
follow-up and mortality 
 
This analysis is based on data from 50,147 HIV-positive patients who initiated ART and 
72,061 patients who were linked to care. Table 1b presents the demographic and baseline clinical 
characteristics of patients included in the primary and secondary analyses. The median age of 
patients at linkage to HIV care was 36 years (Interquartile range [IQR]: 30-43 years) and the 
median age at ART initiation was 37 years (IQR: 31-45 years). The median CD4 cell count at 
linkage to care was 256 cells/mm3 (IQR: 145-383 cells/mm3) and 233 cells/mm3 (IQR: 139-316 
cells/mm3) at ART initiation. Figure 1b shows the characteristics of patients.  
Table 2b displays the Cox proportional hazard results of the primary analysis among patients 
followed from time of ART initiation. Initiating ART in the early era of linkage into care (prior to 
2008) compared to the later era (2008 or later) was significantly associated with mortality (Hazard 
Ratio [HR]: 1.54; 95% Confidence Interval [95% CI]: 1.19 – 2.00). Compared to ART initiation 
at a CD4 cell count of 200-349 cells/mm3 with no other indication other than CD4 status to start 
ART, patients initiating treatment in the later era at a CD4 cell count ≥500 cells/mm3 had a non-
significant risk of death (HR: 0.73; 95% CI: 0.34 – 1.58). Among patients initiating ART without 
other indications, initiating ART in the later era at CD4 cell counts below 200 cells/mm3 had 
significantly worse mortality outcomes compared to starting at 200-349 cells/mm3 without other 
indications. For all CD4 strata, patients with an indication for ART initiation other than CD4 
counts were at higher risk of mortality, with hazard ratio estimates ranging from 2.92 (95% CI: 
2.37 – 3.75) among those initiating ART at 200-349 cells/mm3 in the later era to 15.89 (95% CI: 
12.39 – 20.36) among those initiating ART in the later era at 0-49 cells/mm3. Risk of mortality 
was higher among men compared to women (HR: 1.37; 95% CI: 1.28 – 1.49), increased with age 
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with HR relative to age 30-39 years climbing from 0.69 for young adults to 2.00 among those aged 
50 or more years (p < 0.0001) and was higher among persons without a partner (HR: 1.17; 95% 
CI: 1.06 – 1.28). Given that thousands of people die annually from HIV-attributable causes,20 these 
results are also clinically significant.  
Results of the second analysis are displayed in Table 3b. When stratifying by indication status 
and adjusting for demographic differences, the lower CD4 cell count strata at either time of linkage 
to care or ART initiation in the late era were similarly associated to risk of mortality. For example, 
linking to care in the later era at 100-199 cells/mm3 without any further indication was harmful 
compared to linking at 200-349 cells/mm3 (HR: 1.37; 95% CI: 0.95 – 1.97), which was the same 
for initiating ART in this CD4 stratum (HR: 1.37; 95% CI: 0.92 – 2.04). However, these 
similarities were not true for higher CD4 strata. Compared to CD4 cell counts of 200-349 
cells/mm3, linking to care in the later era at ≥500 cells/mm3 or more was protective (HR: 0.59; 
95% CI: 0.48 – 0.73), while the observed effect of initiating ART in the later era at ≥ 500 cells/mm3 
was not distinguishable from chance alone (HR: 0.82; 95% CI: 0.21 – 3.20). Effects of gender, age 
and having a partner were similar in both analyses. Figure 2b presents Kaplan-Meier survival 
estimates across CD4 strata at linkage and ART initiation, separated by the presence or absence of 
other ART indications. The high CD4 stratum at linkage is more distinguishable. 
Figure 3b displays the relationship between CD4 cell count at linkage to care and CD4 cell 
count at ART initiation. The red horizontal line indicates the 350 cells/mm3 or lower threshold for 
immediate initiation of ART. Thus, points falling much lower than this threshold represent late 
initiators. Three features are apparent in the figure. First, a large portion of patients initiating below 
350 cells/mm3 enrolled in care at very similar CD4 levels, shown by the thick orange diagonal. 
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The second is the continuing diagonal above the 350 cells/mm3 CD4 levels is less well populated 
and corresponds to immediate initiation due primarily to other indications for ART initiation. The 
third is the area below the 350 cells/mm3 cut-offs and to the left of the first feature. This area 
suggests that in the delayed initiation of ART upon 350 and 500 cells/mm3, considerably more 
patients initiate ART below 250 cells/mm3. This is in part due to the frequency of CD4 testing as 
these are conducted every six months. 
These features can be further described through some descriptive statistics of patients in pre-
ART (patients linked to HIV care that are not yet on ART) and their transition to ART. For patients 
linking to care with CD4 cell counts below 350 cells/mm3 the median time between linkage to care 
and ART initiation was 24 days (interquartile range [IQR]: 14 – 48 days). One of the features 
leading to longer delays in ART initiation was screening positive for TB. This is because these 
patients likely initiated treatment for TB prior to initiating ART. Among patients linking to care 
early, the median time between linkage and ART initiation was 311 days (IQR: 168 – 496 days). 
Finally, loss to follow-up within the pre-ART period was relatively low at 5.5 cases lost per 100 
person-years, which is comparable to what has been reported for the entire country (Nsanzimana, 
Kanters, Remera, Forrest, et al. 2015).  
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Figure 1b: Differences in characteristics and times of ART initiation with respect to initiating ART with 
CD4 above 500 cells/mm3 between data sources 
 
Panel A: Non-CD4 determinants of ART initiation   Panel B: Year of ART initiation 
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Figure 2b: Kaplan Meier curves for survival by CD4 cell count strata at linkage and at ART initiation 
and separated by presence or absence of other ART indications among 72,061 HIV positive Rwandans 
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Figure 3b: Smoothed scatter plot relating CD4 cell counts at linkage to CD4 at ART initiation among 
41,144 Rwandans who initiated ART between 2004 and 2011. 
 
 
 
Legend: The intensity of color indicates the density of observations, with orange indicating thousands of observations 
in the immediate vicinity; blue indicating hundreds of observations and purple indicating few observations in the 
immediate vicinity. Among late presenters, most appear to initiate immediately. Among early linkers, there are two 
distinct lines, immediate starts and delayed starts. The area of concern is the non-negligible cluster of individuals who 
link above 350, yet delay initiation well below this level.  
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Table 1b: Demographic and clinical characteristics of patients linked to care and 
initiated ART in Rwanda 
 Linkage to Care 
(IQ Charts and EMR) 
n=72,061 
ART initiation 
(IQ Charts only) 
n=50,147  
 Count (%) or Median (IQR) 
Age at linkage to HIV care 36 (30 – 43) 35 (28 – 42) 
Age at ART initiation 37 (31 – 45) -- 
Sex   
    Male 18200 (36.3%) 26055 (36.2%) 
    Female 31947 (63.7%) 46006 (63.8%) 
Marital Status   
    Single/Widowed/Divorced 12731 (25.4%) 24086 (33.4%) 
    Married/Partner 25988 (51.8%) 34508 (47.9%) 
    Other/Unreported 11428 (22.8%) 13467 (18.7%) 
Mode of diagnosis   
     VCT 31997 (63.8%) 45897 (63.7%) 
     PMTCT 6691 (13.3%) 12880 (17.9%) 
     Hospitalization 2750 (5.5%) 2773 (3.8%) 
     TB Consultation 143 (0.3%) 241 (0.3%) 
     PIT 3310 (6.6%) 4254 (4.9%) 
     Other 5256 (10.5%) 6016 (8.3%) 
Path to Treatment   
     Immediate at linkage to care -- 17141 (23.8%) 
     PMTCT: Immediate at Dx -- 2689 (3.7%) 
     After a Pre-ART period -- 52231 (72.5%) 
Exit Reason   
     Transfer 11285 (22.5%) 14884 (20.7%) 
     Died 2949 (5.9%) 3917 (5.4%) 
     Lost 2167 (4.3%) 7034 (9.8%) 
     Other 498 (1.0%) 1309 (1.8%) 
     Censured at end of study  33248 (66.3%) 42953 (59.6%) 
BMI at linkage to care 21.1 (19.2 - 23.1) 21.3 (19.5 – 23.3) 
CD4 at linkage to care 256 (145 - 383) 394 (210 – 636) 
CD4 at ART initiation 233 (139 - 316) 225 (136 – 305) 
WHO disease stage   
     I 19651 (39.2%) 34281 (47.6%) 
     II 13846 (27.6%) 18113 (25.1%) 
     III 14104 (28.1%) 15525 (21.5%) 
     IV 1734 (3.5%) 1721 (2.4%) 
     Unknown 812 (1.6%) 2421 (3.4%) 
TB Screen   
     Negative 39612 (79%) 53675 (74.5%) 
     Positive 8614 (17.2%) 12265 (17%) 
     Unknown 1921 (3.8%) 6121 (8.5%) 
ART: antiretroviral therapy; Dx: diagnosis; PMTCT: prevention of mother to child transmission; VCT: 
voluntary counseling and testing; BMI: body mass index; EMR: electronic medical records. 
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Table 2b. Cox proportional hazards ratios for demographic variables and CD4 at ART initiation with and without 
indication to initiate ART other than CD4 cell count in Rwanda, 2004-2014 
Variable Hazard Ratio  
(95% CI) 
Variable Hazard Ratio  
(95% CI) 
Early era 
Hazard Ratio  
(95% CI) 
Late era 
Gender  CD4 at initiation   
   Female 1.00 (--)     0-49 cells/mm3, no indication 3.34 (2.45, 4.55) 7.84 (5.51, 11.17) 
    Male 1.37 (1.28– 1.49)     50-99 cells/mm3, no indication 2.00 (1.49, 2.69) 2.58 (1.69, 3.95) 
Age (years)      100-199 cells/mm3, no indication 1.25 (0.99, 1.57) 1.51 (1.08, 2.13) 
   15-19  0.69 (0.49 – 0.96)     200-349 cells/mm3, no indication 1.00 (--) 1.00 (--) 
   20-29  0.84 (0.74 – 0.96)     350-499 cells/mm3, no indication 0.95 (0.62, 1.45) 1.13 (0.67, 1.9) 
   30-39 1.00 (--)     500+ cells/mm3, no indication 0.91 (0.54, 1.52) 0.73 (0.34, 1.58) 
   40-49  1.20 (1.10 – 1.32)     0-49 cells/mm3, with indication 5.91 (4.84, 7.21) 15.89 (12.39, 20.36) 
   50+  2.00 (1.81 – 2.21)     50-99 cells/mm3, with indication 3.56 (2.89, 4.38) 8.3 (6.35, 10.86) 
Marriage      100-199 cells/mm3, with indication 2.71 (2.25, 3.27) 4.6 (3.55, 5.97) 
   Married/partner 1.00 (--)     200-349 cells/mm3, with indication 1.86 (1.54, 2.25) 2.92 (2.27, 3.75) 
   Single/divorced/widowed 1.17 (1.06 – 1.28)     350-499 cells/mm3, with indication 2.02 (1.46, 2.78) 2.68 (1.79, 4.01) 
   Other 1.08 (0.98 – 1.18)     500+ cells/mm3, with indication 2.46 (1.68, 3.6) 2.44 (1.43, 4.15) 
Era of enrolment into HIV care      Unreported 4.98 (4.05, 6.13) 1.41 (1.03, 1.95) 
   Prior to 2008 1.54 (1.19 – 2.00)    
   2008 or later 1.00 (--)    
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Table 3b: Survival analysis for time from linkage to HIV care and time from ART 
initiation among patients in the IQ Charts database in Rwanda, 2004-2011 
 From time of linkage to care From time of ART initiation 
 Hazard Ratio  
(95% CI) 
Hazard Ratio  
(95% CI) 
Simple Unadjusted Models 
CD4 cell count at 
linkage/initiation* 
   <50 cells/mm3 
   50-99 cells/mm3 
   100-199 cells/mm3 
   200-349 cells/mm3 
   350-499 cells/mm3 
   500+ cells/mm3 
   Unknown 
 
4.82 (4.36 – 5.32) 
2.32 (2.07 – 2.59) 
1.43 (1.29 – 1.58) 
1.00 (--) 
0.70 (0.63 – 0.79) 
0.47 (0.42 – 0.52) 
1.62 (1.24 – 2.11) 
 
4.90 (4.38 – 5.49) 
2.55 (2.25 – 2.88) 
1.55 (1.39 – 1.72) 
1.00 (--) 
0.96 (0.75 – 1.22) 
1.55 (1.15 – 2.11) 
7.59 (6.18 – 9.33) 
Full Models 
Gender 
   Female  
   Male 
 
1.00 (--) 
1.56 (1.27 – 1.67) 
 
1.00 (--) 
1.43 (1.32 – 1.56) 
Age 
  15-19 
  20-29 
  30-39   
  40-49 
  50+ 
 
0.69 (0.52, 0.90) 
0.93 (0.84, 1.02) 
1.00 (--) 
1.23 (1.14, 1.34) 
2.02 (1.84, 2.21) 
 
0.78 (0.56 – 1.11) 
0.87 (0.77 – 0.99) 
1.00 (--) 
1.28 (1.16 – 1.42) 
2.05 (1.83 – 2.29) 
Marital Status 
   Married/Partner 
   Single/Div./Widow 
   Other 
 
1.00 (--) 
1.43 (1.33 – 1.55) 
1.89 (1.74 – 2.05) 
 
1.00 (--) 
1.31 (1.19 – 1.44) 
1.72 (1.55 – 1.91) 
Era of enrolment into HIV care 
   Prior to 2008 
   2008 or later 
 
1.40 (1.07, 1.84) 
1.00 (--) 
 
1.45 (1.09, 1.92) 
1.00 (--) 
CD4 cell count at 
linkage/initiation* with/without 
other ART indication 
   0-49 cells/mm3, no indication 
   50-99 cells/mm3, no indication 
   100-199 cells/mm3, no 
indication 
   200-349 cells/mm3, no 
indication 
   350-499 cells/mm3, no 
indication 
   500+ cells/mm3, no indication 
   0-49 cells/mm3, with indication 
   50-99 cells/mm3, with 
indication 
Early ART 
era 
 
4.01 (3.11, 
5.18) 
1.97 (1.5, 
2.6) 
1.31 (1.05, 
1.63) 
1.00 (--) 
0.8 (0.63, 
1.03) 
0.59 (0.48, 
0.73) 
5.88 (4.88, 
7.07) 
Later ART era 
 
6.3 (4.27, 9.31) 
2.15 (1.37, 
3.38) 
1.37 (0.95, 
1.97) 
1.00 (--) 
0.77 (0.55, 
1.09) 
0.53 (0.39, 
0.72) 
15.2 (11.7, 
19.6) 
7.27 (5.49, 
9.63) 
Early ART era 
 
3.11 (2.24, 
4.32) 
1.95 (1.43, 
2.67) 
1.21 (0.95, 
1.55) 
1.00 (--) 
0.8 (0.43, 
1.47) 
0.86 (0.32, 
2.33) 
5.88 (4.78, 
7.22) 
Later ART 
era 
 
7.22 (4.75, 
10.98) 
1.95 (1.15, 
3.3) 
1.37 (0.92, 
2.04) 
1.00 (--) 
0.94 (0.41, 
2.16) 
0.82 (0.21, 
3.20) 
15.7 (11.9, 
20.5) 
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   100-199 cells/mm3, with 
indication 
   200-349 cells/mm3, with 
indication 
   350-499 cells/mm3, with 
indication 
   500+ cells/mm3, with indication 
   Unknown 
3.29 (2.7, 4) 
2.26 (1.89, 
2.71) 
1.91 (1.59, 
2.29) 
1.55 (1.26, 
1.9) 
1.16 (0.96, 
1.41) 
2.41 (1.74, 
3.33) 
 
4.43 (3.38, 5.8) 
2.90 (2.21, 3.8) 
1.89 (1.4, 2.57) 
1.18 (0.88, 
1.58) 
2.84 (1.51, 5.34) 
3.5 (2.82, 
4.34) 
2.6 (2.14, 
3.15) 
1.85 (1.52, 
2.25) 
2.07 (1.45, 
2.96) 
3.95 (2.62, 
5.97) 
9.78 (7.55, 
12.67) 
8.33 (6.23, 
11.14) 
4.54 (3.42, 
6.02) 
2.93 (2.24, 
3.85) 
2.43 (1.47, 
4.02) 
4.78 (2.65, 
8.62) 
2.66 (0.84, 
8.43) 
* For models using time from linkage to care, the CD4 cell counts used are those at linkage to care, and 
for models using time from ART initiation, the CD4 cell counts are those at ART initiation.  
ART: antiretroviral therapy; CI: confidence interval 
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6.7 Discussion 
 
These analyses used the cascade of HIV care framework and CD4 count at ART initiation to 
evaluate the Rwanda national HIV program, quantify the engagement of HIV-positive individuals 
in care and predictive value of CD4 count on mortality among HIV positive patients. These results 
highlight the strengths of Rwanda’s national HIV program, indicated by the high proportion of 
patients retained in care and the high proportion of treated patients with suppressed viral loads. 
Quantifying the cascade of HIV care for Rwanda has also highlighted areas where changes to the 
program and procedures of data monitoring may improve health outcomes; principally, the delay 
between positive diagnoses and engagement in HIV care and lack of data on the stages of the 
cascade of care from diagnosis to linkage to care. Overall, mortality and loss to follow-up in 
Rwanda were low in 2013. Nonetheless, findings on mortality were associated with late 
engagement in care (either with low CD4 counts or opportunistic infections), being male and not 
having a partner, suggestive of lower social supports. The proportion of treated HIV-positive 
individuals with suppressed viral loads compares with many programs in high-income countries, 
such as British Columbia, Canada (Nosyk et al. 2014).  
A strong association between increasing survival outcomes with increasing CD4 cell count at 
time of linkage to HIV care was identified and, despite having a large sample and accounting for 
other mechanisms by which ART is initiated, found limited evidence of survival benefits through 
ART initiation at higher CD4 cell counts (≥500 cells/mm3) in comparison to initiating at 350 
cells/mm3. The limited evidence of survival benefits is in agreement with similar studies in 
developed settings, particularly in Sub-Saharan Africa. Given that many patients are still initiating 
ART at low CD4 counts (Siedner et al. 2015); the improved outcomes observed in persons entering 
          
 
 
83 
HIV care at high CD4 cell counts suggests that optimizing pre-ART and early uptake into HIV 
care services may better optimize clinical implementation.  
There have been three major observational studies from developed settings examining the 
predictive value of CD4 cell count on mortality outcomes at time of ART initiation (Cain, Logan 
& Robins 2011; Sterne, Hernan & Ledergerber 2005; Kitahata et al. 2009). Nonetheless, smaller 
studies in Sub-Saharan Africa have also shown improved survival associated with ART initiation 
in the lower CD4 cell count strata (Mills, Bakanda & Birungi 2012). Our findings add to the 
evidence that despite improved survival in lower CD4 cell count strata, there is limited evidence 
to suggest this trend holds true in higher strata. 
The observed improvement in survival outcomes in patients linking to care early indicate that 
a safe deferral strategy for ART initiation may be possible in regions where ART uptake remains 
poor so long as efforts are made to engage and retain patients in pre-ART care services. However, 
our study has demonstrated that in higher functioning health systems like Rwanda, patients can be 
linked and retained in care prior to the initiation of ART with good survival outcomes. The pre-
ART program in Rwanda includes a variety of clinical and social support. Interventions to improve 
the retention of patients in pre and on ART care in low- and middle-income settings have been 
synthesized elsewhere (Govindasamy et al. 1903). In Rwanda, these may include a responsive 
national surveillance system (Kayibanda et al. 2011), universal health coverage (Lu et al. 2012), 
task shifting of healthcare providers (Shumbusho et al. 2009), performance-based financing (Zeng 
et al. 2014), strong donor support (Asiimwe, Rwiyereka & Kaufman 2010). Particularly strong 
access and availability to healthcare services, may explain the successful uptake of the program. 
This is best observed among the high proportion of men accompanying their female partners to 
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ANC. While this has been encouraged throughout most of Sub-Saharan Africa, the uptake in 
Rwanda (~85%) has been much higher than in other settings (on average ~45%) (Jennings et al. 
2014). Lastly, Rwanda has demonstrated remarkable leadership and strong governance supporting 
an understaffed, under-resourced health system with observable population-level health 
improvements. 
  Nevertheless, linkage to clinical care from the point of testing remains low in Rwanda 
(Mugisha et al. 2014; Nsanzimana, Kanters, Remera, Forrest, et al. 2015), as in many Sub-Saharan 
African countries (Kranzer et al. 2010; Nsanzimana, Kanters, Remera, Forrest, et al. 2015) and a 
greater effort must be made to improve the integration of HIV testing, treatment and care services 
(Kranzer et al. 2010; Nsanzimana, Kanters, Remera, Forrest, et al. 2015). 
These analyses do have limitations. One is that there is no single data source that can inform 
all stages of the cascade of HIV care and the health seeking pathways between them in Rwanda. 
We collated data sources in order to quantify engagement at each stage and predict mortality along 
the cascade. A lack of understanding of the cause of mortality prohibits this analysis from making 
conclusions on the attribution of HIV and AIDS along the cascade. However, the successful 
collation of several sources of data to demonstrate how nationwide routine surveillance and 
monitoring can be used to inform the proportion of engaged patients and mortality along the 
cascade of HIV care at the national level represents a strength of this study. Another strength of 
this study includes the nationally representative sample and large sample size. The current analysis 
is also based on a large number of patients with a CD4 cell count at ART initiation above 500 
cells/mm3 (1,534; 15.7%). An important limitation is the potential presence of measurement bias 
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with respect to indications for initiating ART. Our sample includes a majority of patients who 
began ART with very low CD4 cell counts, although these proportions have changed over time.  
In summary, our study found that the cascade of care is a non-linear pathway wherein 
patients have multiple opportunities to leave and re-engage in care. Understanding the points at 
which individuals are most likely to leave care may improve large-scale delivery of care. We also 
found that initiating ART at a CD4 cell count of >500 cells/mm3 was not importantly associated 
with improved survival, while linking to care at CD4 cell counts of >500 cells/mm3 was strongly 
associated with increased survival. These results should contribute to the discussion that earlier 
linkage to care even with a delay in ART initiation may result in substantial reductions in mortality 
in Sub-Saharan Africa. 
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7.1 Abstract 
 
Introduction: In 2016 Rwanda implemented “Treat All,” requiring the national HIV program 
to increase antiretroviral (ART) treatment coverage to all people living with HIV. Approximately 
half of the 164,262 patients on ART have been on treatment for more than five years, and long-
term retention of patients in care is an increasing concern.  To address these challenges, the 
Ministry of Health has introduced a differentiated service delivery approach to reduce the 
frequency of clinical visits and medication dispensing for eligible patients. This article draws on 
key policy documents and the views of technical experts involved in policy development to 
describe the process of implementation of differentiated service delivery in Rwanda. 
Discussion: Implementation of differentiated service delivery followed a phased approach to 
ensure that all steps are clearly defined and agreed by all partners. Key steps included: definition 
of scope, including defining which patients were eligible for transition to the new model; definition 
of the key model components; preparation for patient enrolment; considerations for special patient 
groups; engagement of implementing partners; securing political and financial support; forecasting 
drug supply; revision, dissemination and implementation of ART guidelines; and monitoring and 
evaluation. 
Conclusions: Based on the outcomes of the evaluation of the new service delivery model, the 
Ministry of Health will review and strategically reduce costs to the national HIV program and to 
the patient by exploring and implementing adjustments to the service delivery model. 
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7.2 Introduction 
 
Sub-Saharan Africa carries the highest burden of HIV, with approximately 70% of all people 
living with HIV worldwide living in the region. Despite major progress by governments, donors, 
and international and national implementing partners, access to antiretroviral therapy (ART) in 
Sub-Saharan Africa remains below the global average, with less than 50% of people living with 
HIV on ART, and coverage is considerably lower in some countries in the region (UNAIDS 
2016c).  
Rwanda is one of a few countries in Sub-Saharan Africa that has achieved high rates of HIV 
diagnosis and ART coverage, along with high rates of retention and medication adherence with 
viral suppression (Elul et al. 2013; NISR-Rwanda 2014). As of the end of June 2016, 164,262 
people – 78% of all PLHIV in Rwanda – were receiving antiretroviral therapy. Retention in care 
is high, at 93% after 12 months on treatment, and viral suppression among those on ART and 
receiving a viral load is also high, at 86% at 12 months and 91.5% and 36 months post ART 
initiation (Lu et al. 2012).  This progress is particularly remarkable given the backdrop of the 1994 
genocide which left the health system in disrepair. In recent years, increased ART coverage has 
evolved with treatment guidelines recommending earlier initiation of ART (Binagwaho et al. 
2014). 
The successes of Rwanda’s national HIV program are closely tied to a series of health system 
improvements made over the past 15 years, including a strengthened infrastructure, introduction 
of community-based health insurance, improved workforce skills, and training of community 
health workers to deliver preventive, diagnostic and therapeutic services at the village level (Group 
ISS 2015; WHO 2016; Binagwaho et al. 2014). 
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Despite successes, Rwanda faces new challenges and opportunities for increasing and 
sustaining access to antiretroviral therapy. In July, 2016 new guidelines were launched 
implementing “Treat All,” under which all identified people living with HIV (PLHIV) would 
immediately begin ART irrespective of immunological or clinical status (WHO 2016). This new 
policy is expected to lead to major benefits in terms of reduced mortality, morbidity and new 
infections (TEMPRANO ANRS 12136 Study Group & The TEMPRANO ANRS STUDY GRP 
2015; Group ISS 2015; Cohen et al. 2011), but challenges  remain to national program to 
significantly increase the number of PLHIV receiving ART: there are more than 17,000 individuals 
who were in pre-ART care by June 2016. An estimated 10% increase in the number of PLHIV 
needing treatment in Rwanda following the shift to Treat All will add additional PLHIV who need 
continuous access to ART; With an annual HIV incidence of 0·27% (95% confidence interval: 
0·18-0·36%), additional HIV positive individuals are anticipated to enter care each year (MoH-
Rwanda 2015).  
The national ART coverage target to reach 81% (the second “90” of the UNAIDS 90-90-90 
targets) (UNAIDS 2014) of PLHIV on ART is expected to be achieved by the end of June 2017, 
with an estimated 92% of PLHIV enrolled in care and 82% on ART. Nevertheless, approximately 
half of the 164,262 patients on ART have been on treatment for more than five years, and long-
term retention of patients in care is increasingly a major challenge for the national program. These 
two challenges of increasing enrolment and ensuring long-term retention have pushed the Ministry 
of Health of Rwanda to implement new operational strategies. These include reorganizing the 
existing patient flow and the frequency of clinical visits and the collection of medication from the 
pharmacy. Patient flow has been simplified by removing two steps - registration and vital signs 
regular checks at HIV clinic reception, clinic consultation for file records; the pharmacist at each 
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clinic has been trained to capture key information required before delivering ARVs at each pick 
up visit in a short time; and unnecessary visits have been removed such pre-treatment and regular 
counselling sessions.   
Previous ART guidelines recommended clinic visits every three months for medical 
consultations, monthly medication pick up, monthly adherence counselling, and every three 
months visit for psychosocial support. The latest ART guidelines, issued in July 2016, recommend 
differentiating ART delivery, with spaced clinic visits and pharmacy pick up for patients who are 
stable on ART, with the anticipated outcomes of increasing efficiencies at the site level for the 
benefit of patients and clinical staff, leading to sustainable cost savings.   
This article summarizes the sequential policy actions taken towards phased implementation of 
spaced clinic visits for stable patients in Rwanda. 
 
7.3 Discussion 
 
Implementation of spaced clinic visits, as outlined in Figure 1 and detailed below, has followed 
a phased approach to ensure that the key steps were defined and agreed by all partners. 
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Figure 1: Reconfiguring service delivery to reach “the Second 90” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Definition of scope 
The first step was to convene a national technical consultation, which was held in August 
2015. This immediately proceeded the meeting of the WHO guidelines development group in 
which the evidence supporting spaced clinic visits was presented (Nsanzimana et al. 2017). The 
national technical consultation included representatives from the WHO, UNAIDS, researchers 
from the University of Rwanda, School of Public Health, international researchers, members of 
the national HIV technical working group, the umbrellas of civil society organizations in the fight 
against HIV and health promotion, the network of people living with HIV, private and public 
health facilities under the leadership of the HIV control program of the Rwanda Biomedical Centre 
(RBC), an implementing body of the Ministry of Health.  At this August 2015 consultation, 
Rwanda adopted its new Treat All policy, which changed ART eligibility to all HIV-positive 
persons regardless of CD4 count. Rwanda also adopted definitions of a “stable patient” who would 
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be eligible for greater spacing between clinic visits – a strategy termed “differentiated care” that 
is designed to reduce transport, economic and logistic burdens of clinic visits on healthy patients, 
and thus promote greater long-term retention in care. 
It was recommended that for the first phase of the new service delivery model a stable 
patient would be defined as “a PLHIV >15 years old who has been on ART for 18 months with 
two viral load results of less than 20 copies/ml using Amplicor HIV-1 DNA test v1.5. and who is 
considered adherent (defined ≥ 90% adhering to taking their self-reported ART medication) under 
ART guidelines”.   Under this initial definition, up to 85% of all PLHIV on ART would be defined 
as “stable.” The last viral load will be considered as recent if the results were reported at least after 
2 months after blood collection for the test.  All adult clients on 2nd and 3rd line treatments 
requesting to be part of the differentiated ART model, and fulfilling the eligibility criteria, are 
further evaluated and, if they show adequate adherence to treatment and viral suppression, are 
enrolled in the new ART model. Similarly, in accordance with other existing national guidelines, 
all members of key population groups can be included provided they meet the general eligibility 
criteria.  
The following patients are currently considered non-eligible for the new model: all PLHIV 
clients on ART less than 18 months; patients on 2nd and 3rd line ART and not meeting adherence 
and viral load criteria; patients co-infected with NCDs such as diabetes, cancer, and heart disease 
in the intensive period of treatment until clinical symptoms are stabilized, pharmacy visit and 
laboratory visits will be coordinated with visits for their chronic conditions until patients is 
stabilized for that condition i.e. patients hospitalized or in acute phase management; malnourished 
PLHIV (calculated body mass index/ Height for Weight and excessive loss of weight below 10% 
of the normal value)  in nutrition follow up services; all HIV positive clients who have TB and/or 
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hepatitis (C and B) co-infections until after six months of ARVs treatment; and children under 15 
years of age defined by the national HIV guidelines as paediatric patients. Patients in this category 
will follow the standard ART guidelines: three monthly medical consultations, monthly 
medication pick up, monthly adherence counselling, and three monthly psychosocial support.  
 
Definition of the Differentiated ART Model  
With the introduction of the Treat All recommendations and the expanding availability of 
ART (Figure 2), it is anticipated that the majority of people will present to care earlier and require 
less intensive clinical care (UNAIDS 2016a). To reflect the different needs and preferences of 
different groups of PLHIV, and to reduce an unnecessary burden on the health system and multiple 
clinical visits for patients, the Rwandan national HIV program adopted a differentiated model for 
ART service delivery.  
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Figure 2: Implementation of “Treat All” in Rwanda 
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The model aims to delink clinical visits from ART refills visits for stable patients by 
decreasing patient clinical visits to once every six months and pharmacy pick-up for medication 
visits (both ARVs and OIs prophylaxis) to once every three months (Jain et al. 2014; Bemelmans 
et al. 2014). Pharmacy visits will be spaced from one to three months, and clinical visits from three 
to six months for patients defined as stable (Babigumira et al. 2011; Nakiwogga-Muwanga et al. 
2014) . Further, the length of adherence counseling sessions prior to initiating ART for patients 
who present well will be reduced from three to one to allow a rapid ART initiation for the newly 
identified patients – within seven days and with the possibility of same-day start – consistent with 
recent evidence (Rosen et al. 2016; Pilcher et al. 2017; Mutasa-Apollo et al. 2017) (Table 1).   
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Table 1: “Standard of Care” vs. New Service Delivery Model 
 
Group Services Standard of Care 
New Service 
Delivery Model 
Stable patients* 
Clinical visits frequencies 3 months 6 months 
Medicine pick ups 1 month 3 months 
Counseling sessions 
(prior ART initiation) 3 sessions 1 session 
Peer support, CHWs No Yes 
Specific populations:  
Pregnant women, Key 
populations, Children <15 
years, 2nd, 3rd lines, and TB 
or HB/CV co-infection 
Clinical visits  3 months 
3-6 months  
(Case by case) 
Medicine pick ups 1 month 
1-3 months  
(Case by case) 
Counseling sessions  
(prior ART initiation) 3 sessions 2 Sessions 
*Stable patients are defined as: >15 years old, on ART for 18 months with two viral load results of less than 20 
copies/ml, and evidence of adherence to ART 
 
Preparation for enrolment in the new model 
Selection of stable patients for the new ART model is anticipated to take a month. High 
volume sites will enrol patients in cohorts (i.e. groups of patients attending the clinics at the same 
time) and these facilities will take a maximum of three months to enrol all patients in cohorts. The 
clinics can organize a reasonable number of cohorts given total number of patients (20-30) per 
cohort.    
Health providers at health facility level will use patient registers and patient charts to 
classify patients receiving ART in different categories including: patients eligible for the new 
model; patients non-eligible for new model; and special considerations (pregnant and 
breastfeeding women, adolescents, patients with non-communicable diseases (NCDs), patients 
with other co-infections, and other considerations to be addressed on a case-by-case basis). 
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Health providers, supported by clinical mentors, will coordinate routine clinical consultations, 
planned medicine pickup with laboratory visits to reduce visit frequencies for patients.  During the 
preparation phase, health providers will register stable patients (those eligible for the new spacing 
model) who have the same day visits and group them as a cohort. These patients/cohorts will be 
required to attend clinic on the same day to receive the same services. 
Patients eligible for new ART delivery model are required to participate in one to two 
education and counselling sessions. During these sessions, health providers assess willingness to 
participate in the model, explain the benefits and risks related to the model, and summarize how 
the model works (how patients will be seen - either separately or in groups; coordination for 
different visits; community providers’ interventions; when patients move from one location to 
another, and so on). If eligible patients are pregnant women, adolescents, or patients with any 
chronic diseases that have a different consultation schedule, education sessions are adapted to a 
particular group, focusing on challenges for that specific group and how ART model will be 
aligned with the exiting conditions. 
In parallel, support has been provided to community HIV services platforms to improve 
linkage and retention in treatment and adherence for all PLHIV including children born to key 
populations. At the community level, community healthcare workers and volunteers refer children 
to health facilities for HIV services. Facilities also work with community structures, including 
support groups and peer educators, for adherence support promotion, and retention in care. 
Considerations for specific populations 
Pregnant or breastfeeding mothers on ART will require different follow-up and health 
providers need to coordinate their clinical and pharmacy visits with ANC or PMTCT visits on a 
quarterly basis.  A different frequency of clinic visits for pregnant women is used from the 
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beginning of pregnancy until the end of the breastfeeding period. At the end of breastfeeding 
period, pregnant and breastfeeding mothers who meet all other eligibility criteria can then be 
enrolled in the new ART model.  However, follow up of exposed and infected new born and 
younger children remains a special case requiring more regular contact with health services, both 
at the clinic and in the community.  
Due to school routines and other competing priorities, adolescents at schools are scheduled 
for pharmacy and clinical visits every three months, timed with school break periods. All 
adolescents in school continue in this model until the end of their secondary education and at least 
19 years of age. After this time, they are transitioned to the spacing model as adult patients 
provided all other eligibility criteria are met. Adolescent out of school are be considered on a case-
by-case basis based on virological, adherence and socio-economic criteria. 
Engagement of implementing partners 
Civil society and the private sector have been engaged to provide inputs through a civil 
society organization (CSO) consultation held in February 2016. This meeting engaged numerous 
community partners and their constituencies, including the NGO umbrella groups for health CSOs 
and PLHIV, as well as the CCM Secretariat, UNAIDS, and MOH/RBC. A second consultation 
was held during a mid-term review of the national ART program in June 2016. During this process, 
civil society groups and implementing partners were encouraged to voice concerns on the new 
ART and service delivery model. Concerns were raised about implementation considerations: 
Increase of lost to follow up while contacts to clinics will be spaced- quality of household storage 
of drugs and associated losses or misuse.  
In mid 2016 the RBC conducted a series of consultative meetings and workshops with 
health care providers, clinical mentors, district pharmacy directors, local leaders and community 
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health workers. The objective of this consultation process was to seek support and feedback for 
the implementation of the new service differentiated model. During these consultations, experience 
sharing from the providers helped RBC to refine implementation steps including for example, the 
need to increase the storage space at the District Pharmacies. 
Securing political and financial support 
The recommendations from the technical working group were presented to the Minister of 
Health, Minister of State for Public health and Primary Health Care, and the Permanent Secretary 
for Health, for agreement in December 2015. Following this, a costed plan was presented to US 
President’s Emergency Plan for AIDS Relief (PEPFAR) to request US$4 million one-time 
additional central funding to cover the transition to three-month drug pick-ups nationally for stable 
patients and the related supply chain monitoring in order to increase the national buffer stock to 
support the rollout of the three-month drug pick-ups. PEPFAR approved US$3.67 millions of this 
request in June 2016 during PEPFAR’s Country Operational Plan (COP) review meeting. 
Since 2005, the funding allocation for commodities in Rwanda is done by using a “common 
basket” mechanism; largely depending on external donor contributions. Under the Coordinated 
Procurement and Distribution System (CPDS) all actors in quantification, procurement and 
distribution from government, bilateral and multilateral partners meet regularly to estimate the 
needs and submit their report to Resource Management Committee (RMC) of the CPDS. The RMC 
requests financial contributions from each partner. In 2016, Of the total needs for ARVs, laboratory 
commodities and drugs for opportunistic infections prophylaxis and treatment; PEPFAR 
contributed 26 million USD (not including the central funding amount), the Global Fund 
contributed 19 million USD while the government of Rwanda has been investing in supporting 
infrastructure, running costs and personnel for HIV supply chain systems. 
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Forecasting drug supply 
The national HIV Quantification Committee drafted a supply plan for all ARV drug needs 
in Rwanda in December 2015. The quantification exercise was supported with the use of 
Quantimed, a quantification software tool developed by USAID’s Strengthening Pharmaceutical 
Systems Project (Management Sciences for Health 2006), took into account the implementation 
of “ Treat All “ in July 2016, and the required levels of buffer stock to transition to spaced clinic 
visits and dispensing for stable patients.  It was estimated that 196,933 patients would be started 
on ART in 2017. In order to implement the three-month drug supply policy within the supply chain 
system as early as possible, a one-time procurement of additional products was determined to be 
necessary to top up all health facilities so they have the required stock to administer to patients.  
Based on procurement and supply chain systems, it was estimated to consider six month’s supply 
time for these additional quantities to be in place before the launch of the new guidelines.  
Implementation of the three-month drug supply policy will occur as soon as the buffer 
stock was in place at facility level. In line with current practices within the national supply chain 
system, health facilities will calculate and order additional quantities necessary for subsequent 
orders. Additional shipments are needed for procurement to meet the demand on the national 
commodities supply due to the change in the service delivery model to three-month drug pick-ups.  
The cost of the entire ARV procurement needed to cover the transition was calculated at $US 
3,677,180 USD. It was estimated that additional extra cost on other supply chain expenditures is 
minimal and could be managed within existing budget. 
Ongoing monitoring of the supply chain on at least a quarterly basis will be put in place to 
adjust future shipments, monitor stock status, and avoid situations of expiry or stock out of 
medications. A full review of the implementation of the new policy and its effect on the distribution 
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and storage system by the new supply chain mechanism is planned within the first quarter of 
rollout.  Outputs from this review will inform future decisions regarding inventory control and 
distribution and procurement, as well as the national quantification of commodities, in order to 
realize cost savings and ensure commodity security.  Based on all of these factors, the 
implementation of the 3-month drug pick-ups is, planned to start in December 2016.  
Revision of ART guidelines 
The revision of comprehensive HIV guidelines in Rwanda is carried out every two years 
based on most recent evidence available and priorities for the country and is a broadly consultative 
process involving experts from national technical working groups, implementing partners, bilateral 
and multilateral funding partners involved in HIV response in Rwanda, and external experts. The 
revision and approval of the 2016 guidelines was concluded with the endorsement by the Ministry 
of Health. A nationwide training of health care providers was undertaken over a three-month 
period to ensure that at least two nurses in each of the 500 health centers in Rwanda were trained 
to implement the new guidelines. Trainings consisted of an overview on basics in HIV testing, 
treatment, and follow up, the benefits of the Treat All strategy, and evidence supporting 
differentiated service delivery and how best it can be implemented according to the country 
context. The trainings combined both expert presentations and groups discussions. At the end of 
each session, participants were encouraged to suggest improvements in the implementation plan. 
In addition, RBC has established clinical mentorship teams (1 nurse and 1 doctor) who received 
advanced training in HIV management, located at each district hospital and supporting all health 
centers in the catchment area. These teams provide continuous education and skills transfer to the 
nurses responsible for managing ART.  At the end of each training, participants received a written 
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summary of the guidelines and the Ministry of Health issued an official letter to implement the 
new changes. 
Dissemination and Implementation 
Each health centre was tasked to assess the number of stable patients and clinical services 
implementing partners will contact sites regularly to ensure that all sites are implementing the new 
service delivery model according to the national guidelines. Health centers are supported by 
clinical mentors to identify stable patients ahead of implementation. Implementation will be 
phased to allow for adaptation as necessary.  Starting in October 2016, stable patients having an 
appointment will be asked to come back after 6 months and will be told to keep coming monthly 
for their drug pick-ups only until the three-month drug pick-ups are aligned with the patient’s new 
clinical visit schedule pending additional drugs for three months pick-ups are expected to arrive in 
December 2016. These two appointments are conducted in different offices and drug pick up at 
pharmacy takes approximately five minutes while clinical visit in a consultation room is estimated 
to 20 minutes per patient. With an estimated average of ten consultations a day per health care 
provider, the spacing of clinical visits is expected to result in the following benefits: reduced 
burden on the clinics; increased time and quality of care for cases that need more clinical 
investigation; reduced frequency of travel for patients; and reduced likelihood of inadvertent 
disclosure of status as clients will spend less time in clinic services.  
On December 1, 2016 patients with appointments for ARVs will receive three month’s 
supply if classified as stable and will be asked to come back one week before the end of their three-
month stock. The transition to three-month drug pick-ups is expected to rollout over the course of 
three months so that at the end of the three-month period, beginning in December 2016, all stable 
patients will be receiving three months of drugs and will align one of every two three-month drug 
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pick-ups with one of the six-clinical visits (Table 2). During this period, special support will be 
needed to make adjustments in case issues arise.  
Table 2: Roll out of 3-month ARV pick-ups for stable patients 
 
 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 
Group A 3 months   3 months   
Group B 1 month 3 months   3 months  
Group C 1 month 1 month 3 months   3 months 
 
Expected challenges include:  stock outs (while additional bolus funding has been added 
to increase the buffer stock, adding an additional layer into the supply chain is a potential cause of 
stock out); loss to follow up (a potential negative effect of less frequent clinic contact); sharing of 
pills between patients; and issues of home storage of ARVs and confidentiality. To mitigate these 
anticipated challenges, a quantification and distribution team has been established and tasked to 
meet every two weeks to monitor implementation and report regularly to the leadership of the RBC 
and MoH for real time changes and decisions making. The technical working group will continue 
to discuss the role of community workers in implementation of the new model in the framework 
of peer support to the network of people living with HIV.  
Implementation of the new model will be adaptive so that on a quarterly basis, changes 
may be incorporated according to information and data received during implementation. For 
example: three-month pick-ups may be better implemented in rural settings than in urban areas 
given high patients mobility in urban areas; if this is found to be the case, a two-month pick up 
may be proposed for such areas. 
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Monitoring and Evaluation  
The National HIV program with support from PEPFAR through CDC and WHO has 
established a technical group in strategic information to design how the new model will be 
evaluated on technical performance and financial reporting. Rwanda has a good M&E 
infrastructure for HIV with the TRACNet database that has been operating since 2004 and has 
recently been successfully integrated into Health Management Information System (HMIS). Since 
2010 The TRACNet/HMIS has an interoperability system with Electronic Medical Record (EMR) 
and captures most of HIV individual patient data from testing to enrolment and follow up, covering 
305 health facilities out of 500 existing in Rwanda. These systems will provide key data to track 
progress in the implementation of Treat All and outcomes of the new service delivery 
(Nsanzimana, Remera, Kanters, Forrest, et al. 2015). Enhanced indicators will be included such as 
number of patients that came for clinical visits and drug pick-ups will be added in existing M&E 
systems. Financial indicators will be included based on visit and pick-up indicators, including case 
load of health workers and time spent to consult the patient. 
7.4 Conclusions 
 
Based on the success of the new service delivery model, the Ministry of Health will review 
and seek to further strategically reduce costs to the national HIV program and to the patient by 
exploring and implementing adjustments to the service delivery model. For example, moving to 
12-month clinical visits and six-month prescription drug refills, and expanding the definition of 
“stable patient” to be more inclusive and reach more PLHIV.  These and other modifications such 
as viral load results turnaround time, adherence measurement to the service delivery model will 
seek to support the continued delivery of ART as part of the national HIV program while 
maintaining quality. 
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8.1 Abstract  
 
Background: Currently, there is limited evidence on the effectiveness of second-line 
antiretroviral therapy (ART) in Sub-Saharan Africa. To address this challenge, outcomes of 
second-line protease inhibitor (PI) based ART in Rwanda were assessed.  
Methods: A two-stage cluster sampling design was undertaken. 49 of 340 health facilities 
linked to the open-source electronic medical record (EMR) system of Rwanda were randomly 
sampled. Data sampling criteria included adult HIV positive patients with documented change 
from first to second-line ART regimen. Retention in care and treatment failure (viral load above 
1000 copies/mL) were evaluated using multivariable Cox proportional hazards and logistic 
regression models.  
Results: A total of 1688 patients (60% females) initiated second-line ART PI-based regimen 
by 31st December 2016 with a median follow-up time of 26 months (IQR 24-36). Overall, 92.5% 
of patients were retained in care; 83% achieved VL < 1000 copies/ml, 2.8% were lost to follow-
up and 2.2% died. Defaulting from care was associated with more recent initiation of ART- PI 
based regimen, CD4 cell count <500 cells/mm3 at initiation of second line ART and viral load > 
1000 copies/ml at last measurement. Viral failure was associated with younger age, WHO stage 
III&IV at ART initiation, CD4 cell count <500 cells/mm3 at switch, atazanavir based second-line 
ART and receiving care at a health center compared to hospital settings. 
 Conclusions: A high proportion of patients on second-line ART are doing relatively well in 
Rwanda and retained in care with low viral failure rates. However, enhanced understandings of 
adherence and adherence interventions for less healthy individuals are required. Routine viral load 
measurement and tracing of loss to follow-up is fundamental in resource-limited settings, 
especially among less healthy patients.   
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8.2 Background  
 
According to the 2016 estimates of the Joint United Nations Program on HIV/AIDS 
(UNAIDS), 36.7 million people lived with HIV globally, and approximately half were on 
antiretroviral therapy (ART) (UNAIDS 2016c, 2016b). Sub-Saharan Africa (SSA), in particular, 
accounts for more than 80% of the global population of people living with HIV (PLHIV) 
(Kharsany & Karim 2016). Since the introduction of ART in 1996, there have been substantial 
declines in morbidity and mortality related to HIV (Kharsany & Karim 2016; Haas et al. 2015). 
Despite this achievement, a considerable number of people have failed to maintain a sustained 
virological and immunological response to ART (Biset Ayalew M, Kumilachew D, Belay A, Getu 
S, Teju D, Endale D, Tsegaye Y 2016).  
The World Health Organization (WHO) recommends the use of a two 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) backbone and a non-
nucleoside/nucleotide reverse transcriptase inhibitor (NNRTI) as a first-line ART; and, in the off 
chance of treatment failure, proposes a switch to a second-line regimen composed of a ritonavir-
boosted protease inhibitor (PI/r) with two NRTIs (WHO 2016). The number of PLHIV switching 
from first- to second-line ART regimens is increasing and this shift is related to several factors. 
Primarily, non-adherence to medication, as a result of, adverse events or non-continuous 
medication access was reported in many studies as the key cause of treatment failure (Hosseinipour 
et al. 2013). Additionally, as ART scale-up in SSA and elsewhere was initiated in 2004 (Kharsany 
& Karim 2016; Haas et al. 2015), more PLHIV began receiving treatment. Unavoidably, even 
under optimal circumstances, treatment failures will occur overtime, resulting in an increase in the 
number of individuals in requiring second-line ART. Other factors, such as increased resistance 
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testing, improved adverse events detection and enhanced country access to affordable medications 
will also likely contribute to improved accessibility to second-line ART (Haas et al. 2015).  
Since the launch of second-line regimens in SSA, outcomes of large-scale national ART 
programs were assessed only in a few studies (Laurent et al. 2011; Nsanzimana, Kanters, Remera, 
Forrest, et al. 2015; Wilhelmson et al. 2016; Sherr et al. 2009; Bartlett & Shao 2009; Shao & 
Williamson 2012). Botswana and Rwanda are two countries in SSA achieving the highest ART 
coverage >80% (UNAIDS 2016c, 2016b). Of the estimated 220,000 PLHIV in Rwanda, 
175,398(80%) were receiving ART by December 2016 (Nsanzimana, Kanters, Remera, Forrest, et 
al. 2015). Rwanda, for example, has demonstrated a high rate of patients on first-line ART (>90%) 
(Nsanzimana, Kanters, Remera, Forrest, et al. 2015). Similarly, the number of patients on second-
line ART in Rwanda has also increased substantially in the last decade from 388 patients in 2007 
to 7,390 by the end of December 2016, representing ~4% of all patients on ART. Given this 
progression, the purpose of this study is to assess the outcomes associated with the rapid expansion 
of second-line ART access in Rwanda (WHO 2006). 
8.3 Methods 
 
Study design and data sources  
By the end of 2016, a total of 553 health facilities were offering HIV treatment in Rwanda. 
Among them, 513 had enrolled 7390 patients on second-line ART. Since the open-source 
electronic medical record (EMR) system was available in only 340 of the 553 health facilities, this 
constituted our sampling frame. A two-stage cluster sampling design was undertaken to randomly 
select 49 of the 340 eligible sites where all patients were considered for analysis. 
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A comprehensive list of health facilities providing second-line ART in Rwanda was 
compiled using the Health Management Information data hosted at the Rwanda Biomedical 
Center. This list formed the basis of our first sampling frame, which consisted of our randomly 
selected sample of health facilities. We restricted our selection to health facilities that had a fully 
functioning EMR system. There were no other expected differences with health facilities that were 
in the process of EMR roll out. Our stratification was balanced, enabling equal opportunity for the 
inclusion of urban, rural, small and big sites.  
Our data source consists of electronic medical records. After selecting 49 sites, we 
determined the data sampling criteria to include all adult patients (aged 15years or older) on 
second-line ART. The total number of patient data used for the study was 1,689, representing 
~25% of the total patients on second-line regimen in Rwanda. Since Rwanda is currently in the 
process of transferring HIV related data sources to a national electronic database, some data are 
still stored locally. Two authors (DS, VN) visited all 49 health facilities and extracted data backups 
from EMR local servers using mysql software and exported them to STATA version 14 to conduct 
the analyses.  
Study population and definitions 
Our study included patients aged 15 years or older, who had switched to second-line ART 
as of 31st December 2016. First-line ART regimens were composed of one NNRTI plus two NRTIs 
and second-line regimens were PI-based, in accordance with national guidelines. Two key possible 
reasons for change may be due to first-line treatment failure (virological and/or immunological) 
or the result of adverse-effects to any compound in first-line combinations or prior exposure to 
antiretroviral drugs. We defined virological failure as having a viral load (VL) > 1000 copies/mL 
after at least 12 months on first-line ART with self-reported good adherence to medication (>90% 
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no dose missed). Viral load failure was used as an approach to confirm treatment failure. The VL 
suppression threshold of < 1000 copies/mL and undetectable VL < 20 copies/mL were in 
accordance with the 2016 WHO consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection (WHO 2016).  
We defined retention as alive and in care on second-line ART at the time of data collection 
(31st December 2016) and with no met criteria for loss to follow-up (having missed contact with 
the health facility during 3 consecutive months). Deaths were assessed using recorded medical 
data in the EMR, which included deaths that occurred outside of the health facilities. Deaths were 
recorded within the national mortality registry. Both viral suppression and loss to care (the reverse 
of retention) served as the outcomes. The explanatory variables for this analysis were all measured 
at the initiation of first line ART and included demographic variables (age, sex, marital status, 
body mass index (BMI), clinical variables (TB screening status, CD4 cell count, WHO stage, viral 
load, date of ART initiation, type of ART regimen), and health facility-level variables (type of 
health facility: district hospitals, health centers and referral hospitals).   
Statistical analyses 
Data are presented as medians and interquartile ranges (IQRs) for continuous variables and 
frequencies and percentages for categorical variables. Fisher’s exact test was used to assess the 
association between outcome of interest (retention and viral load suppression) and each predictor. 
We used multivariate Cox proportional-hazards regression to analyse time to discontinuation (loss 
to follow-up or death) on second-line ART. The regression model included the following 
covariates: age, gender, CD4 cell count strata, WHO clinical stage, ART regimens, viral load, and 
type of health facilities at the time of first ART. The overall dataset contained only one case of 
missing value which was not considered for retention outcome. We controlled all different 
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antiretroviral backbones and PI based combinations for each individual patient to assess 
differences in ART formulations vis-à-vis retention and viral suppression.   
The proportional hazard model test was used to ensure that the proportional assumption 
was met. For model selection, we used Aikaike Information Criteria (AIC) to identify the model 
that best-balanced parsimony and minimized residuals.  
To model virological suppression, multiple logistic regression was used to analyse viral load 
suppression using the latest viral measurements. Finally, we calculated the probability of a subject 
not being suppressed given a set of predictors in order to obtain adjusted coefficients. The 
coefficients were expressed as adjusted odds ratios (OR). The model diagnostics were performed 
to assess the goodness of fit using Hosmer and Lemeshow test, deviance, and Pearson's Statistics. 
All analyses were conducted using STATA statistical software, version 14. 
Ethical approval 
Data used for this study were anonymized, routinely collected program data maintained by 
the Rwanda Biomedical Centre, Division of HIV/AIDS, STIs and Other Blood Borne Infections. 
The use of routine program data was approved by the Rwanda National Ethics Committee. The 
Rwanda Ministry of Health also granted approval for data access and use to the principal 
investigator (SN) for the purposes of improving program performance in Rwanda.  
8.4 Results 
 
Among the 181,921 (82.7%) individuals on ART in Rwanda (Nsanzimana, Kanters, 
Remera, Forrest, et al. 2015), 174,252 (95.8%) received first-line ART and 7,625 (4.2%) received 
second-line ART by 31st December 2016 (Shearer et al. 2017). Figure 1 presents a flow diagram 
of the second line ART Rwanda study sites and the patient selection process. 
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In our analysis, 1688 eligible patients were included, all of which had initiated second-line 
ART in 49 randomly selected health facilities representing ~25% of all patients on second-line 
ART nationwide. Table 1 presents the baseline characteristics of the selected patients. There were 
more women (60%) in the sample.  
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Table 1: Baseline characteristics of patients on second-line ART in Rwanda stratified by 
retention and viral suppression 
 
Characteristics 
Total  
Retained 
Defaulting from 
care Viral load suppression (copies/ml) 
Alive LTFU Died Total  <= 1000 > 1000  
n (%) n (%) N (%) n (%) n (%) n (%) n (%) 
Median age (IQR) 41 (33,49) 
Age category(year) 
15-29 327 (19) 300 (92) 24 (7) 3 (1) 327 (19) 242 (74) 85 (26) 
30-39 426 (25) 390 (92) 28 (7) 8 (2) 426 (25) 344 (81) 82 (19) 
40-59 841 (50) 785 (93) 35 (4) 21 (2) 842 (50) 718 (85) 124 (15) 
60+ 94 (6) 87 (93) 2 (2) 5 (5) 94 (6) 84 (89) 10 (11) 
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18) 
Sex        
Female 1031 (61) 952 (92) 55 (5) 24 (2) 1032 (61) 866 (84) 166 (16) 
Male 657 (39) 610 (93) 34 (5) 13 (2) 657 (39) 522 (79) 135 (21) 
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18) 
Marital status 
Single 344 (20) 309 (90) 27 (8) 8 (2) 344 (20) 259 (75) 85 (25) 
Married/Cohabitatin
g 648 (38) 602 (93) 30 (5) 16 (2) 649 (38) 540 (83) 109 (17) 
separated/Divorced 98 (6) 89 (91) 7 (7) 2 (2) 98 (6) 86 (88) 12 (12) 
Widowed 226 (13) 214 (95) 6 (3) 6 (3) 226 (13) 198 (88) 28 (12) 
Missing 372 (22) 348 (94) 19 (5) 5 (1) 372 (22) 305 (82) 67 (18) 
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18) 
ART Initiation period 
2009 and before 1062 (63) 1004 (95) 34 (3) 24 (2) 1063 (63) 892 (84) 171 (16) 
2010-2012 502 (30) 447 (89) 44 (9) 11 (2) 502 (30) 400 (80) 102 (20) 
2013-2016 123 (7) 110 (89) 11 (9) 2 (2) 123 (7) 96 (78) 27 (22) 
Total 1687 (100) 1561 (93) 89 (5) 37 (2) 1688 (100) 1388 (82) 300 (18) 
TB Screening        
Negative 1458 (86) 1356 (93) 75 (5) 27 (2) 1459 (86) 1213 (83) 246 (17) 
Positive 151 (9) 138 (91) 8 (5) 5 (3) 151 (9) 111 (74) 40 (26) 
N/A 79 (5) 68 (86) 6 (8) 5 (6) 79 (5) 64 (81) 15 (19) 
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18) 
Body mass index       
Normal weight 964 (57) 894 (93) 50 (5) 20 (2) 965 (57) 783 (81) 182 (19) 
Underweight 186 (11) 165 (89) 13 (7) 8 (4) 186 (11) 144 (77) 42 (23) 
overweight & Obese 538 (32) 503 (93) 26 (5) 9 (2) 538 (32) 461 (86) 77 (14) 
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18) 
Median CD4 (IQR) 418 (248, 618) 
> 500 cells/mm3 638 (38) 606 (95) 26 (4) 6 (1) 638 (38) 599 (94) 39 (6) 
 <= 500 cells/mm3 1050 (62) 956 (91) 63 (6) 31 (3) 1051 (62) 789 (75) 262 (25) 
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Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18) 
WHO stage        
Stage 1-2 1042 (62) 971 (93) 51 (5) 20 (2) 1042 (62) 881 (85) 161 (15) 
Stage 3-4 623 (37) 570 (91) 36 (6) 17 (3) 624 (37) 489 (78) 135 (22) 
missing 23 (1) 21 (91) 2 (9) 0 (0) 23 (1) 18 (78) 5 (22) 
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18) 
Second-line ARV regimen       
LPV/r +dual NRTI 1097 (65) 1011 (92) 55 (5) 31 (3) 1098 (65) 920 (84) 178 (16) 
ATV/r + dual NRTI 591 (35) 551 (93) 34 (6) 6 (1) 591 (35) 468 (79) 123 (21) 
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18) 
Median VL (IQR) 20 (20, 100)       
Viral load results       
<= 20 copies/mL 1056 (63) 1002 (95) 43 (4) 11 (1)    
21-1000 copies/mL 331 (20) 303 (92) 20 (6) 8 (2)    
> 1000 copies/mL 301 (18) 257 (85) 26 (9) 18 (6)    
Total 1688 (100) 1562 (93) 89 (5) 37 (2)    
Retention        
Retained     1562 (93) 1305 (84) 257 (16) 
Not retained     126 (7) 82 (65) 44 (35) 
Total         1688 (100) 1387 (82) 301 (18) 
 
VL: viral load; TB: tuberculosis; BMI: body mass index; ART: antiretroviral therapy; WHO: World Health 
Organization; ATV/r: ritonavir boosted atazanavir; LPV/r: ritonavir boosted lopinavir; NRTI: nucleoside/nucleotide 
reverse transcriptase inhibitors; IQR: interquartile range; LTFU: lost to follow-up.  
 
 
 
The median age range was 35 - 44 years and approximately 38% of patients had initiated ART at 
WHO stage 3 or 4. The majority of patients (64%) had initiated second-line ART prior to 2010 
resulting in median follow-up time of 26 months (IQR 24 - 36). 
In total, 1562/1688 (92.5%) individuals were retained in care, 126 (7.5%) were loss to 
follow-up and 37 (2.2%) had died. Retention appeared to be lowest among those aged 25 -34 years, 
and among singles, and the least healthy. Retention was 89.0% in individuals who were 
underweight and 90.7% among patients screened positive for tuberculosis, and 90.4% among those 
with CD4 cell counts below 350 cells/mm3 at initiation of ART. 
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In all 1688 individuals, at least one viral load result was available, regardless of whether 
patients had subsequently defaulted from care. Of these, 1387 of 1688 (83%) individuals were 
virologically suppressed (<1000 copies/ml) at last follow-up, whereas 1056 (63%) achieved 
undetectable viral loads (<20 copies/ml). Viral failure with VL > 1000 copies/mL was found in 
301 of 1689 (18%) individuals. Of all those retained in care, a higher proportion were virologically 
undetectable at the time of the last available viral load test result compared to those lost to care 
(64% vs 43%). Virological failure was also higher among those who were lost to care (35% vs 
16%). Retention in care was 94% for those who were virologically suppressed and 85% for those 
who were not suppressed. 
Hazards for defaulting from care 
 
The predictors of defaulting from care are presented in Table 2.  
          
 
 
115 
Table 2: Predictors of attrition and virological failure on second-line ART 
Predictors 
Multivariate analysis 
Defaulting from care   Virological failure  
 
Adjusted hazard 
ratio 
(95% CI) p-value 
Adjusted odds 
ratio (95% CI) p-value 
Age category (years). Reference category Age 40-59 * 
15-29 years 0.85 (0.42, 1.71) 0.654 2.22 (1.46, 3.38) <0.001 
30-39 years 1.03 (0.58, 1.81) 0.930 1.45 (1.03, 2.05) 0.032 
60+ years 1.87 (0.80, 4.38) 0.147 0.74 (0.36, 1.53) 0.421 
Sex *     
Male vs. female 0.87 (0.53, 1.43) 0.585 1.07 (0.80, 1.43) 0.644 
Marital status. Reference category single * 
Married/Cohabitating  0.48 (0.26, 0.90) 0.023 0.96 (0.64, 1.45) 0.857 
Separated/Divorced  0.69 (0.24, 1.96) 0.487 0.56 (0.27, 1.14) 0.110 
Widowed  0.57 (0.24, 1.34) 0.197 0.71 (0.40, 1.26) 0.242 
Missing  0.31 (0.15, 0.65) 0.002 1.02 (0.68, 1.54) 0.916 
ART initiation. Reference category 2009 and before * 
2010-2012  2.43 (1.47, 4.01) 0.001   
2013-2016 2.49 (1.00, 6.18) 0.049   
TB Screening. Reference category TB negative + 
Positive  1.26 (0.64, 2.49) 0.504 1.40 (0.92, 2.13) 0.117 
No screening  3.04 (1.49, 6.22) 0.002 1.01 (0.54, 1.88) 0.979 
 BMI category. Reference category recommended weight + 
Underweight BMI< 1.94 (1.05, 3.57) 0.034 0.99 (0.66, 1.50) 0.965 
Overweight BMI > 1.23 (0.73, 2.06) 0.432 0.80 (0.59, 1.09) 0.155 
CD4 Category +     
< 500 copies vs. > 500 cells/mm3 2.12 (1.20, 3.75) 0.009 5.40 (3.75, 7.77) <0.001 
WHO Stages. Reference category 
Stage 1-2 *     
Stage 3-4  1.22 (0.77, 1.96) 0.399 1.56 (1.18, 2.06) 0.002 
Missing  0.49 (0.06, 3.73) 0.489 1.36 (0.46, 3.99) 0.574 
 Second-line regimen +     
ATV/r + 2 NRTI vs. LPV/r + 2 NRTI 0.52 (0.29, 0.93) 0.027 1.48 (1.12, 1.95) 0.005 
Viral load suppression +     
> 1000 copies/mL vs <1000 copies/mL 2.95 (1.83, 4.76) <0.001   
Health facility types +     
HC vs. RH/PV 0.93 (0.52, 1.65) 0.799 1.55 (1.11, 2.17) 0.010 
DH vs. RH/PV 1.23 (0.68, 2.22) 0.496 0.92 (0.63, 1.34) 0.653 
* variable measured at initiation of ART, + variable measured at switch to second line ART. 
CI: confidence interval; DH: district hospital; HC: health centre; PH: provincial hospital; RH: regional hospital; TB: 
tuberculosis; BMI: body mass index; ART: antiretroviral therapy; WHO: World Health Organization; ATV/r: ritonavir boosted 
atazanavir; LPV/r: ritonavir boosted lopinavir; NRTI: nucleoside/nucleotide reverse transcriptase inhibitors.  
BMI categories: underweight=< 18.5 kg/m2, normal weight=18.5-24.9 kg/m2, overweight& obesity =25 kg/m2 or greater  
          
 
 
116 
These included ART initiation period from 2010-2012 and from 2013-2016 relative to 2009 or 
earlier (adjusted hazard ratios [HR] 2.43, 95% confidence interval [CI] 1.47 - 4.01 and HR 2.49, 
95% CI 1.00-6.18), CD4 cell count < 500 cells/mm3 vs CD4 cell count > 500 cells/mm3 at initiation 
(HR 2.12, 95% CI 1.20 - 3.75), lopinavir/ritonavir (LPV/r) vs. atazanavir/ritonavir (ATV/r) based 
second-line regimen (HR1.91, 95% CI 1.08 - 3.40) and viral load > 1000 copies/ml vs < 1000 
copies/ml at latest measurement (HR 2.60, 95% CI 1.71 - 3.94). In addition to these clinical 
variables, being married or cohabitating with a partner, relative to being single, was protective of 
defaulting from care (HR 0.48, 95% CI 0.26-0.90). 
Risk factors for virological failure  
The following risk factors were associated with virological failure in multivariate analysis: 
Age groups 15-29 years and 30-39 years compared to age group 40-59 years (adjusted odds ratios 
(OR): 2.22, 95% CI 1.46 - 3.38 and OR 1.45, 95% CI 1.03 - 2.05), CD4 cell count <500 cells/mm3 
vs. CD4 count > 500 cells/ mm3 at ART initiation ( OR 5.40, 95% CI: 3.75 - 7.77), WHO stage III 
& IV care compared to WHO stage I and II at program enrolment (OR, 1.56, 95% CI 1.18 - 2.06), 
ATV/r compared to LPV/r based second-line regimen (OR 1.48, 95% CI 1.12 - 1.95) and receiving 
care at a health center relative to regional or provincial hospital (OR 1.55, 95% CI 1.11 - 2.17). 
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8.5 Discussion 
 
Our study is the first to report on retention and viral load outcomes using a national 
representative sample of second-line ART patients in Rwanda. We found that, overall, a high 
proportion of patients were retained in care after a median follow-up of 26 months. The estimated 
92.5% retention was higher than that reported in previous studies in similar settings (Wilhelmson 
et al. 2016; Assefa et al. 2011). High retention in care in the Rwanda HIV program was also 
previously reported (Nsanzimana, Kanters, Remera, Forrest, et al. 2015; Ndahimana et al. 2016). 
Several possible reasons for high rates of retention in care include the highly decentralized health 
system that provides easy to access HIV services (98% of health facilities in Rwanda offer 
integrated, comprehensive HIV services). Further, there is a strong network of PLHIV that 
supports peer adherence to medication including home visits, awareness and education activities 
in the communities. In addition, Rwanda has a robust electronic monitoring and surveillance 
system that allows early warning signs of lost to follow-up, which initiates home visits by health 
care providers. Finally, health care seeking behavior in the Rwandan PLHIV population is high 
(Nsanzimana, Kanters, Remera, Forrest, et al. 2015). 
Our study identified key factors associated with defaulting from care: initiating at higher 
viral loads, low CD4 cell count, less clinical engagement, and time of treatment switch. Other 
studies from SSA and Asia have investigated predictors of attrition in care (Ajose et al. 2012; 
Wilhelmson et al. 2016; Boettiger et al. 2015; Hosseinipour et al. 2010; May Myat Win et al. 
2011). Across many settings, loss to follow-up on second-line patients was significantly higher 
among those with low CD4 cell count at baseline, and previously undiagnosed treatment failure 
on a first-line regimen (Wilhelmson et al. 2016; Boettiger et al. 2015; Fox et al. 2010; Hosseinipour 
et al. 2010; May Myat Win et al. 2011; Kanters et al. 2017; Laker et al. 2014; Ongubo et al. 2017; 
          
 
 
118 
Smith, Jeganathan & Ray 2006; Jobanputra et al. 2015). Other findings in similar settings reported 
that advanced disease at initiation was associated with attrition on second-line ART, and is likely 
the result of mortality (Johnston et al. 2012), as well as higher viral load and age (Boettiger et al. 
2015). Studies from Malawi (Hosseinipour et al. 2010), Thailand (May Myat Win et al. 2011) and 
South Africa (Fox et al. 2010) reported that adherence was the major determinant of treatment 
failure.  
In this study, viral suppression rate (VL< 1000 copies/mL) among second-line patients in 
Rwanda was estimated to be 83%. This rate is consistent with similar results observed in other 
resource limited settings with an average of 80% viral suppression after 12 months on second-line 
ART (Ajose et al. 2012; Wilhelmson et al. 2016). Results obtained from this study are generally 
consistent with other studies in developing countries. For example, the pooled proportion of 
virological failure in a recent systematic review and meta-analysis on second-line ART in low- 
and middle-income countries was 23.1%, 26.7% and 38.0% at 12, 24 and 36 months, respectively 
(Ndahimana et al. 2016). In many settings, virological failure was observed in the first 6 months 
following second-line ART start (Ndahimana et al. 2016). However, the reported results had large 
variations between studies and comparison of treatment failure might be difficult due to different 
cut offs used for viral load suppression across countries.   
Patients who were lost to care were more likely to be viraemic than patients who were 
retained in care – a finding observed also by others (Stinson et al. 2014). This has important 
implications for evaluating progress towards the UNAIDS 90-90-90 targets. For instance, 
assessing virological suppression (the third 90) only among patient retained in care will 
overestimate success unless losses to care are taken into account.  
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In Rwanda, a previous study reported that only 23% of patients presenting virological 
failure ( > 1000 copies/mL ) had drug resistance mutations suggestive of third line ART, though 
77% with high viral load could still remain on efficacious second-line therapy (Ndahimana et al. 
2016, 2015). This reinforces the need for intensive adherence for patients presenting suboptimal 
viral load suppression before switching to costly and complicated salvage therapies. The same 
challenge was also reported in other resource-limited countries (Ajose et al. 2012; Jobanputra et 
al. 2015; Ndahimana et al. 2015).  
The HIV program in Rwanda has made major shifts since 2009, when no new drug classes 
were available for cases of virological failure (20). The new recommendation was implemented in 
2013, when LPV/r based regimens were replaced by ATV/r based regimens. In our analysis, 
patients who started anti-retrovirals after 2010 had better retention on ART, yet no better VL 
outcomes.  
For this study, we controlled the distributions of backbones for both LPV/r and ATV/r. 
There was equal distribution of zidovudine, tenofovir and abacavir for each PI-based combination; 
lamivudine was maintained across all second-line regimens as per national guidelines. Patients 
treated with ATV/r were significantly more likely to experience virological failure. A recent 
systematic review of six randomized controlled trials on the comparative efficacy of second-line 
ART did not find a difference in efficacy between LPV/r or ATV/r plus two NRTIs and LPV/r 
with raltegravir. Although ATV/r had a greater numerical efficacy compared to LPV/r, differences 
were not statistically significant (Kanters et al. 2017). Another study conducted in Uganda (Laker 
et al. 2014) compared LPV/r and ATV/r in patients failing first line ART (2NRTI+1NNRTI) and 
confirmed comparable potency and efficacy. Being on LPV/r was twofold associated with 
defaulting from care, which could be due to the higher pill burden and adverse gastro-intestinal 
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drug reactions associated to LPV/r causing low adherence to medication (Al-Dakkak et al. 2013). 
A recent study in Malawi among patients receiving ATV/r also reported that bilirubin levels 
predicted VL failure (Ongubo et al. 2017). ATV/r prescription with related increased bilirubin has 
been associated with high interpatient disparities with hyperbilirubinemia and jaundice resulting 
into premature discontinuation of atazanavir and subsequently impact on virological outcome 
(Smith, Jeganathan & Ray 2006). 
A major strength of our analyses is the relatively large sample size corresponding to 25 % 
of all people living with HIV on second-line ART in Rwanda. We also used routinely reported 
data that reflects more precisely the everyday life of patients. In addition, we had few missing data 
and all our patients had at least one viral load measured in the last 12 months on ART. Data were 
collected from a diverse population of patients in large, medium and small sites.  In addition, we 
managed to successfully demonstrate how nationwide routine surveillance open MRS data could 
be used to inform on patients’ retention and viral load suppression.  
Our study also has several limitations. First, the data was collected from an open electronic 
medical record system for which individual patient-level data were routinely reported. As such, 
not all desired variables were available – most importantly adherence to HIV medication and 
outcomes among those lost to care. Second, we could not distinguish reasons for switching to 
second-line ART other than virological failure. Third, the sampling population only included 340 
of the 513 health facilities with second-line patients. Thus, there is a risk of selection bias innate 
to the data availability. Finally, as with all observational studies, confounding through unmeasured 
covariates need to be considered when interpreting the reported associations.  
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8.6 Conclusions 
 
In conclusion, our study suggests that patients on second-line ART within Rwanda are doing 
relatively well, with high levels of retention in care and viral suppression. A better understanding 
of adherence and adherence interventions for those that are less healthy is required. Importantly, 
routine viral load measurement and tracing of loss to follow-up is fundamental in resource limited 
settings in order to minimize the risk of treatment failure.  
8.7 Declarations 
 
Ethics approval and consent to participate 
The use of the routine program data was approved by the Rwanda National Ethics Committee. 
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9.1 Abstract 
 
Background: In Rwanda, third line ART has been introduced in 2012 for all patients with 
virological failure on first (NRTIs) and second line (PI) based regimens. We aimed to characterize 
the outcomes of these patients over 5 years on integrase inhibitors based treatment. 
Setting: Rwanda has a mature HIV epidemic, with 3% prevalence and 82% of all people living 
with HIV receiving ART. Individual patient data were collected from medical records in all health 
facilities offering this therapy. 
Methods: We collected data from all individuals who ever started third line anti-retroviral 
therapy between June 2012 and September 2017 in Rwanda and calculated the proportion of 
patients achieving viral suppression at 12 and 24 months on therapy. Genotyping was conducted 
in all patients at baseline. 
 Results: In total, 53 Patients started third-line ART and were followed for a median of 43 
(IQR 29-54). Overall, 93.3% and 90.9% achieved VL less than 1000 copies/ml after 12 and 24 
months respectively. The regimen was well tolerated with 8.8% of participants experiencing severe 
adverse events and 90.9% self-reported good adherence. The majority of patients were susceptible 
to raltegravir and ritonavir boosted darunavir. 
 Conclusion: Overall, our findings demonstrate the feasibility of providing third-line ART in 
a routine program in resource limited setting; however, it raises concerns about patients who failed 
all available treatment options. 
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9.2 Introduction 
 
The World Health Organization (WHO) recommends the use of non-nucleoside reverse 
transcriptase inhibitor (NNRTI)-based regimens in first-line antiretroviral therapy (ART) against 
HIV, boosted protease inhibitor (bPI)-based regimens in second-line ART, and integrase inhibitors 
in third-line ART (WHO 2016) . While the vast majority (≥90%) of the 16 million individuals 
currently receiving ART are on first- and second-line regimens, the number of people requiring 
third-line regimens continues to rise (WHO 2016). Most developing countries do not currently 
provide third-line ART because of limited data and high cost. We report outcomes from Rwanda’s 
national HIV program, one of the first cohorts providing third-line ART in sub-Saharan Africa. 
9.3 Methods 
 
Rwanda’s Ministry of Health has been providing eligible HIV patients with ART since 2004. 
By September 2016, 92% of 214,000 individuals with HIV were receiving ART on first-line and 
4% on second-line ART, as depicted in figure 1.  A total of 553 health facilities were offering 
HIV treatment in Rwanda. Among them, 23 had enrolled 53 patients on third-line ART using an 
open electronic medical record (EMR) system implemented in Rwanda since 2010. We included 
in our analysis all patients ever started third-line anti-retroviral therapy between June 2012 and 
September 2017 in Rwanda national HIV program. Our data source was electronic medical 
records. Two authors (ER, MR) visited all the third line health facilities and extracted data 
backups from EMR local servers using mysql software and exported them to STATA version 14 
to conduct the analyses. 
According to the national HIV guidelines, patients were provided with third line ART 
following virological failure on second-line regimens and selection of antiretroviral drugs based 
on genotyping results using Stanford HIV drug resistance database (Rhee et al. 2003). National 
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guidelines consider virological failure as two viral load results above 1,000 copies/mL separated 
by at least three months and a behavioural adherence intervention. We calculated the proportion 
of patients achieving viral suppression after third-line initiation regardless of the time treatment 
was initiated, using simple statistics for 95% CI to assess the difference between outcome variables 
and independent variables. Patients were censored at date of death, date stopping ART, or on 
September 30, 2017. We also calculated accumulated drug resistance mutations, self-reported 
adherence and treatment-limiting adverse events.  
This study received approved by the Rwandan National Ethics Committee for analysis and 
publication of routine program implementation activities under Rwanda Biomedical Center. 
9.4 Results 
 
By end of September 2017, 53 patients were enrolled on third line of ART. The median age 
was 43 years (IQR 29-54) and 56.6% were female. Patients were on first-line ART for a median 
period of 44 (IQR 24-75) months and on second line ART for 46 (IQR 30-59) months. Patients 
were followed for a median of 36 (IQR 13-47) months on third-line ART. The median CD4 cell 
count at start of third-line was 196 cells/µL (IQR 75-329) and the median viral load decreased 
from 52,600 copies/ml at the initiation to 20.85 copies/ml for the latest viral load. Viral load results 
were obtained for 51 patients at baseline, 30 patients had at 12months, while 22 patients achieved 
24 months on third line ART.  
Overall, 93.3%, 90.9% of all patients achieved VL less than 1000 copies/ml after 12 months 
(N=30) and 24 months(N=22) on third line ART respectively. Only one patient died and no lost 
follow up. The proportion of patients with high viral load >1000 copies decreased from 82,3% at 
baseline to 6,7% at 12 months and 9.1% after 24 months on ART (figure 2). Similarly, the median 
BMI increased from 20.4 [IQR: 15.9-24.6] to 22 [IQR: 19.6 - 25.8].  
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Genotyping was conducted in 83.8% of all patients across all reverse transcriptase and protease 
inhibitors prior to initiation of third line ART; 96.5%,63.4% and 75.8% of patients had two or 
more resistance mutations to NRTIs, NNRTIs and PIs respectively.  75.47% and 77.36% had at 
least one mutation on NRTI and NNRTI respectively. Overall, the majority of patients were 
susceptible to raltegravir and darunavir/ritonavir. All patients received a combination of boosted 
darunavir, raltegravir, etravirine and in addition +/- 2 NRTIs. Adherence was assessed in 44 
patients at initiation of third line ART and 40 (90.9%) self-reported good adherence to medication. 
Overall, 93.3 % and 90.9% of patients achieved viral suppression < 1000 copies/mL at 12 and 24 
months respectively (Figure 2); Overall the regimen was well-tolerated, with 8.8% of participants 
experiencing a treatment-limiting adverse events, including skin rash, gastro intestinal intolerance 
and hepatotoxicity. 
9.5 Discussion 
 
Our report exemplifies one of the first evaluations of third-line ART in Sub-Saharan Africa. 
We included in our analysis all patients who ever initiated third line ART in Rwanda. We found 
that overall viral suppression after 12 and 24 months was high given that these patients had already 
experienced failure on multiple various regimen. The reported 90.9% of patients achieving viral 
load less than 1000 copies/ml after 12 months was marginally higher than previously reported 
elsewhere (Meintjes et al. 2015; Mata-Marín et al. 2015; Prasitsuebsai et al. 2017). Our findings 
on virological suppression are consistent with other studies on multiclass resistant treatment 
outcomes using raltegravir, darunavir and etravirine in developed and developing countries as 
reported in South Africa, France, Mexico, and Thailand (Fagard et al. 2012; Mata-Marín et al. 
2015; Prasitsuebsai et al. 2017; Meintjes et al. 2015). Our study identified that close to 10% of 
multi-drug resistant patients had virological failure after more than two years on third line ART. 
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Although, there is limited data available on virological failure in third line therapy; our findings 
are consistent with other studies with an average rate of virological failure ranging from 10-40% 
mainly due to poor adherence (Mata-Marín et al. 2015; Prasitsuebsai et al. 2017; Charpentier et al. 
2012). 
In this cohort, genotyping resistance testing was done in all patients who had failed second line 
PI based therapy to inform third line regimen selection. The majority of our patients were 
susceptible to raltegravir and darunavir, although etravirine (NNRTI second generation) has 
included in the national guidelines as part of third line combination; the possibility of resistance to 
etravirine after failing first generation of NRTI has been reported previously (Charpentier et al. 
2012; Cotte et al. 2009; Scherrer et al. 2009) and merits further research. Overall, our findings 
demonstrate the feasibility of providing third-line ART in a routine program setting in contrast of 
clinical trials; however, it raises important questions about the future treatment options for patients 
failing available treatment in the context of resource-limited backgrounds. Important limitations 
of our study are related to the small number of patients on third line ART. In addition, this was 
retrospective analysis using routinely available data and thus we were not able to measure key 
factors that may have influenced treatment outcome. 
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Table1: Characteristics of study participants alive on third line antiretroviral therapy in  
               Rwanda. 
Characteristic Baseline value 
End point value (as of 
December 2017) 
Current Age (yr)  
     Median 43  
     Interquartile range 29-54  
Female sex – n (%) 30 (56.6%)  
Education – n (%)  
     No school 9 (21.43%)  
     Primary school 24 (57.14%)  
     Secondary school or more 9 (21.43%)  
Marital status – n (%)    
    Married 29 (54.72%)  
    Divorced-widowed 10 (18.87%)  
     Single 14 (26.46%)  
HIV clinical stage at ART initiation–  
n (%)  
  
     Stage 1 11 (20.75%)  
     Stage 2 8 (15.09%)  
     Stage 3 20 (37.74%)  
     Stage 4 14 (26.42%)  
CD4 T-cell count at ART Initiation– 
cells/mm3  
  
     Median 196 - 
     Interquartile range 75-329 - 
Body-mass index (Initial)– kg/m2    
     Median 20.4 23.1 
     Interquartile range 15.9-24.6 19.7-30.1 
Body-mass index (current)– kg/m2    
     Median 22.04  
     Interquartile range  19.6 - 25.81  
First-line regimen used – n (%)   
TDF- Based 5 (9.43)  
AZT-Based 24 (45.28)  
D4T Based 18 (33.96)  
Others 6 (11.32)  
Second-line regimen used – n (%)   
2NRTI+LPV/r  37 (69.81)  
2NRTI+ATV/r  7 (13.21)  
Others 3 (5.66)  
N/A 6 (11.32)  
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Third-line regimen used – n (%)   
DRV/r+RAL+ETV 31 (58.49)  
2NRTI+ DRV/r+RAL 13 (24.53)  
2NRTI+ DRV/r+RAL+ ETV 1 (1.89)  
Other PI + RAL + ETV 8 (15.09)  
Others   
Major NRTI mutations*   
    None 13 (24.53)  
At least one 40(75.47)  
Major NNRTI mutations*   
    None 12 (22.64)  
  At least one 41(77.36)  
Major protease mutations*   
    None 19 (38.00)  
    At least one 34 (62)  
All three mutations combined   
    None 11 (20.75)  
   At least one 42 (79.24)  
Median Viral load  
52.600 copies /ml  
(IQR: 7,380-153,000).  
20.85copies/ml (IQR:<20 
- 5320) 
 *Mutations were classified as major based on International Antiviral Society guidelines [6]. 
Major NRTIs mutations (on the genotyping test result, thymidine analogue mutations are not specified rather 
nucleoside reverse transcriptase inhibitor mutations): 
M46I, I54V, V82A, V75M, E44D, Y115F, G190A, M230L, F77L, I50V, L74I, F116Y. 
 
Major NNRTIs mutations: 
V118I/wt, K45I, K101H, Y188L, K311N, V2921I, K103N, A98G, V106I, V108I, Y181I, H221Y, G190A, Y318F, 
E138A, V179I, V189I, F227L. 
  
PIs major mutations: 
L10F/wt, I13V/wt, I15V, M36I, K55R/wt, H69K, A71T, I93L, L33F, L24I, G73S, K20R, L63D, L38W, R41K, I64V, 
E35D, M46I, L24I, E35D, I93L, K20J, M461MV, G16E, K20R, H69K, K70R, T74S, L89I, K45R, E47A, M61I, 
I62V, E25D, I13V, I85V. 
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Figure 1: Flow of Patients on ART by regimen in Rwanda. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ART: Antiretroviral therapy; NRTI: Nucleoside Reverse Transcriptase; NNRTI: Non-Nucleoside 
Reverse Transcriptase; DRV: Darunavir; ETV: Etravirine; RAL: Raltegravir.  
People living with HIV on ART 
in Rwanda (N=181,921) 
Patients on Second line ART  
(n= 7,625) 
) 
First line ART combination 
2NRTI+1NNRTI 
Patients on first line ART 
(n= 174,252) 
Second line ART combination 
2NRTI+boosted PI 
Third line ART patients (n=53)  
All were included in our 
analysis 
Third line ART combination 
DRV/r+RAL+ETV (+/- 2NRTI) 
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Figure 2. Viral load suppression at baseline,12 and 24 months on third line ART 
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10.1 Abstract 
 
Background: Female sex workers (FSWs) and their clients are drivers of HIV epidemic in 
the Sub-Saharan African region. FSW have high prevalence rates of HIV and may engage in 
unprotected sex with multiple partners. Rwanda has identified FSWs as a key population to 
implement effective prevention strategies for HIV infection and for immediate antiretroviral 
therapy (ART) of infected FSW. Prevention strategies include education, access to male condoms, 
antiretroviral therapy for infected FSWs and pre-exposure prophylaxis (PrEP) for uninfected 
FSWs. Given constrained resources for HIV in Rwanda, it is important to understand how the 
incidence and prevalence of HIV among the FSW community is affected by different prevention 
efforts.  
Methods: To estimate the effects of targeted prevention strategies on the HIV epidemic for 
FSWs and sex clients, we developed a dynamic Markov model to estimate the prevalence and 
incidence of HIV for FSWs and the residual community in Rwanda. Promotion of condom use as 
well as the expected widespread introduction of PrEP in 2019 were also incorporated. We 
considered the following six states: 1) HIV negative; 2) undiagnosed HIV; 3) diagnosed HIV 
without ART; 4) on ART with suppressed and 5) unsuppressed viral load; and 6) death. Our 
Markov model used national level demographic data, sexual sero-behavior data of the three 
populations, HIV associated morbidity and mortality to estimate the incidence and prevalence of 
HIV starting at 2017 with a time horizon of 10 years.  
Findings: We observed the HIV epidemic being controlled with the current HIV treatment 
and prevention strategies that are in place at the national level. These efforts also prevented a spike 
in the HIV incidence and prevalence among FSWs and their male partners. Introduction of testing 
and improved ART coverage further mildly reduced prevalence among FSWs and sex clients, 
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whereas a worst-case scenario in coverage and testing had an opposite effect. A 30% improvement 
in condom use among FSWs reduced HIV prevalence by 6-7% over 10 years among FSWs and 
sex clients. Improvement in condom use among the general population reduced the prevalence by 
0.24%. Lastly, introducing PrEP among female sex workers in 2019 with increasing coverage 
would reduce the incidence of HIV among FSWs by 50% in 2027. 
Interpretation: Implementation of different prevention strategies offer differing preventive 
effects. The findings of our study have implications to other countries in Sub-Saharan Africa with 
concentrated HIV epidemic in FSWs. 
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10.2  Introduction 
 
Female sex workers (FSWs) are a key population in the Sub-Saharan African HIV epidemic 
as they have a high prevalence of HIV, may engage in unprotected sex, and may have multiple 
partners. While there is some regional variation, the estimated HIV prevalence in the FSW 
population is 10- to 20-fold higher than in the general population (WHO 2011). In Rwanda the 
HIV prevalence among FSWs is estimated to be approximately 50% (Ngugi et al. 2012). In 
response, Rwanda has developed in the last two decades, a strong national response to control its 
HIV epidemic, including  the FSW population (MoH/RBC-Rwanda 2012). It has made impressive 
achievements in HIV care through progressive treatment guidelines and reduced the number of 
new HIV infections by 50% and the overall number of AIDS related deaths by 78% from 2004 to 
2014 (MoH/RBC-Rwanda 2012). The national prevalence of HIV has been stable at 3% as of 2013 
(Nsanzimana, Kanters, Remera, Forrest, et al. 2015). However, the country  still faces challenges 
with high concentrations of HIV in the FSW population; 46% of these women are estimated to be 
HIV positive (MoH/RBC-Rwanda 2015b), and HIV incidence among this population is 3.5% per 
100 person-years (95% CI: 1.6, 5.4), compared with the general population incidence rate (0·27 
per 100 person-years, 95% CI 0·18-0·35) (Nsanzimana et al. 2017; Braunstein et al. 2009). Given 
that FSWs are more likely to have multiple sexual partners and may engage in unprotected sex, 
targeted interventions within this community may yield important public health benefits. 
Rwanda has specified efforts to test and treat HIV+ FSWs with antiretroviral therapy (ART) 
regardless of CD4 counts, in an effort to reduce HIV transmission (MoH/RBC-Rwanda 2012). 
Targeted efforts include an intensive prevention package for FSWs. Mobile services and outreach 
activities have been implemented to reach FSW populations regardless of their location or work 
environment (MoH/RBC-Rwanda 2012). At the facility level, services such as HIV counselling 
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and testing, family planning and sexual reproductive health services, STI screening and treatment, 
and condom provision are offered to FSWs (MoH/RBC-Rwanda 2012). Outreach involves hotel 
and bar-based services, street services, and opportunities to engage FSWs involved in incidental 
transactions (MoH/RBC-Rwanda 2012). Health care providers receive training to minimize stigma 
faced by FSWs and prevent avoidance for  accessing health care services (MoH/RBC-Rwanda 
2012). In addition, implementation of pre-exposure prophylaxis (PrEP) targeted at FSWs is 
currently being considered for the next revision of HIV and AIDS National Strategic Plan for the 
year 2019. This targeted intervention of PrEP along with the other efforts to increase utilization of 
other HIV services and ART coverage for FSWs will likely result in reduced likelihood of HIV 
transmission.  
It is therefore vital to understand how the incidence and prevalence of HIV will be affected 
by Rwanda’s specific initiatives for FSWs. Given constrained resources for HIV treatment and 
prevention services, it is important to estimate the prevalence and incidence rates of HIV over time 
for strategic planning. Using nationally representative and FSW specific data in Rwanda 
(Mutagoma et al. 2015; Nsanzimana et al. 2017; Nsanzimana, Remera, Kanters, Forrest, et al. 
2015; Nsanzimana, Kanters, Remera, Forrest, et al. 2015; Nsanzimana, Remera, Kanters, Chan, et 
al. 2015), we developed a dynamic Markov model to estimate the prevalence and incidence rates 
of HIV amongst FSWs and sex clients over the next 10 years. In this study, we estimated the effects 
of ART, PreP and condom use based prevention strategies on the HIV epidemic in Rwanda. In 
particular, we examine the evolution of incidence and prevalence in the FSW population, male 
clients and in the overall population. 
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10.3  Methods 
 
Model structure 
We developed a nationwide dynamic Markov model (Aalabaf-Sabaghi 2007) for transmission 
of HIV from 2017 to 2027 to estimate the incidence and prevalence of HIV among FSWs, sex 
clients, and the general population in Rwanda. Our model includes national level demographic 
data, sexual and sero-behavioral information of the three populations, HIV associated morbidity, 
all-cause mortality, and HIV-related mortality. We considered the HIV transmission, testing 
patterns, adherence to ART, and their likelihood for viral suppression for FSWs, their male 
partners, and the general population. Finally, as introduction of PrEP to FSWs is expected in 
Rwanda by year 2019, the model assumes and captures an expected 40% PrEP up-take in FSW by 
the end of 2019 with a gradual increase to 80% PrEP use in the year 2027.  
For each population, our Markov model considered the following six states: 1) HIV negative; 
2) undiagnosed HIV+; 3) HIV+ virally suppressed on ART; 4) HIV+ not virally suppressed on 
ART; 5) HIV+ without ART; and 6) death. Here, state four represents a setting where under current 
ART regimen viral suppression is not achieved, and state five represents a setting where the patient 
has discontinued ART for the duration of the cycle. Figure 1 displays the transition pathways 
between the six states. In addition, we retained transitions in from one population to another, 
remaining in the same state. That is, in each cycle some transition is accounted for from belonging 
to the general population and to engaging in sex work or buying sex, and some FSWs and clients 
disengaging from having paid sex and moving back to the general population risk scheme for 
acquiring HIV. A time horizon of 10 years was considered starting in 2017. Cycle duration was 
set to one year and transition probabilities derived accordingly.  
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Model parameterization 
Population sizes movement between populations 
The size of the three considered populations were obtained from recent nationwide surveys and 
are presented in Table 1 (individual calculations for numbers in Table 1 are outlined in 
Supplementary Table 1). The model also assumes an annual growth rate of 2.4% (UNAIDS 
2016a) in Rwanda’s population, as well as separate mortality rates for HIV negative individuals, 
undiagnosed or non-virally suppressed HIV+ individuals, and virally suppressed HIV+ individuals 
on ART (see Supplementary Table 2). Movement of individuals between the different population 
groups were considered as follows: We assumed that 47,644 active FSWs reside in Rwanda. We 
assumed that on average FSW would remain active for 10 years before retiring and, as a base case, 
that the number of FSWs would remain constant over the next 10 years (relative to country 
population growth). Identical entry and exit rates were assumed for male clients. For scenario 
analyses where the size of the FSW population was allowed to vary over time, the size of the sex 
client population was modified accordingly by holding number of sexual encounters and sex 
clients per FSW constant (the same as assumed for the base case, see below) and mathematically 
solving for number of sex clients.  
Transmission between populations 
We assumed HIV transmission occurs between FSWs and clients as well as between sex 
clients and their life time partners in the general population. We did not assume FSWs transmit 
directly to the general population. We assumed an average number of 52 sex clients per year per 
FSW, as well as an average number of 2.5 exposures (sexual acts) per client. HIV transmission 
probabilities were calculated using the equations provided in the Supplement (see section HIV 
transmission probabilities). This equation incorporates the size of each population, the HIV 
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prevalence in the client group, the average number of sexual exposures for each group, condom 
use or use of PreP, the risk of HIV transmission per sexual intercourse (unprotected and protected), 
and the type of intercourse (anal vs vaginal). The values assumed for these parameters are 
presented and justified in Supplementary Table 2. 
Transmission between populations 
The transition probabilities for the six states (Figure1) are presented and justified in 
Supplementary Table 2. These are derived from multiple nationwide surveys and longitudinal 
studies conducted in Rwanda (References provided in the appendix). In addition, general and 
Rwanda specific estimates of likelihood of adherence to ART is incorporated. The model was 
programmed in R v.3.4.2, and figures were produced using the ggplot package.  
Model validation 
We validated our model using data collected from 2010 (MoH/RBC-Rwanda 2010) and 
2015 (MoH/RBC-Rwanda 2015b) on the prevalence for FSWs and the general population. The 
estimated HIV prevalence among FSWs were 51% in 2010 and 45% in 2017 (see Supplementary 
Figure 1). The HIV prevalence among clients was estimated to be 10% in 2015. The estimated 
national HIV prevalence has remained constant at approximately 3% over the past decade.  
Analysis 
We recorded the evolution of annual HIV prevalence and incidence from 2017 to 2027 in our 
Markov model. For each analysis, 1,000 simulations with multinomial allocations of people to 
different Markov states each year were performed. Base case scenario input parameters are all 
presented in Table 1 as well as in Supplementary Table 1 and Table 2 as described in the 
methods section. We considered worst and best-case scenario analysis for key parameters related 
to testing behavior and ART coverage, condom use and PrEP uptake, as well as growth or decline 
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in the FSW population. The considered parameters and the assumed worst and best-case estimates 
are presented in Table 2.  
10.4  Results 
 
Model calibration is presented in Supplementary Figure 1. The projected 2015 prevalence 
estimates were nearly identical to the 2015 survey estimates. 
Base case 2027 projections 
The overall incidence rate of HIV (per 1000 person-years) over time in Rwanda is illustrated 
in Figure 2. With the current HIV testing and ART coverage, the annual overall population 
incidence rate decreases from 2017 (1.45 per 1000 person-years) to 2027 (1.17 per 1000 person-
years). With the introduction of PrEP in 2019 the annual incidence decreases further with a notable 
additional decrease in 2020, and a continuing decrement to 1.05 per 1000 person-years) in 2027. 
The number of people living with HIV increases from 344,594 in 2017 to 394,869 by year 2027 
(Figure 3), which corresponds to a 1.37% annual growth (note, the general population growth rate 
is 2.4%). With the current HIV testing and ART coverage, the annual incidence of FSWs living 
with HIV remains stable over the 10-year period. With the introduction of PrEP, the incidence 
among FSW decreases from 46.5 per 1000 years in year 2017 to 11.8 per 1000 years (Figure 4). 
The number of HIV positive FSWs decreased from 21,469 in 2017 to 15,006 in 2027 (see also 
Supplementary Figure 2). Among sex clients, incidence decreases from 19.5 per 1000 person-
years in 2017 and 12.2 per 1000 person-years in 2027. The number of male partners infected with 
HIV rises from 24,631 to 26,183, corresponding to an annual growth of 0.6% (i.e., only a quarter 
of the annual overall population growth). The evolution of the number and proportion of FSWs 
and sex clients living with HIV in the base case scenario are presented in Supplementary Figures 
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2 and 3. Overall evolution of proportion of FSWs and sex clients in each of the six states for the 
base case scenario are presented in Supplementary Figure 4. 
Scenario analysis 
Table 2 presents the worst-case and best-case scenarios for 2027 prevalence estimates for the 
selected scenario analysis parameters. Figure 5 presents the tornado diagrams illustrating each of 
the three populations’ sensitivities to changes in the explored parameters (i.e., magnitude of change 
in results under the worst and best-case scenarios). For the parameter of testing and treatment, we 
observed the following trends: Increased testing for FSWs was associated with a small reduction 
in HIV among sex clients. Increased testing of the general population and national coverage of 
ART were associated with a reduction in HIV prevalence among FSWs and the latter was also 
associated with a reduction in sex clients.  Finally, improved adherence to ART had a moderate 
impact on HIV prevalence in both FSWs and the general population, but a worsening in ART 
adherence was associated with a larger negative effect with increased HIV prevalence. Changes in 
testing or ART related parameters, however, never exceeded 1%. For use of condoms, the best-
case scenario for increased use among FSWs reduces the prevalence by 7.76% (36.43% vs 
28.67%) among FSW population and by 6.21% (18.66% vs 12.45%) among sex clients. In the 
worst-case scenario with decreased condom use among FSWs, however, the models estimate a 
3.4-4.3% increase in HIV prevalence in both populations. An increase in condom among FSWs 
reduces the prevalence in the overall population by 0.1%. The best-case scenario of increased 
condom use in the general population leads to 0.17% absolute decrease in HIV prevalence in the 
overall population (i.e. a 6.4% relative reduction) but does not affect the prevalence among FSWs 
or male partners. Similarly, a worst-case reduction in condom use in the general population is 
associated with an increase in prevalence. The best-case scenarios for PrEP use among FSW results 
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in a 1.53% reduction in prevalence among FSW, whereas in the worst-case scenario a 2.95% 
increase in HIV prevalence can be expected. Best case scenarios for condom use and PrEP use 
yields the largest reduction in prevalence overall, and no further reduction is observed from added 
HIV testing, ART coverage and adherence under this scenario. However, in the worst-case 
scenarios for condom use and PrEP further increase in HIV prevalence will result if combined with 
worst case scenarios for HIV testing, ART coverage and adherence. 
10.5  Discussion  
 
Our findings highlight a number of key components for containing and reducing the HIV 
epidemic in Rwanda. First, a continued promotion of ART based prevention strategies, particularly 
in high-risk group like FSWs, is essential to stabilize the incidence and prevalence. Equally 
relevant, any worsening in these parameters would have severe negative consequences. Second, 
the expected introduction of PrEP will likely have a substantial impact on the incidence and 
prevalence of FS and clients and to a minor extent in the general population. Most notably, the 
incidence of HIV among FSWs is expected to halve over the next 10 years with the introduction 
of PrEP in 2019.  
After implementing the test-and-treat strategy in 2016 Rwanda has observed drastic 
improvements in several HIV related outcomes. The national ART coverage and testing has 
increased considerably in the last decade. The overall number of people who are now aware of 
their HIV status and treated with ART has also improved. In combination, these measures have 
led to a stabilization of the overall HIV prevalence in Rwanda. Meanwhile, the annual percentage 
increment in overall number of people living with HIV (2.1%) is superseded by the annual 
population growth rate, resulting in a slight decrease in the overall prevalence. It appears that the 
continuing epidemic may largely be driven by the concentrated epidemic of HIV among FSWs 
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and their clients. However, it is important to recognize that accomplishments that with “treat all 
HIV FSW” policy implemented in Rwanda since 2013; without that, both the incidence and 
prevalence among FSWs and their male partners would have experienced a drastic upsurge.  
As Rwanda prepares to plan for its fourth edition of its National Strategy Plan for HIV/AIDS, 
it recognizes the necessity for a continued focus on FSWs. Efforts to increase the testing of HIV 
in FSWs and ensuring lifelong ART in HIV positive FSW with provision at diagnosis will need to 
be continued, along with efforts to improve consistent condom use. Our model clearly shows that 
the latter will have a substantial effect on HIV prevalence in the FSW and general population. 
Promoting condom use among FSWs will dramatically reduce prevalence among sex clients over 
the next 10 years. Finally, the planned introduction of PrEP to FSWs in 2019 will have a substantial 
effect on the FSW population as the incidence of HIV drops drastically after its (modelled) 
introduction and continues to decline steeply. The individual prophylactic efficacy of increased 
testing and ART coverage, condom use, and PreP uptake among HIV negative FSWs hold much 
promise, and in the long run, may be the long-term strategy to control the HIV epidemic in 
Rwanda. 
Our model and analyses have several strengths and limitations. Our model capitalized on 
access to rich up-to-date nationwide Rwandan specific data sources and interaction with the 
Ministry of Health officials who were available to provide the local context. As a result, the 
majority of transition probabilities are directly informed by data with high internal validity. This 
stands in contrast to many Markov models, where scattered data from several countries typically 
necessitate questionable assumptions to derive transition probabilities. The utilized data, however, 
are all cross-sectional and not representative of the local sub-populations of FSWs that may have 
different geographical challenges and constraints. There was also limited information on 
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behaviours of sex clients, and as a result, it was necessary to indirectly model these via the links 
to FSWs and the general population. To estimate the HIV transmission probabilities for our 
Markov model, we had to rely on self-reported data on sexual behaviors, which are likely subject 
to some bias. Lastly, our model did not include other key risk populations (e.g. men who have sex 
with men, male sex workers, and sero-discordant couples) in Rwanda.  
Continuing to improve the quality and access of existing prevention and treatment 
interventions along with the new investment in PrEP in FSWs will likely have the largest public 
health impact on the HIV epidemic. While HIV care in Rwanda has been among the best in sub-
Saharan Africa in terms of expanding ART coverage through investments in HIV infrastructure, it 
will require tremendous continued efforts. Introducing PrEP will require more resources, and this 
needs to be complemented and supported with other aspects of the HIV treatment cascade. 
Improving access and adherence to ART and condom use, along with achieving 80% coverage of 
PrEP are ambitious targets. Such efforts will require multi-sector response and coordinated 
participation and actions across all groups of stakeholders in Rwanda. Health care providers will 
need to receive continued training to minimize stigma and discrimination faced by FSWs in order 
to ensure that they will not avoid accessing key health care services such as regular HIV testing, 
PrEP, and ART. As well, economic empowerment and opportunities with educational support are 
also likely required for this key population to control the concentrated HIV epidemic (WHO 2011).  
Despite the progress made in containing the HIV epidemic in Rwanda, the concentration of the 
HIV epidemic remains high in marginalized groups such as FSWs. There have been limited 
investigations on FSWs. Future research that needs to be prioritized include FSWs’ ability to 
negotiate condom use with their clients and ways to increase diagnostic testing of HIV and other 
STIs in FSWs. Existing barriers that affect FSWs’ acceptability and adherence to ART and PrEP 
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should be explored and addressed to remove barriers that are institutionalized. This study has 
demonstrated the need for continued efforts to improve and expand the quality of existing HIV 
services (e.g. more testing and ART), as well the potential gain of adopting a targeted intervention 
strategy such as PrEP in FSWs and other key drivers of the HIV epidemic not only in Rwanda, but 
also in other Sub-Saharan African countries. 
Table1: Sizes of the three populations and number of individuals within each state for each 
population 
Parameter Base value 
Lower 
bound 
Upper 
bound 
Source 
FSW population  
HIV- (State 1) 24,300 13,340 48,950 BBSS SW Rwanda 20155 
Undiagnosed HIV (State 2)  2,691 2,318 3,053 BBSS SW Rwanda 20155 
HIV+ with viral suppression on 
ART (State 3) 
11606 4478 39236 BBSS SW Rwanda 20155 
HIV+ without viral suppression 
on ART  
(State 4) 
2513 970 8496 BBSS SW Rwanda 20155 
HIV+ not on ART  
(State 5) 
3,890 1,894 10,266 BBSS SW Rwanda 20155 
Total size 47,644 25,000 111,000 ESPHS Rwanda 201115 
Male partners population  
HIV- (State 1) 159,300 38,070 -- BBSS SW Rwanda 20155 
Undiagnosed HIV (State 2)  2,301 550 -- BBSS SW Rwanda 20155 
HIV+ with viral suppression on 
ART (State 3) 
10,126 2,420 -- UNAIDS 201612; Nsanzimana 20154 
HIV+ without viral suppression 
on ART  
(State 4) 
2,193 524 -- UNAIDS 201612; Nsanzimana 20154 
HIV+ not on ART  
(State 5) 
3,080 736 -- UNAIDS 201612 
Total size 177,000 42,300 177,000 ESPHS Rwanda 201115 
Overall population  
HIV- (State 1) 11,589,295 11,559,295 11,609,295 NISR 20154; UNAIDS 2016 
Undiagnosed HIV (State 2)  20,000 18,182 22,727 UNAIDS 201612 
HIV+ with viral suppression on 
ART (State 3) 
131,520 113,436 146,316 UNAIDS 201612; Nsanzimana 20154 
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Parameter Base value 
Lower 
bound 
Upper 
bound 
Source 
HIV+ without viral suppression 
on ART  
(State 4) 
28,480 24,564 31,684 UNAIDS 201612; Nsanzimana 20154 
HIV+ not on ART  
(State 5) 
40,000 22,000 62,000 UNAIDS 201612 
Total size 11,809,295 -- -- NISR 20154 
 
 
 
 
Table 2: Different scenario analyses on ART, condom and PrEP, and changes in the 
number of FSWs.  
  
Description 
Input 
Output: Prevalence (%) at Year 2027 
Female sex workers 
(FSWs) 
Male partners Overall population 
Base 
case 
Worst 
case 
Best case Base  
case 
Worst 
case 
Best 
case 
Base  
case 
Wors
t 
case 
Best 
case 
Base  
case 
Wor
st 
case 
Best 
case 
Scenario 1: Changes in testing and treatment for ART 
A) Probability 
of HIV test for 
SW 
0.71 0.50 0.90 36.43 36.43 36.43 18.66 18.75 18.60 2.64 2.64 2.64 
B) Probability 
of HIV test for 
general 
population 
0.46 0.30 0.80 36.43 36.75 36.06 18.66 18.61 18.69 2.64 2.64 2.63 
C) % of 
national 
coverage of 
ART 
0.80 0.60 0.90 36.43 36.68 36.32 18.66 18.79 18.59 2.64 2.64 2.63 
D) % of 
consistent 
adherence to 
ART 
0.90 0.74 0.95 36.43 37.41 36.01 18.66 19.74 18.17 2.64 2.69 2.61 
E) Parameters 
above 
combined 
-- -- -- 36.43 37.87 35.48 18.66 19.91 18.06 2.64 2.70 2.60 
Scenario 2: Changes in condom and PrEP use 
A) % of 
consistent 
condom use for 
SWs* 
0.45-
0.55 
0.30-
0.40 
0.75-0.85 36.43 40.70 28.67 18.66 22.06 12.45 2.64 2.69 2.54 
B) % of 
consistent 
condom use for 
General 
population 
0.30 0.2 0.45 36.43 36.46 36.39 18.66 18.69 18.62 2.64 2.76 2.47 
C) % of 
consistent PrEP 
use for SWs* 
0.40-
0.80 
0.20-
0.60 
0.50-0.90 36.43 39.38 34.90 18.66 18.88 18.54 2.64 2.65 2.63 
D) Parameters 
above 
combined 
-- -- -- 36.43 44.69 28.13 18.66 22.45 12.40 2.64 2.83 2.36 
Scenario 3: Changes in number of FSWs 
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A) Probability 
of women 
entering as a 
sex worker 
0.000
4 
0.0008** 0.0002*** 36.43 24.52 44.73 18.66 17.00 19.65 2.64 2.63 2.64 
Combined scenarios 
A) Scenarios 1 
and 2 
combined 
-- -- -- 36.43 47.86 28.13 18.66 24.56 12.34 2.64 2.93 2.35 
B) Scenarios 1, 
2, and 3 
combined 
-- -- -- 36.43 54.07 46.50 18.66 22.29 8.77 2.64 3.15 2.51 
Prevalence (%) at year 2017: FSW = 45.1%; MP = 15.7%; Overall population = 2.9% 
* Intervals represent starting point (2017) and end point (2027) assuming a linear increase over 10 years 
**2x times more young girls choosing to enter sex work assumed as the worse case 
***1/2 times less young girls choosing to enter sex work assumed as the best case 
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Figure 1: Model structure for HIV transmission 
  
 
Acronyms: HIV, human immunodeficiency virus; ART, antiretroviral therapy; “+”, positive; and “- “, negative
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Figure 2: Overall HIV incidence over time with or without PrEP 
 
 
 
 
Acronyms: PrEP, pre-exposure prophylaxis 
 
Figure 3: Number of overall population living with HIV 
 
 
 
Acronyms: PrEP, pre-exposure prophylaxis 
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Figure 4: Incidences of HIV among FSWs and male partners over time with or without 
PrEP 
 
 
 
 
Acronyms: PrEP, pre-exposure prophylaxis; MP, male partners; SW, female sex workers 
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Tornado diagrams for each population illustrating model sensitivity to worst-case/best-case 
changes on tested parameters. 
 
 
 
 
 
 
Acronyms: PrEP, pre-exposure prophylaxis; MP, male partners; SW, female sex workers; GP, general population; ART, antiretroviral therapy 
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CHAPTER 11. GENERAL DISCUSSION OF THESIS 
  
 
This thesis provides further evidence on linkage and retention to HIV care services in the 
Rwanda national HIV program. In this section, we synthesize and discuss main findings from 
studies presented in different chapters with implications for HIV control in Rwanda. We made 
recommendations for national HIV program improvement and future research to fill the gaps 
identified in this project. The present PhD project studied key areas of the entire national HIV 
program, focussing on parameters of HIV diagnosis and linkage to care, evaluation of clinical 
outcomes on first, second and third lines ART, and explorers the main drivers of the epidemic. 
The added value of the PhD project is in driving successful policy change from a deep exploration 
of the program’s data.  
In the aftermath of the genocide against the Tutsis in 1994, no one would expect a country 
like Rwanda to overcome several challenges related to the tragedy. As we described before 
(chapter 3), despite the situation, the program scaled up rapidly around main programs areas 
outlined in the national strategic plan on HIV and AIDS in a multisector response approach such 
as community awareness, HIV testing services, treatment and linkage to care, retention and 
adherence, evidence based to inform policy changes and ensuring uninterrupted supply of 
medicines.  
After 2 decades, the program results were impressive, with more than 80% of people living 
with HIV accessing medication, new infections estimated decline more than 50% and AIDS related 
deaths dramatically reduced by 78% and consequently life expectancy among people living with 
HIV increased by 25 years. In addition, the country implemented strong data systems. Our main 
objectives were to identify the main programmatic gaps and fix them using deep analysis of 
routinely reported data. 
  153 
 
 
 
11.1 Parameters of HIV diagnosis and linkage to care 
 
  Knowledge of HIV burden in Rwanda was not fully understood as demographic and health 
surveys conducted previously in 2005, 2010, and 2015 assessed only HIV prevalence and risk 
factors which limited proper policy decision making. Knowledge of HIV epidemic required better 
understanding of where and to whom HIV new infections, are coming from; measuring incidence 
provides an entry point to care and this stage was critical information the country needed. We 
therefore assessed for the first time the incidence of HIV in Rwanda in a longitudinal household 
survey (chapter 5). Our findings showed an estimated national incidence of 0.27 infections per 100 
person-years  (Nsanzimana et al. 2017). The incidence was comparatively lower than in other 
countries in the Eastern and Southern Africa (Braunstein, van de Wijgert & Nash 2009) , but the 
incidence was 50% higher than the UNAIDS Spectrum/EPP model estimated incidence of HIV in 
Rwanda (MoH/RBC-Rwanda 2015a). Surprisingly the overall prevalence of HIV assessed in DHS 
has been reported stable at 3% for more than a decade (Chapter 4). At several occasions, policy 
makers and scientists debated on such unchanged figure that could be only possible with a balanced 
mortality and new infections yet this was not fully studied. Two studies conducted in the 
preparatory phases of this PhD complimented this discussion providing new evidence on trajectory 
pathways of PLHIV from diagnosis, linkage to care, lost to follow up and deaths in the national 
program for pre-ART and on ART patients (chapter 6). 
These studies provided more accurate data to understand the HIV epidemiology in the 
country, the importance of early diagnosis and linkage to care and informed future mathematical 
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model estimates and updated situation of HIV epidemic in Rwanda for better program planning. 
Concerning the areas of improvement identified in these studies. We found that the incidence of 
HIV was significantly driven by young adults and singles (chapter 5) who accounted for more than 
half of all new infections. Similarly, this paradox among adolescents was observed almost for all 
stages of the cascade of care (chapter 6) examining the transition probabilities of the HIV 
continuum of care in a cross-sectional analysis of the national program. Further in multi drug 
experienced patients, adolescents had sub-optimal adherence on first and second line therapy 
(chapter 9) suggesting that adherence interventions should be targeting this group in particular. 
Our results on measuring incidence showed that breakouts appear to be key contributor to HIV 
epidemic in Rwanda. Quantifying HIV incidence and prevalence is the first step to measure the 
HIV cascade of care.  
A high proportion of patients entering care in Rwanda HIV program were retained and achieve 
high viral suppression rates (82%). The mortality was low both in pre-ART (0.6%) and on ART 
(1%) stages. Main risk factors for mortality include older age, CD4 count at initiation and male 
sex (Chapter 6). The issue of men adherence and retained in care in Rwanda was underestimated 
previously, while many countries struggled to achieve couple counselling and testing during 
antenatal care, Rwanda was the first country to achieve the highest proportion (85%) of males 
accompanying their wives for pregnancy tests in antenatal care. These studies demonstrated a real 
need for special programs targeting men and adolescents such as health clubs already tested in 
some US-PEPFAR supported countries.  
In the pre-ART era, CD4 count have been used to measure treatment outcomes, we 
evaluated the effect of baseline CD4 cell count at linkage to HIV care and at initiation of 
antiretroviral therapy on mortality in HIV positive adult patients in Rwanda in a nationwide cohort 
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study (Chapter 6). Our results showed a strong association between mortality and increasing CD4 
cell count at time of linkage to care. Although CD4 has been used previously used as a basis for 
initiation of ART, the benefits of early start of ART regardless of CD4 cell count were reported in 
different studies and clinical trials to inform new WHO guidelines (Mills, Bakanda & Birungi 
2011; Cohen et al. 2011).  
Our findings supported the changes in the Rwanda ART guidelines, in 2015 to treat all 
HIV+ regardless of CD4 cell count expected to substantially reduce mortality among people living 
with HIV in Sub-Saharan Africa. Nevertheless, surveillance of CD4 cell counts at HIV diagnosis 
and initiation of ART will still remain important to monitor whether more individuals are tested 
earlier and retained in care. Countries will need to build adequate capacity and quality of testing 
to meet the viral load requirements for monitoring treatment outcomes.  
HIV program in Rwanda considered moving away from CD4 threshold even before WHO 
guidelines recommendations (chapter 9). The strategy was to shift to “treat all” particular groups 
of people in particular all pregnant women and children under five years of age in 2010. Key 
populations such as those with, HIV-TB, HIV- chronic hepatitis B and C co-infected patients in 
2013 and finally widely adopted in 2015 to all people living with HIV. There is a need for 
innovative approaches to engage people and retain them in care under optimal adherence that 
requires real time program data, and adaptation of interventions to the need of patients as well as 
increased funding to HIV programs in Sub-Saharan Africa. Policy development and 
implementation do not always happen at the same track especially in resource limited settings. 
Our policy study provided an example of different steps for consideration from guidelines 
adoption to implementation in the newly adopted recommendation in Rwanda to initiate ART for 
all HIV+ clients. The study detailed phased implementation of spaced clinic visits for stable HIV-
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positive patients in Rwanda to support treat all. We described key policy developments and 
implementation of comprehensive differentiated service delivery such as definition of scope in 
national and international scientific consultations, categorization of patients to patients to 
transition from monthly to quarterly medicine pick-ups and clinical visits change from quarterly 
to bi-annual. We also assessed political, and financial implications especially for additional 
commodities required to implement the new guidelines. Our analysis resulted into a cost plan for 
additional $4 million to increase national commodities buffer stock which was funded by the 
United States President’s Emergency Plan for AIDS Relief (PEPFAR). 
Results from a systematic literature review conducted to assess the impact of reduced 
frequency of clinic visits and medication pick-up on antiretroviral treatment outcomes suggest that 
less frequent clinical visits led to better retention in care with no differences in virological and 
mortality outcomes comparing less and frequent visits (Mutasa-Apollo et al. 2017).  
These findings compliment the Rwanda decision to implement a nationwide differentiated 
service delivery model whereby medical clinics for stable patients changed from quarterly to only 
twice a year and drug pick-ups from monthly to quarterly. Accelerating initiation to ART has been 
associated with better health outcomes. Not only treat all HIV+ is beneficial, immediate initiation 
could reduce the risk of lost to follow up and mortality among those with advanced disease and 
those at high risk of transmitting the virus (Ford et al. 2018; Ford & Nsanzimana 2016). These 
findings informed WHO and Rwanda ART guidelines recommendation on accelerated ART 
initiation, including the possibility of same day ART start. 
Our data driven and policy analysis studies provide greater value to understand the HIV 
situation in Rwanda towards achieving UNAIDS 90-90-90 targets. However, our first cascade of 
care presented in chapter 6 was analysed at the beginning of this PhD project; it would be 
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worthwhile to examine what happens after 3 years since the current PhD’s goal was to suggest 
improvements to the national HIV program where greatest needs are. The latest updates on HIV 
cascade of care for Rwanda is depicted in figure 1.   
The UNAIDS suggested that by 2020, 90% of all people living with HIV should know their 
HIV status, 90% of those diagnosed should have access to ART and 90% of all people on ART 
should maintain viral suppression (the 90-90-90 targets) (UNAIDS 2014). These targets were 
based on the fact that the benefits of early initiation outweigh reasons for delay (Cohen et al. 2011) 
(The INSIGHT START Study Group 2015) (TEMPRANO ANRS 12136 Study Group & The 
TEMPRANO ANRS STUDY GRP 2015). As many countries struggled to implement strategies to 
reach the targets with only 66%, 77% and 82% achievements to first, second and third 90 
respectively(UNAIDS 2017a). Rwanda has almost achieved each of those and now raising the bar 
to 95-95-95 by 2023 (MoH/RBC-Rwanda 2016). Of 224,664 people estimated living with HIV in 
Rwanda in 2018 (UNAIDS EPP 2018), 88% have been identified through comprehensive 
combination of strategies targeting key populations, pregnant women and their partners, and sero-
discordant couples; implementation of HIV index testing for partners and family members of 
newly identified PLHIV and most recently launched HIV self-testing and HIV case based 
surveillance. These transformations contributed greatly to achieve almost the first 90, known as 
the hardest to reach and consequent linkages to ART and viral suppression may be affected. 
Nonetheless, the country has to find 26,644 HIV+ people not yet diagnosed and link them to care 
in addition to those who will continue to be newly identified HIV+.  
Rwanda is a successful example of ART services scale up; 94.4% of all identified PLHIV 
in Rwanda are on antiretroviral therapy as of April 2018. This resulted from the policy change in 
2016 recommending a test and treat approach in the national guidelines, eliminating CD4 
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eligibility thresholds totally. The country currently provides ART to 186,868 patients, representing 
~94.4% of infected individuals diagnosed in care, a significant increase from 153,000 patients 
~73% of infected individuals in 2015 (Nsanzimana, Kanters, Remera, Forrest, et al. 2015). Despite 
these, children and adolescents aged 15-24 years are disproportionally reached with lower than 
70% tested for HIV and 80% initiated on ART compared to adults. National program strategies 
need to be refocussed in particular to these groups to avoid that there are overshadowed by the 
overall rate of achievements. More granular data will be required not only to initiate more people 
on ART but also to achieve long term good adherence with largely known benefits (Ford et al. 
2010; Carrieri et al. 2003), The national HIV guidelines in Rwanda published in 2016 suggest a 
same day ART initiation to reduce lost to follow up between testing and care; New evidence is 
now available about clinical benefits and feasibility of same day ART initiation  (Kok et al. 2015). 
Rwanda also achieved the third 90; Of all PLHIV on ART in Rwanda, 91% achieved VL 
less than 1000 copies/Ml. The last 90 requires innovative strategies and laboratory infrastructure 
to maintain adherence and retention in care and to reduce lost to follow ups. Rwanda HIV program 
uniqueness in this field relied on strong access to viral load turn-around time which has been 
improved through the implementation of a decentralized sample referral and transportation system 
linking health facilities to the nine VL testing hubs and the use of a web based Laboratory 
Information System. The investments made by the country improve warehousing and supply chain 
efficiencies and strengthen laboratory network capacity to manage laboratory stock. Consequently, 
viral load testing access has been multiplied nine folds in the last five years.  
Adapting care to the needs of individual patients such as children and adolescents will be 
necessary to improve viral suppression in a longer term. Strengthening genotyping capacity will 
be required to precisely know when to switch before accumulation of resistance mutations. 
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Figure 1: HIV Cascade of Care in Rwanda, adapted from national HIV progress report, 
April 2018.  
 
Adapted from Rwanda national HIV progress report, RBC: April, 2018 
Figure2: Projected people living with HIV, incidence and AIDS related deaths in Rwanda, 
2018
Towards 90-90-90 targets: HIV cascade of Care in Rwanda,April 2018
198,020 (88%) of 
PLHIV identified.(2)
186,868 (94.4%) of
identified PLHIV are 
on ART.(3)
169,695 (91%) of 
PLHIV on ART are VL 
suppressed(4)
224,664 PLHIV(1)
Data sources:
* 1 .EPP Spectrum 2018
* 2 Estimated using EPP Spectrum, DHS and HMIS
* 3. Health Management Information System of the MoH
* 4 Source: PEPFAR Supported sites 
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Projected PLHIV, incidence and AIDS related 
deaths in Rwanda  
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The trend and current state of HIV epidemic in Rwanda summarised in figure 2.  
 
Since the first case of HIV in Rwanda, in the early 1980s, the Government demonstrated 
efforts and commitment in fighting the HIV-AIDS epidemic. Concrete HIV interventions and 
services were implemented after the genocide against the Tutsis in 1994. Significant changes in 
incidence, number of PLHIV on ART and reduction of AIDS related deaths were observed with 
the support of Global Fund and PEPFAR, in 2004. The prevalence of HIV remained constant for 
the last decade, the analysis of HIV prevalence data in 2010 and 2015 stratified by sex and age 
groups indicate that, HIV epidemic in Rwanda is aging as the highest prevalence shift overtime to 
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the right; consequently the number of adults living with HIV on ART continue to rise; however, 
HIV+ children below 15 years old declined significantly in accordance to reduced transmission of 
HIV from mother to child from 10.9% in 2004 to 1.5% in 2018 (MoH/RBC 2017) giving a hope 
for an AIDS free generation in Rwanda. 
What makes Rwanda HIV program unique could be explained by:  
First, a highly decentralized and integrated HIV clinical service ~98% of health centers in 
Rwanda provide comprehensive HIV services. As a geographically small, but densely populated 
and homogenous, Rwanda has eliminated many barriers to accessing care by offering localized 
clinical services. Offering decentralized services reducing the travel burden to clinical services has 
been shown to be among highest predictors of retention in care (Govindasamy, Ford & Kranzer 
2012) 
Second, the country’s leadership from top to down has implemented performance-based 
contracts for central and local leaders, health and non-health professionals. These contracts serve 
as direct commitment and hold accountable all leaders to achieve set indicators. HIV among other 
country’s priorities benefited significantly from this initiative. 
Third, a program with a robust data surveillance systems for HIV care service including 
Health Management Information System, Electronic Medical record and health commodities 
supply chain systems; For example, laboratory information system provides quantification 
information and minimizes laboratory commodities stock outs. Strong routine centralized 
surveillance systems are  key to examining the progress of any program for better patients care 
(Diaz et al. 2005; Koenig et al. 2017). 
Remaining challenges relies on early monitoring, prevention and management of HIV drug 
resistance; HIV prevalence among female sex workers and similar key populations remaining very 
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high. In addition, HIV program in Rwanda is highly depending on external resources to combat 
HIV. Significant decline in funding (figure 3) demonstrated an urgent need for the country to 
develop a sustainable funding plan to diversity sources of means otherwise, significant gains may 
be lost if not sustained. The next mile could be even more resources and innovations demanding. 
 Figure3: Rwanda HIV external funding declining  
    
11.2 Clinical outcomes on second and third line ART 
 
Having analysed critical gaps in HIV diagnosis and linkage to care is essential to understand 
how optimal individual patient adherence to ART is important to prevent treatment failure and 
disengagement from care. 
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Treatment outcome data for patients on salvage therapy is scarce in resource limited settings 
(WHO 2016).   
We assessed the treatment outcome for patients who failed first and second line ART available 
regimens.  
Our nationwide study assessing retention in care and treatment failure for patients on second line 
ART suggested that overall, 92.5% of patients on second line ART in Rwanda were retained in 
care; 83% achieved VL < 1000 copies/ml, 2.8% were lost to follow up and 2.2% died. This study 
is the first to analyse outcome of patients on second line ART in Rwanda with a national 
representative sample. 
Although our results show high proportion of patients achieving good retention in care and 
low failure on second line ART, these rates are lower compared to those of patients on first line 
ART (chapter 6). Defaulting from care was significantly associated with more recent initiation of 
ART- PI based regimen, CD4 cell count <500 cells/mm3 at initiation of second line ART and viral 
load > 1000 copies/ml at last measurement while Viral failure was associated with younger age, 
WHO stage III&IV at ART initiation, CD4 cell count <500 cells/mm3 at switch, atazanavir based 
second-line ART and receiving care at a health center compared to the hospital. Similar results 
were obtained in other surveys with an average of 80% viral load suppression and virological 
failure ranging from 23%-28%  (Ajose et al. 2012).   
These results strongly suggest the need for regular viral load monitoring and adherence 
support especially to patients likely to default from care across all stages of treatment cascade and 
all regimen transitions. The study on outcomes from Rwanda’s first national cohort of third-line 
ART indicated that, over 90% of all 55 patients ever started on third line ART achieved VL 
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suppression less than 1000 copies/ml. Only one patient died and all were retained in care (chapter 
7) Our results were comparable to data reported in other similar cohorts (Meintjes et al. 2015).  
Regrettably, close to 10% of multi-drug resistant patients had virological failure for all 
available treatment options in Rwanda raising critical concerns for financial accessibility of further 
regimen in resource limited countries. Poor adherence is most of the time associated with treatment 
failure and drug resistance (Levison et al. 2012; Wallis et al. 2011).  
In our study, more than 70% of the patients had accumulated at least one mutation on NRTI 
and NNRTI, however the majority were still susceptible to raltegravir and darunavir/ritonavir. 
Similar studies reported comparable treatment outcome on a third line combining 
darunavir/ritonavir, and raltegravir, recommending that this can be used as a standardized third-
line regimen (Chimbetete et al. 2018; Rawizza et al. 2013; Meintjes et al. 2015) . The selection of 
a proper regimen depends most of the time on expert opinion based on available evidence, which 
is very dynamic. The Rwanda National HIV guidelines recommend the use of 
darunavir/ritonavir+raltegravir+etravirine in addition to a two NRTI based backbone for treatment 
of patients who failed previous protease inhibitors and/or NNRTIs. Given that this is the most 
expensive treatment combination available in the country; while an average cost on first line is 
100 USD per patient per year; average cost per patient per year on second line is 500USD; the cost 
on third line is 6 times more , ranging between 3000-3500 USD per patient per year  (MoH-Rwanda 
2018; Management Sciences for Health 2006).   
Failing these regimens critically has both financial and clinical implications for 
management of these patients in a resource limited context. The Rwanda national HIV program 
heavily depend of donor support, the main funding partners are Global fund and US-PEPFAR; 
more than 50% decline in funding was observed over a five-year trend and expected to continue; 
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Rwanda’s gross national income is 700 USD per capita it ranks 159 in UNDP’s Human 
Development Index 2016 (World Bank,2015) and significant financial barriers remain to achieve 
a sustainable HIV response in the near future. 
There is a strong need for the Ministry of Health of Rwanda to develop a diversified source 
of funding including increased domestic investment, more efficiencies and innovations to sustain 
the HIV program. 
Our analysis guided the national HIV program to select second line regimen in the new Rwanda 
ART guidelines version 2017 (MoH/RBC-Rwanda 2017). 
 
 
11.3 Key drivers of HIV epidemic in Rwanda  
 
HIV prevalence in the general population in Rwanda is 3% and HIV annual incidence ~ 0.27% 
(chapter 5); Female sex workers represent the only group with an alarming high prevalence with 
almost one out of two sex workers are HIV infected (Household community survey reference). 
The magnitude and dynamics of sex work in Rwanda’s HIV program is not well understood due 
to the fact that the national programme data collection tools do not allow for easy identification of 
sex workers when in contact with facilities due to stigma and confidentiality reasons; though it is 
an important group in the society. The study on national household incidence (Chapter 5) revealed 
that people engaged in sexual activities had also six times more risk to acquire HIV. Although the 
Rwandan constitution criminalizes sex work, this group continue to be considered as a bridge to 
HIV transmission from sex workers to their male sexual clients and to the general population. The 
national HIV strategic Plan considers FSW as key population but needed to assess which 
interventions could be implemented to reduce the transmissions. 
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Although the impact of sex work on the rate of new HIV infections varies widely in Sub-
Saharan Africa, it impacts significantly on the HIV/AIDS epidemics in a number of countries in 
this region. For example, FSWs, their clients, and the sexual partners of clients made up a third of 
all new HIV infections in Ghana in 2009, 10% of all new HIV infections in Uganda, and 14% of 
HIV infections in Kenya in the same year  (Bórquez et al. 2016). 
Our projected analysis of incidence of HIV among female sex workers and their male partners 
in Rwanda using a Markov model examining intervention effects (Chapter 8) provided important 
data for future strategic planning. The study found significant success of current program 
interventions (ART, condom use) to reduce HIV incidence among FSW, increased coverage that 
could result into 6-10% reduction on HIV prevalence every year. We also estimated that 
introduction of Prep expected in Rwanda in 2019, could prevent more new infections among FSW 
by 0.24%. Our findings will have greater impact in the development of the Rwanda National 
Strategic Plan 2018-2023 as FSW remains the key driver of new HIV infections in the country.  
There is a need to examine barriers and facilitators at different levels of care, which influence entry 
into and engagement in the continuum of health services for FSWs in Rwanda.   
Similarly, our analysis has implication to strategic planning in other countries with 
concentrated epidemic in key populations such as FSW, MSM. Using Markov model to this 
analysis was motivated by its wide success in health economy; it has the advantage for combining 
different stages of transition probabilities. The majority of transition probabilities were directly 
informed by data with high internal MoH validity. Our model main limitation includes self-
reported data on sexual behaviors, which are likely subject to some bias; the model did not include 
other key risk populations (e.g. men who have sex with men, male sex workers, and sero-
discordant couples) in Rwanda.  
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All other projects were either research studies, routine program data analysis or policy 
implementation; In this project, we preferred to conduct this model to predict the future of HIV 
among FSW which was highly needed by the Rwanda Ministry of Health. Follow up project 
ongoing include a cohort of HIV negative FSW that will be tested for HIV after 12 months, we 
expected that results from this survey also will contribute to respond to this important question. 
As illustrated in the figure below; the relationship between female sex workers, male 
clients of sex workers and general population in Rwanda is worrying due to the role of this network 
in the continuous transmission of HIV. The presented mapping of key populations locations could 
facilitate precision of interventions according to where the highest needs are; for example, western 
province that accounted for more new infections (chapter 5) has a concentrated number of 
fishermen; the same province shares 2 main border areas with DRC where truck drivers and sex 
workers are also represented in high proportions. The capital of Rwanda, Kigali has HIV 
prevalence three times higher than other provinces (Chapter 5) and estimated to host more than 
3000 active sex workers in several hot spots and truck drivers stop points (Mutagoma et al. 2015).  
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11.4 Policy implications  
 
Despite the reported high performance of Rwanda national HIV program, our project 
identified several areas of improvement in strategic planning, program implantation, monitoring, 
evaluation and strategic information towards the country commitment to achieve 90-90-90 
UNAIDS global targets by 2030 
Our first study on HIV incidence and prevalence underlines challenges associated with 
breakouts of new HIV infections and significant number of growing infections among youth and 
19
Key populations hotspots in Rwanda, 2017
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singles. This reality implies new strategies in the testing and condom use program area. Majority 
of the individuals possibly driving infections didn’t know they are HIV+ though testing services 
are free of charge across the country. The country should put in place new strategies for individuals 
who are hard to reach with existing testing and linkage to care services. Our findings revealed also 
that mathematical modelling such as UNAIDS Epi Spectrum estimating HIV indicators in most 
countries could have been underestimating the rates of HIV in different countries. The models 
should be recalibrated to reflect this paradox of outbreaks. Countries could plan nationwide 
household HIV incidence surveys for better precision without relying only on estimates.  
Our studies on HIV care continuum in Rwanda and effect of baseline CD4 count on 
mortality demonstrated the need to focus on males, adolescent and less healthy HIV–positive 
patients in national strategic planning. Furthermore, continuum of care is not a single trajectory 
pathway, individuals re-engage and disengage from care at different stages, the national program 
and beyond should be aware of these multiple pathways to improve timely linkage and retention 
in care. 
In our different project studies; treatment outcome for first, second and third line regimens 
demonstrate increasing treatment failure by regimen respectively; rigorous and innovative medical 
and laboratory monitoring should be introduced to maintain individuals on successful treatments 
without unnecessary changes to second and third lines in resource limited context. However, 
resource limited countries do not systematically implement drug resistance testing before initiation 
and switching of ART regimen, consequently, patients maintained on a failing treatment are at 
great risk to accumulate drug resistance mutations. Therefore, the World Health Organization 
guidelines need to strongly recommend regular and systematic drug resistance testing especially 
for patients who are not suppression viral load.  Although we reported a high rate of retention in 
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care in Rwanda, the national program has to put more efforts to retain those at high risk to 
disengage from care. The UNAIDS 90-90-90 targets should be updated to reflect those defaulted 
from care who are potentially at risk of treatment failure.  
HIV epidemic in Rwanda is largely driven by the condensed epidemic of HIV among FSWs 
and their male partners. As the Country develops its National HIV Strategic Plan 2018-2023, it 
should focus more on interventions targeting FSWs and their networks such as testing, linkage to 
care, improve consistent condom use and introduction of PreP among HIV negative FSW. As 
presented in Chapter 3 and Chapter 11; The city of Kigali has a substantial HIV prevalence among 
general population (6% Vs 3%) and FSW (52% vs 46%) probably due to the population migration 
and legacy of post genocide effects; In this context, a specific strategy for Kigali city to combat 
HIV is highly recommended.   
11.5 Recommendations for further research  
 
1. Due to the importance of high HIV prevalence among FSWs in Rwanda; follow up studies 
to our model are needed to determine HIV incidence and associated factors to increase 
program precision in decision making. This PhD project already initiated this follow up 
study which is at early stage of implementation. This prospective follow-up over 12 months 
of a cohort of female sex workers (FSW) in Kigali will provide key data on behavioural 
determinants of linkage and retention in care and estimation of HIV incidence among a 
cohort of HIV-negative female sex workers in Kigali, the capital of Rwanda. 
2. Given that the HIV epidemic in Rwanda is driven by key populations, there is a need to 
further investigate patients’ trajectories in different stages of care especially for key and 
priority populations (FSWs, MSM, Adolescents, Males). 
  172 
3. As Rwanda get closer to achieving UNAIDS 90-90-90- targets by 2020, we recommend 
an operational study to assess the progress towards achieving this goal after 
implementation of “treat all” and differentiated service delivery model  
CHAPTER 12. OVERALL CONCLUSION OF THE THESIS 
 
We conducted this project to identify gaps in the entire national HIV program and 
recommend clinical and public health interventions to improve the country’s program. Our 
findings reflected in seven studies, demonstrated a high performance of HIV program in Rwanda, 
with a relatively stable prevalence; improved cascade of care across different treatment regimens. 
Nonetheless, several gaps were highlighted with increasing needs to focus on key and priority 
populations; adolescents, males and delayed linkages to care should be prioritized to maintain a 
sustainable and cost-effective program. Further, due to increased number of patients failing 
available treatment options, strengthening viral load and genotyping testing should be prioritized 
to maximize patients’ treatment outcomes and prevent future epidemic of HIV drug resistance. 
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